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Abstract 
 
Leukaemic stem cells (LSCs) are believed to have originated from haemopoietic 
stem cells (HSCs) or early progenitors, which reside within a hypoxic niche in the bone 
marrow. Hypoxic adaption in HSCs is mediated by hypoxia-inducible factor-1 (HIF-1), 
which, under hypoxic conditions, acts as a transcription factor to induce the expression of 
hypoxic response genes.  Under normoxic conditions, HIF-α is targeted for degradation by 
Prolyl-4-hydroxylases (PHDs). HIF-1α has been shown to play an essential role in 
maintaining LSCs.  Negative regulator PHD has been implicated in various forms of cancer, 
although the role of PHD in leukaemia has not been clarified.  
The overall aim of this study was to investigate the role of PHD isoforms in the 
transformation and function of LSCs. A mouse model lacking PHD isoforms was used (PHD 
KO), allowing the collection of PHD KO haemopoietic stem and progenitor cells (HSPCs). 
HSPCs were then transformed in vitro to produce pre-LSCs which were assessed for 
cellular function under optimal conditions, hypoxic conditions and in response to 
chemotherapy. 
This study has indicated that under optimal conditions pre-LSCs lacking PHD1, 
PHD2 or both PHD1 and PHD2 had a reduced growth rate. Pre-LSCs lacking PHD2 also 
showed a significant increase in apoptosis. Following treatment with chemotherapy or 
radiation, pre-LSCs lacking PHD1, PHD2 or PHD1 and PHD2 responded better to 
chemotherapy and radiation treatment and had an increased frequency of cell death.  
In vivo experiments were performed in which pre-LSCs were prepared and 
transplanted to lethally irradiated mice, allowing us to identify if the absence of PHD 
isoforms had an effect on the leukaemic potential of pre-LSCs. Overall we report that 
mice transplanted with WT pre-LSCs had impaired survival and developed leukaemia at a 
higher rate than mice transplanted with pre-LSCs lacking PHD1, PHD2 or PHD1 and PHD2.  
Overall these results indicate that PHD isoforms may play a role in the 
development of leukaemia and the response to treatment and warrants further 
investigation into the role of PHD in leukaemia.  
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1 Introduction 
 
1.1 The Haemopoietic System 
The haemopoietic or blood system is responsible for the maintenance and 
protection of every tissue in the body. The cells that comprise the haemopoietic system 
are generated in a strictly regulated process called haemopoiesis. In adult systems, 
multipotent haemopoietic stem cells (HSCs) located in the bone marrow, are responsible 
for the production of all the cell types within the haemopoietic system.  
 
1.1.1 Organisation of the stem cell compartment 
The haemopoietic system exists as a cellular hierarchy with cells progressing 
through a number of differentiated states and becoming transiently more mature. HSCs 
lack the mature markers that are used to identify mature cells but they do express cell 
markers that are specific to undifferentiated, primitive cells. Primitive cells also show 
differences in their behavioural patterns and these can be used to organise primitive 
populations into a hierarchy based on functionality, as well as the expression of cell 
markers.   
  Long-term (LT)-HSCs are known to be the most primitive cells within the stem cell 
hierarchy and to have the unique ability to self renew through symmetrical division, 
allowing the production of two identical HSCs, whilst also possessing the ability to 
undergo asymmetrical division to produce one stem cell and one differentiated cell (Suda 
et al, 2011). This allows the pool of HSCs to be maintained in the bone marrow, 
preventing them from becoming depleted, during the production or renewal of blood 
cells, in response to infection or injury. Self renewal is a unique ability in HSCs that is not 
shared by differentiated or mature cells and is one of the defining qualities of a stem cell. 
Short-term (ST)-HSCs are considered to be the second most primitive cell population. Like 
LT-HSCs, ST-HSCs are known to contribute to the generation of lineage positive cells.  
15 
 
Throughout the hierarchy, cells become transiently more mature, eventually committing 
to a specific lineage of mature blood cell. 
 
 
 
 
 
  
 
Figure 1.1. Organisation of the stem cell hierarchy.  
The haemopoietic system is organised into a cellular hierarchy. Cells can be identified based on 
the expression of cell surface markers or by their behaviour. LT-HSCs are considered the most 
primitive cell type within the hierarchy and possess the unique ability to self renew, as well the 
generation of mature cells. ST-HSCs are also known to contribute to haemopoiesis. MMPs 
(Multipotent progenitor cells) are considered part of the stem cell hierarchy although they have 
lost the ability to self-renew. MMPs remain multipotent with an ability to differentiate into all 
mature cell lineages. Cells are believed to become transiently more mature throughout the 
hierarchy 
 
1.1.2 Identification and Isolation of stem cells by stem cell markers 
Stem cells can be identified based on the expression of various cell surface 
markers (Savona & Talpaz, 2008; Benveniste et al, 2009). Identification of these markers 
also makes it possible to isolate specific populations within the stem cell compartment, in 
order to study the similarities or the differences between these cells. CD34 is a cell 
surface marker which is commonly used to identify HSCs. LT-HSCs are known to express 
low levels of CD34 (CD34lo), whereas ST-HSCs are known to express high levels of CD34 
LT-HSC MPP2 MPP1 ST-HSC 
differentiation 
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(CD34hi). This difference is used to distinguish these populations and is often used in the 
study of the human haemopoietic system. The expression of CD34 can be analysed by 
staining cells with anti-CD34 antibody and determining the expression of CD34 by flow 
cytometry. LT-HSCs or ST-HSCs populations can also be separated by fluorescent activated 
cell sorting (FACS), which allows populations to be isolated based on positive staining with 
specific fluorescent antibodies. 
There are several surface markers and specific combinations of surface markers 
that are used to study HSCs in the mouse (Challen et al, 2009; Wang et al, 2009, Kiel et al, 
2005). Cells within the stem cell compartment, including LT-HSCs, ST-HSC and Multi 
Potent Progenitors (MMPs), are known to lack the expression of lineage markers. As cells 
become more committed, lineage markers will be expressed dependent on the lineage to 
which that the cell is committed. However, primitive cells are not committed to any 
lineage and do not express any lineage markers. Antibody cocktails can be used to stain 
cells with antibodies specific for most known lineage markers. Cells can then be analysed 
by flow cytometry and those that are negative for the expression of any lineage markers 
(Lin-) can then be selected through gating the population. Cells within the stem cell 
compartment are also known to express high levels of CD117 (c-Kit) and Sca1. Cells within 
the Lin- fraction can be further gated for the expression of Sca1 and c-Kit, resulting in the 
identification of the stem cell compartment. This is a common method and is referred to 
as LSK or KLS gating (Lin-Sca+c-Kit+ or c-Kit+Lin-Sca+). For the purpose of this report, this 
strategy will be referred to as LSK gating. The stem cell compartment can then be 
scrutinised further by identifying LT-HSCs, ST-HSCs and MMPs based on the expression of 
markers CD150 and CD48, commonly referred to ‘SLAM’ (Signalling Lymphocyte 
Activation Molecule) staining (Challen et al, 2009; Calaminus et al, 2012). Figure 1.2 
represents an example of SLAM staining, depicting how primitive cells can be 
distinguished. LT-HSCs are known to be CD48+CD150- and are therefore seen in the 
bottom right quadrant of the plot. ST-HSCs are known to be CD48-CD150- and are 
visualised in the bottom left quadrant of the plot. Cells that are CD48-CD150+ and 
CD48+CD150+ are referred to as MMP1 and MMP2 respectively. This method of 
identifying stem cells is commonly used to isolate populations that can be used in further 
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studies to assess the properties of specific cells within the stem cell compartment. For 
example, LT-HSCs or ST-HSCs can be isolated to assess the self renewal potential of 
individual populations by utilising the reconstitution assay. 
 
 
                                                 
 
(Figure taken from Calaminus et al, 2012) 
Figure 1.2. Example of SLAM staining strategy for the isolation of the stem cell compartment.  
The stem cell compartment can be analysed following antibody staining and FACS analysis. Cells 
can be stained with a cocktail of antibodies against common lineage markers to determine the 
fraction of the cell population that is primitive and is not expressing lineage markers (Lin-). A. Lin- 
cells can then be analysed for expression of Sca-1 and c-Kit to identify the LSK fraction. B. Within 
the LSK fraction, cells can be further separated into different quadrants of the stem cell 
compartment depending on the expression of CD150 and CD48. Dot plot represents typical SLAM 
gating showing LT-HSCs (I), ST-HSCs (II), MMP1 (III) and MMP2 (IV). 
 
1.1.3 Studying the properties of the stem cell compartment 
HSCs also possess other qualities that distinguish them from less primitive cells 
such as quiescence. HSCs are known to be largely non-dividing with only 1-3% of the HSC 
population actively proliferating (Venezia et al, 2004). Quiescence in HSCs is considered to 
be essential to maintain the stem cell pool over long periods. The reduced proliferation 
CD150 
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D
4
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In Lin- fraction In LSK fraction 
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III IV 
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helps to prevent the exhaustion of HSCs, as well as minimising the accumulation of 
random mutations, which are acquired through proliferation (Thoren et al; 2008; Li, 
2011). The bone marrow is thought to contain two pools of HSCs; one pool which divides 
approximately every 145 days and which is responsible for maintaining the HSC pool, and 
another which is actively dividing and is responsible for the generation of lineage cells 
(Forristal et al, 2013). 
There are several assays that are used routinely to study the self renewal capacity 
of HSCs. A reconstitution assay can be used to assess the reconstitution ability or 
‘stemness’ of HSCs following transplantation into recipient mice, which is considered a 
measure of self renewal ability. HSCs are responsible for the reconstitution of the entire 
haemopoietic system. HSCs can be isolated by FACS and transplanted to lethally 
irradiated mice to test their ability to reconstitute the haemopoietic system of the 
recipient mice. However, the long term survival of the mouse would also depend on the 
self renewal of HSCs to prevent exhaustion of the HSC pool, diminishing the production of 
new cells. Failure of the cells to reconstitute the haemopoietic system may be due to a 
reduced ability to maintain the stem cell pool. This assay is also commonly used in studies 
which aim to determine the requirement of specific genes in the maintenance of stem 
cells by assessing the self renewal of HSCs in absence of target genes. Single cell 
reconstitution assays can be used to examine whether a single HSC has the ability to 
reconstitute the entire haemopoietic system (Ema et al, 2006). This involves transplanting 
a single HSC, along with support bone marrow, into a lethally irradiated mouse and 
monitoring the reconstitution of the blood system by the single HSC. Self renewal can also 
be assessed using an in vitro colony assay. Cells can be seeded into semi-solid media, 
which when cultured, will allow self renewing cells to develop colonies. Only cells that 
possess self renewal ability will generate colonies, allowing the frequency of self renewing 
cells to estimated (Ema et al, 2006). 
1.1.4 Generation of mature blood cells 
HSCs are the most primitive cell population within the haemopoietic system and 
are responsible for the generation of multipotent progenitor cells. Progenitor cells 
become committed towards myeloid or lymphoid lineages, forming either common 
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myeloid progenitors (CMP), or common lymphoid progenitors (CLP). These immature 
progenitor cells will continue to differentiate, eventually leading to the generation of 
mature red and white blood cells. The mature cells of the haemopoietic system consists 
of red blood cells (erythrocytes) and multiple lineages of white blood cells (leukocytes), 
which comprise the immune system, all of which must be tightly regulated in order to 
ensure tissue homeostasis and maximum immune protection.  
 
(Figure taken from Wang & Wagers, 2011) 
Figure 1.3. Production of multilineage mature blood cells.  
HSCs are responsible for the generation of mature blood cells that are required in tissue 
homeostasis and effective immune responses. Multiple lineages of blood cells exist and each play 
distinct role. The regulation of blood cell differentiation is critical in order to ensure adequate and 
efficient production of all lineage and many factors are involved in regulating this process. 
1.1.5 Effector cells of the haemopoietic system 
The delivery of oxygen to hypoxic tissues and our immune systems response to 
potentially harmful pathogens are critical processes in maintaining the health and survival 
GMP 
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of our body. Blood cells are required in high quantities and these short lived cells need to 
be constantly replenished so as not to diminish the blood cell pool and limit the function 
of the blood system.         
 
1.1.5.1 Red blood cells 
Red blood cells or erythrocytes are responsible for the delivery of oxygen around 
the body. Erythrocytes are rich in haemoglobin, an iron containing molecule that is 
capable of binding oxygen molecules and which is responsible for the red colour of the 
cells (Testa, 2004). Erythrocytes circulate the body through the circulatory system where 
they bind oxygen in the lungs and deliver it to other tissues throughout the body 
(Hattangadi et al, 2011). Red blood cells circulate for around 120 days before they have to 
be replaced (Hattangadi et al, 2011). Low oxygen concentration or hypoxia, is an 
important factor in regulating the production of red blood cells and is considered a signal 
that an increase in the delivery of oxygen molecules is needed to areas where oxygen is 
low.  Erythrocyte production or erythropoiesis is stimulated in response to Erythropoietin 
(EPO), a hormone which is released by the kidneys in response to hypoxia (Gregoli et al, 
1997; Testa, 2004). The production of red blood cells is critical for the maintenance of 
oxygen homeostasis within tissues and a number of medical conditions including 
polycythaemia and anaemia may arise if this process becomes dysregulated 
(Minamishima & Kaelin, 2010).  
 
1.1.5.2 White blood cells  
White blood cells or leukocytes consist of multiple lineages of cells that make up 
our immune system. Our immune system acts as a defensive barrier that fights against 
pathogens and infectious agents that invade our body. Immune cells play multiple roles in 
the prevention of infection and disease with different cell lineages being responsible for 
different roles. For example, dendritic cells are one of our first lines of defence by 
circulating and monitoring our blood and tissues for invading pathogens (Fong & 
Engleman, 2000). They are responsible for recognising and presenting foreign antigens to 
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other immune cells and initiating an immune response. Macrophages are large phagocytic 
cells that engulf invading microorganisms and digest them to prevent further infection 
(Wynn et al, 2013). These are examples of myeloid lineage cells that form our early 
responses and help initiate a more specific response. Lymphocytes play more specialised 
roles and can adapt to protect the body against specific pathogens and viruses. Different 
blood cells are identified by the specific pattern of cell surface markers that they express. 
The immune system is a large network of cells and every immunological threat requires a 
different response and the production of specific cells. The production of white blood 
cells is tightly regulated by a vast network of cytokines and growth factors such as Stem 
Cell Factor (SCF) and Interleukin-3 (IL-3), which stimulate haemopoiesis and the 
production of myeloid cells (Robin & Durand, 2010; Runnstrand, 2004). Cytokines are 
often secreted by circulating immune cells that detect the threat and dictate what type of 
response is needed.  
 
1.1.6 Control of stem cell fates 
Throughout adult life, HSCs are responsible for the maintenance and 
reconstitution of all the cells of the haemopoietic system (Benveniste et al, 2009; Challen 
et al, 2009; Wang et al, 2012). They must be able to differentiate into mature blood cells 
as well continuing to maintain the stem cell pool. Excessive proliferation and 
differentiation would diminish the stem cell pool and limit the function of the 
haemopoietic system by preventing the generation of new cells. The HSC stem cell pool is 
maintained through the tight regulation of several stem cell fates. HSC fates include self 
renewal, remaining quiescent, differentiating to CLP or CMP lineages and undergoing 
apoptosis. Stem cell fates are controlled by various factors including intrinsic and extrinsic 
signals which alter the genetic signature of HSCs and direct them towards the appropriate 
cell fate.  
1.1.7 Hox genes in haemopoiesis 
Hox genes are a family of conserved genes, well known for encoding 
homeodomain-containing transcription factors, which play a critical role in establishing 
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axial patterning and tissue fate during embryogenesis (Brunschwig et al, 1999). However, 
Hox genes are also believed to have a role in the regulation of HSCs and their 
differentiation (Lawrence et al, 1996). In mammals, there are 39 known Hox genes which 
are arranged into 4 clusters (A, B, C, D) based on sequence homology, and are found on 4 
different chromosomes (Argiropoulos & Humphries, 2007). A large majority of Hox genes 
of clusters A, B and C are known to be expressed in haemopoietic cells (Argiropoulos & 
Humphries, 2007). The observation that different Hox family members were seen to be 
expressed in different lineages of haemopoietic cells, led to the implication that Hox may 
be involved in establishing the lineages of blood cells, much in the same way that they 
determine tissue fates during development (Lawrence et al, 1996). In addition, studies of 
Hox gene expression in haemopoietic cells have reportedly shown that the expression of 
individual Hox genes changes throughout the cell hierarchy. For example, Sauvageau et al 
found that HOXA10 gene is highly expressed throughout human CD34+ cells, but is down 
regulated in more mature populations. Similarly, HOXB3 was only seen to be expressed in 
early progenitors (Sauvageau et al, 1994). Since then, several studies have been 
conducted using retroviral constructs overexpressing Hox genes and transgenic knock out 
models, aiming to further clarify the role of Hox, and numerous reviews are available 
detailing the phenotypes of these studies. Hoxa9 is known to be essential for the 
regulation of haemopoiesis and Hoxa9-defiecient mice show defects in B and T-cell 
lymphopoiesis and myelopoiesis (Huang et al, 2012). Although the role of Hox genes in 
haemopoiesis has been intensively studied, the mechanism by which they regulate this 
process remains largely unknown. 
Meis1 is thought to interact with Hox proteins and is frequently linked to 
haemopoiesis. Like many Hox genes, Meis1 is also known to be expressed in the most 
primitive cells, but is down regulated in differentiated cells. Although the precise role 
played by Meis1 is unclear, is it thought to be important in the regulation of haemopoiesis 
(Argiropoulos et al, 2007). Meis1-/- mice are known to die at day 14.5 of embryonic 
development due to multiple haemopoietic and vascular defects (Simsek et al, 2010). 
Many Hox proteins are known to contain binding regions, allowing them to form 
complexes with several partner proteins including Meis1 (Shen et al, 1997). Studies by Hu 
23 
 
et al suggested that Hoxa9 may play a role in upregulating Meis1. The study showed that 
overexpression of Hoxa9 in mouse bone marrow cells resulted in the up regulation of 
Meis1 mRNA and protein. Furthermore, in cells which were lacking Hoxa9 (Hoxa9-/-), 
Meis1 expression was significantly reduced. These studies show a close connection 
between Meis1 and Hoxa9 expression in the bone marrow and may indicate that 
expression of both proteins is required for the regulation of haemopoiesis (Hu et al, 
2009).  
 
1.2 The Bone Marrow Microenvironment 
HSCs reside within the bone marrow, which contains specialized 
microenvironments that can affect cellular function, referred to as a niche (Kiel et al, 
2005).  The bone marrow niche was first proposed in 1978 by Schofield (Schofield, 1978) 
and has since then been the subject of many studies attempting to unravel the controlling 
factors in HSC function (Lo Celso & Scadden, 2011). Various studies have shown that the 
endosteal surface of the bone marrow along with osteoblastic cells found in the HSC 
niche play a role in maintaining HSC and influencing fate decisions (Calvi et al, 2003; 
Grassinger et al, 2010; Zhang et al, 2003) The niche environment is thought to interact 
with residing cells, altering their function through the secretion of cytokines and other 
growth factors, which help the cell to balance between self-renewal, differentiation and 
expansion (Kiel et al, 2005).  
 
1.2.1 The osteoblastic niche 
Different microenvironments within the bone marrow are thought to contribute 
to different aspects of HSC function. For example, the oesteoblastic niche is associated 
with LT-HSCs and is thought to regulate quiescence (Eliasson et al, 2010; Forristal et al, 
2013). The oestoblastic niche is thought to be located close to the endosteal surface 
where slow-cycling or quiescent HSCs have been found (Eliasson et al, 2010; Forristal et 
al, 2013). Studies by Lo Celso et al showed that following transplantation of HSCs 
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extracted from donor mice to recipient mice, HSCs homed to a region close to the 
endosteum, with more mature subsets located progressively further from the endosteal 
region. Furthermore, they found that cells which were quiescent where localised within 
close proximity to osteoblasts (Lo Celso et al, 2009). Bone-forming osteoblasts that reside 
within this region have also been linked to HSC maintenance. Studies have shown that an 
expansion of osteoblasts in mice yielded an increase in HSCs, suggesting that osteoblasts 
play a role in HSC maintenance (Taichman & Emerson, 1994). Osteoblasts have also been 
linked to differentiation and are suspected to regulate myeloid differentiation through 
the secretion of granulocyte-macrophage colony stimulating factor (GM-CSF), a cytokine 
that is well known to regulate myeloid maturation (Taichman & Emerson, 1994). 
 
1.2.2 The vascular niche 
The vascular niche is more frequently linked to ST-HSCs and proliferation (Forristal 
et al, 2013). Following injury, HSCs have been seen to mobilize into the vascular regions, 
where they associate with endothelial cells (ECs). ECs help to create a niche that 
promotes HSCs expansion (Guerrouahen et al, 2011). HSC expansion is particularly vital 
following transplantation or injury when there is a risk of the stem cell pool collapsing. 
Following transplantation, HSCs home to the bone marrow through the recognition and 
binding of cell surface molecules with their corresponding partners. HSCs express a 
number of adhesion molecules, which are known to bind with receptors expressed on 
ECs, allowing HSCs to migrate into the vascular region following transplantation 
(Guerrouahen et al, 2011). Studies have shown that the co-culture of HSCs with ECs can 
increase expansion of HSCs through the secretion of various angiocrine factors that 
promote haemopoiesis (Butler et al, 2010; Kobayashi et al, 2010).   
 
1.2.3 The hypoxic niche 
The bone marrow is believed to contain regions of low oxygen concentration that 
are referred to as hypoxic. The physiological oxygen concentrations (pO2) of the bone 
marrow can be evaluated using the Kroghian model, a 2D, multilayer mathematical 
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model.  Chow et al devised the model which measures oxygen tensions within the 
heterogeneous environment of the bone marrow (Chow et al, 2001). Results of this study 
showed that oxygen tensions within the bone marrow are variable and that most 
primitive HSCs were located in regions with low oxygen concentration (Chow et al, 2001). 
Hypoxic regions in the bone marrow are long believed to influence haemopoiesis and low 
oxygen concentration is well known to regulate the balance amongst differentiation, 
expansion and quiescence (Pollard et al, 2010).  
 
 
 
Figure 1.4. Architecture of the bone marrow.  
HSCs within the bone marrow are suspected to reside within specific niches that help to regulate 
their functions. HSCs are believed to interact with the niche environment and the cells within 
them to regulate stem cell fate decisions. HSCs with different proliferation potential are thought 
to reside in distinct niches. Quiescent, self-renewing LT-HSCs are believed to reside within areas of 
low oxygen known as the hypoxic niche. Hypoxia and hypoxia signalling is believed to be essential 
for the maintenance of HSCs. 
HSCs are suspected to interact with the hypoxic environment, undergoing changes 
in their gene expression in order to adapt to this environment. HSCs display a hypoxic 
profile within the bone marrow which is believed to be essential for their maintenance 
(Simsek et al, 2010; Nombela-Arrieta et al, 2013). HSCs are known to express Hypoxia 
(Adapted figure taken from Moore & Lemischka, 2006) 
Oxygen concentration 
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Inducible Factor (HIF-1α), which is thought to be essential for HSC maintenance (Takubo 
et al, 2010). The hypoxic environment is also considered to be important in the regulation 
of quiescence in HSCs (Eliasson et al, 2010; Guitart et al, 2010; Forristal et al, 2013).  
 
1.2.4 HSCs metabolic response to hypoxia 
HSCs are shown to have a slower metabolism and proliferate at a slower rate than 
more mature cells. The quiescent state of HSCs has been linked to the availability of 
oxygen and the cells adaptation to the hypoxic environment (Forristal et al, 2011; Eliasson 
et al, 2010; Guitart et al, 2010).  
The unique metabolic profile of HSCs and the reduced metabolic rate is 
considered to be a response to the hypoxic conditions within the bone marrow. Hypoxic 
adaption includes the differential regulation of metabolism, which helps the cell to 
survive without oxygen (Simsek et al, 2010; Suda et al, 2011). Cellular respiration requires 
oxygen in order to produce sufficient levels of ATP, which is used as an energy source to 
allow the cell to progress through the cell cycle. However, in hypoxic conditions where 
the oxygen concentration is low, the cell must adapt by slowing down proliferation or 
becoming quiescent, in an attempt to reduce its oxygen requirement. The mechanism 
that allows the cell to adapt to low oxygen is its ability to shift from a conventional 
method of energy production, the Kreb cycle, to glycolysis. 
Complete cellular respiration requires oxygen and therefore, cannot be completed 
in hypoxic conditions. Energy production involves several cycles of chemical reactions, 
some of which require oxygen (aerobic) and some of which that do not (anaerobic). The 
first cycle of respiration is glycolysis. Glycolysis does not require oxygen and so this cycle 
can be utilised during hypoxia for energy production. This process requires glucose which 
is broken down to produce two molecules of ATP, two molecules of NADH and two 
molecules of pyruvic acid or pyruvate (Suda et al, 2011). This stage of energy production 
yields only small amounts of ATP but does not require oxygen and so can still be utilised 
in hypoxia. The genetic profile of HSCs that is expressed in hypoxic conditions includes 
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many of the genes required by the cell to switch to anaerobic respiration (Suda et al, 
2011).  
 
 
(Figure taken from Sitkovsky & Lukashev, 2005) 
Figure 1.5. Cellular respiration by glycolysis and the TCA cycle.  
Under anaerobic conditions when oxygen is not freely available, glucose is utilised in the 
production of small amounts of ATP in the process of glycolysis. When oxygen is available, full 
cellular respiration is possible and the tricarboxylic acid (TCA) cycle and oxidative phosphorylation 
takes places, allowing larger amounts of ATP to released, providing the cell with the energy source 
needed for proliferation. 
 
When oxygen is available, the cell is able to complete full aerobic respiration, 
yielding much greater amounts of ATP. The aerobic stages of respiration are pyruvate 
oxidation and the TCA cycle or Krebs cycle, which takes place following glycolysis.  In the 
presence of oxygen, pyruvate, produced during glycolysis is oxidised to acetate and 
subsequently converted to acetyl CoA in the first step in the TCA cycle (Jin et al, 2013).  
The TCA cycle is a series of chemical reactions which involves both the oxidation and 
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reduction of molecules. This series of reactions results in the release of free energy which 
is stored in oxidised electron carriers NAD+ and FAD (Sharma et al, 2005). These 
molecules go through a process called oxidative phosphorylation in which, electron 
carriers are oxidized and ATP is formed (Sharma et al, 2005). The TCA cycle is a continual 
process and products are constantly re-entered into the cycle. The cycle is regulated by 
the concentrations of starting materials, for example, oxygen. The TCA cycle is commonly 
linked to hypoxic responses and some of its products are thought to regulate expression 
of hypoxia signalling factors (Suda et al, 2011). Considering that a metabolic switch to 
glycolysis is a major response to hypoxia, it is logical that alternative metabolic processes 
would be involved in controlling this adaptation. 
A recent study conducted by Simsek et al looked at the metabolic profile of stem 
cells and found that HSCs could be characterised by this distinctive profile (Simsek et al, 
2010). Furthermore, HSC populations can be enriched based on their metabolic status. 
The study showed that LT-HSCs have lower levels of mitochondrial respiration, which is 
likely attributed to the utilisation of glycolysis and the lower energy requirements of the 
cell. This study also showed that LT-HSCs had a higher rate of glucose-derived 13C lactate, 
a product of glycolysis, which is further evidence of a metabolic shift to glycolysis. 
Furthermore, HSCs showed a significant up regulation of numerous hypoxia related genes 
including Bax, Tgfb1, Notch1 and Epo (Simsek et al, 2010). This suggests that the 
induction of hypoxia related genes may be responsible for the metabolic shift of HSCs and 
that these are likely to be essential for the maintenance of HSCs. 
 
1.2.5 Studying HSCs and the hypoxic niche 
Although HSCs may appear to be hypoxic, their residence within the hypoxic niche 
has been challenging to explore and is not confirmed. This is due to a lack of techniques 
available, capable of achieving live imaging of the bone marrow cavity and the cells within 
it. The expression of HIF-1α is commonly used as to indicate hypoxia conditions as it is a 
vital component in hypoxic adaptation. However, a recent study conducted by Nombela-
Arrieta et al has highlighted the controversies surrounding the hypoxic nature of HSCs and 
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how HIF-1α expression may not be an accurate indication of hypoxia (Nombela-Arrieta et 
al, 2013).  In this study, Nombela-Arrieta et al utilized hypoxic marker pimonidazole 
(PIMO), which forms adducts under hypoxic conditions. Detection of hypoxia by PIMO 
staining was combined with real time imaging of HSCs within the bone marrow. Results 
showed that HSCs are not always in hypoxic regions as was originally proposed and that 
their distribution throughout the bone marrow cavity was random. They also stained for 
HIF-1α and showed that HSCs expressed HIF1-α regardless of their proximity to hypoxic 
regions (Nombela-Arrieta et al, 2013). However, regardless of the requirement for 
hypoxic conditions, the ability of HSCs to adapt to hypoxic conditions is essential for their 
survival (Takubo et al, 2012). 
 
1.3 The Hypoxia Signalling Network 
Hypoxia can affect cellular function and behaviour in a number of ways; however, 
it is needless to say that cells require oxygen to survive and that cells that reside within 
hypoxia must have the ability to adapt to low oxygen environments. The hypoxia 
signalling pathway contains several components that are thought to be essential for 
normal cellular function and survival in hypoxic environments.  
1.3.1 Hypoxia signalling 
Hypoxic adaption is mediated by the HIF, which facilitates transcription of hypoxia 
response genes. HIF is known to be responsible for the transcriptional activation of 
approximately 100-200 genes that aid hypoxic adaptation including genes involved in 
erythropoiesis, angiogenesis, autophagy and glycolysis (Kaelin & Ratcliffe, 2008).  
HIF proteins exist as an unstable alpha subunit (HIF-1α or HIF-2α) located in the 
cytoplasm, and a stable beta subunit (HIF-1β or HIF-2β), located within the nucleus.  In 
environments of low oxygen or hypoxia, HIF-1α and HIF-2α are stabilised, allowing them 
to translocate to the nucleus, where they bind to HIF-1β and HIF-2β respectively. The 
dimerization of HIF subunits allows HIF to recruit transcriptional coactivators p300/CBP 
and PKM2, which interact with two transactivation domains N-terminal transactivation 
domain (NTAD) or, and or C-terminal transactivation domain (CTAD) (Kaelin, 2005; 
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Schofield & Ratcliffe, 2004; Greer et al, 2012). This interaction allows HIF to bind 
conserved DNA sequences known as hypoxia response elements (HREs), inducing the 
transcription of the genes needed to facilitate hypoxic adaptation such as VEGF and EPO 
(Metzen et al, 2002).  
 
(Figure adapted from Greer et al, 2012) 
Figure 1.6. Hypoxia signalling by hypoxia inducible factors (HIFs). 
Cellular adaption to hypoxic conditions is mediated by the hypoxia signalling pathway. Hypoxia 
inducible factors (HIFs), are transcription factors that bind to hypoxia response elements (HREs) to 
induce the transcription of hypoxia response genes. HIF proteins exist as an unstable alpha 
subunit (HIF-α) and stable beta subunit (HIF-β). Under hypoxic conditions, HIF-α is stabilised, 
allowing it translocate to the nucleus and dimerise with HIF-β. This dimerisation allows HIF to bind 
HRE regions as well as co-factors, in order to facilitate transcription of the genes required for 
hypoxic adaptation. 
 
When oxygen is freely available (under normoxic conditions), hypoxia signalling 
and therefore HIF expression, is not required and must be repressed. A family of prolyl 
hydroxylase domain (PHD) proteins can post translationally modify HIF-α, affecting the 
stability of the alpha subunit and preventing its dimerisation with the beta subunit.  
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PHDs (also called EglN or HPH family),  exist as a family of oxygen-, Fe2+- and α-
ketoglutarate (also called 2-oxoglutarate), -dependent family of dioxygenases that can 
split molecular oxygen and utilize it in the addition of oxygen molecules to target 
substrates, marking them for recognition by other components (Schofield & Zhang, 1999; 
Takubo et al, 2010). PHD can hydroxylate specific, highly conserved proline residues in the 
oxygen dependant domain (ODD) of the HIF alpha subunits, marking HIF for degradation 
(Jaakkola et al, 2001; Ivan et al, 2001; Yu et al, 2001).  
The protein structure of PHD contains a two-histidine-one-carboxylate facial triad 
which facilitates a catalytic iron centre. This provides two free positions that can bind 
both 2-oxoglutarate and molecular oxygen simultaneously. Oxygen molecules are split 
from the co-substrates, one of which is used in the oxidative decarboxylation of 2-
oxoglutarate forming succinate and CO2. The other oxygen atom forms highly reactive 
iron intermediate Ferryl (Feiv=O), which binds and oxidises proline residues on HIF-α. PHD 
also requires ascorbate to complete hydroxylation, which is thought to reduce the levels 
of catalytic iron that are left uncoupled if HIF-α is not oxidised. This allows PHDs iron 
centre to remain oxidised and inactive (Kaelin et al, 2002; Schofield & Zhang, 1999). 
Hydroxylation of Pro-402 and Pro-564 enables von-Hippel Lindeu protein (pVHL) to form 
two hydrogen bonds with HIF-α, allowing it to bind strongly (Hon et al, 2002; Min et al, 
2002). pVHL is an E3 ubiquitin ligase, which catalyses the polyubiquitination and 
proteasomal degradation of HIF-α. 
 
1.3.2 Regulation of hypoxia signalling  
PHDs are often considered to be oxygen sensors and are key factors in the 
induction of hypoxia signalling and the cells tolerance to hypoxic conditions (Safran & 
Kaelin, 2003; Schofield & Ratcliffe, 2004). Therefore, the regulation of the hypoxia 
signalling pathway, often involves the regulation of PHD. PHDs dependence on co-factors 
helps to regulate the hydroxylation activity of PHD and therefore, the activation of the 
hypoxia signalling pathway. PHDs are active in normoxic conditions due to the availability 
of oxygen, which is an essential substrate for PHD activity (Kaelin, 2008). Several 
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intermediates of the Kreb cycle are also thought to regulate the activity of PHD including 
citrate, succinate, fumarate, malate, oxaloacetate and pyruvate (Kaelin & Ratcliffe, 2008). 
These metabolic products are only produced when oxygen is available and when PHD 
activity is required to prevent activation of the hypoxic pathway and so their 
concentrations are closely linked to PHD activity. α-Ketoglutarate, also named 2-
oxogluterate, is an intermediate product of the Kreb cycle and is also an essential 
substrate in the hydroxylation reaction. In hypoxia, the Kreb cycle does not take place and 
α-ketoglutarate is not produced. The absence of α-ketoglutarate inhibits PHD activity and 
allows HIF-α to stabilise, activating the hypoxic response and facilitating a metabolic 
switch to glycolysis (MacKenzie et al, 2007).  
Fumarate is well known to inhibit PHD activity and is thought to outcompete α-
ketoglutarate binding, preventing the hydroxylation reaction. Fumarate hydratase (FH) is 
the enzyme responsible for the production of fumarate. FH mutations are frequently 
linked to cancer. (Sudarshan et al, 2011). In cells carrying FH mutations, fumarate 
accumulates in the cell and inhibits PHD. This leads to the stabilisation of HIF which is 
commonly associated with poor prognosis (Sudarshan et al, 2011). Succinate is also an 
inhibitory factor of PHD activity. Succinate is a product of the hydroxylation reaction and 
is produced by PHD in a negative feedback loop in which PHD can regulate its own activity 
(Kaelin & Ratcliffe, 2008). Defects in the enzyme succinate dehydrogenase (SDH) have 
also been linked to cancers, with an accumulation of succinate leading to over 
stabilisation of HIF (Mackenzie et al, 2007; Pollard et al, 2005; Selak et al, 2005).  
Reactive oxygen species (ROS) can inhibit PHD, although the mechanism through 
how ROS acts is unclear. It is suspected that this is through direct inhibition of PHD or 
through the up regulation of Kreb cycle intermediates (Kaelin & Ratcliffe, 2008). Nitric 
oxide (NO) is known to stabilise HIF through direct inhibition of PHD. Interestingly, 
inducible nitric oxide synthase (iNOS) is a HIF target gene, creating a negative feedback 
loop and helping to provide tight regulation of HIF expression (Kaelin & Ratcliffe, 2008).  
Meis1 has also been linked to the regulation of the hypoxia signalling pathway. 
Simsek et al provided several lines of evidence which suggested that Meis1 may regulate 
the expression of HIF-1 (Simsek et al, 2010). This study identified an evolutionary 
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conserved Meis1 binding site with the sequence of HIF-1. Furthermore, when siRNA was 
used to knock down Meis1 expression, HIF-1 expression also showed a significant down 
regulation (Simsek et al, 2010). This suggests that hypoxia signalling may also be 
regulated by Meis1, a factor which is known to have a role in regulating normal 
haemopoiesis. 
 
(Figure taken from Chan & Giaccia, 2010) 
Figure 1.7. Regulation of hypoxia signalling by PHD. 
Prolyl hydroxylases (PHDs) can hydroxylate 2 conserved proline resides on the HIF-α subunit. 
Hydroxylated proline resides can then be recognised by E3 ubiquitin ligase VHL, resulting in HIF-α 
becoming polyubiquitinated and marking it for proteasomal degradation. PHD activity is known to 
be dependent on oxygen, Fe2+, ascorbate and 2-oxoglutarate which are cofactors in the 
hydroxylation reaction which also results in the formation of CO2 and succinate.  
 
1.3.3 Multiple isoforms of HIF 
HIF proteins exist as heterodimers composed of an α and β subunit. These 
subunits are part of a basic Helix-Loop-Helix PER-ARNT-SIM (bHLH-PAS) family of 
transcription factors. In lower animals such as C.elegans and drosophila, only one isoform 
of HIF exists. (Greer et al, 2012) However, in higher animals, there are three isoforms of 
HIF proteins, HIF-1, HIF-2 and HIF-3. In humans, HIF proteins are encoded for by 
34 
 
conserved genes namely HIF1A (encodes HIF-1), EPAS1 (encodes HIF-2) and HIF3A, which 
encodes multiple splice variants of HIF-3 (Xia et al, 2012). 
The existence of three conserved HIF genes, suggests that the translated proteins 
have distinct, non-overlapping functions.  HIF-1 and HIF-2 have been extensively studied 
and there is a lot a literature available concerning the individual properties and functions 
of these proteins (Holmquist-mengelbier et al, 2006; Hu et al, 2006; Ravel et al, 2005). 
Specific HIF-1 target genes, as well as exclusive HIF-2 target genes have been 
identified, suggesting distinct functions between HIF-1 and HIF-2. However, HIF-1 and 
HIF-2 have also been shown to have some overlapping targets. The selectivity of HIF 
target genes is thought to involve the HRE sequences in the CTAD to which HIF proteins 
bind (Holmquist-mengelbier et al, 2006). Differences in HIF induced gene transcription 
may also be related to cell type, as well as hypoxic conditions. HIF-1 is seen to be 
ubiquitously expressed, however HIF-2 transcripts are seen to be enriched in particular 
cell types such as vascular endothelial cells, kidney fibroblasts, hepatocytes and glial cells 
(Hu et al, 2006; Park et al, 2003).  
Studies by Stroka et al detected the stabilisation of HIF-1α detected in various 
tissues of mice which were exposed to moderate levels of hypoxia. Immunohistochemical 
analysis of brain, kidney, liver, heart, and skeletal muscle showed that HIF-1α 
stabilisation differed between the tissues and was dependant on the length of exposure 
and the oxygen concentration (Stroka et al, 2001). Bracken et al preformed studies using a 
variety of non-haemopoietic cell lines showing that HIF1-α was stabilised in the cell lines 
between 4 and 24 hours following exposure to hypoxia. However, Bracken et al also 
observed that HIF-1α induction varied between cell lines (Bracken et al, 2006). This study 
showed that HIF-1α was highly expressed in 293T cells following 2% oxygen exposure, 
although HIF-1α expression was still detected at 5%. These studies suggest that HIF 
protein expression and hypoxic response is cell specific and may relate to differences in 
the cells’ sensitivity to hypoxia. 
Bracken et al also investigated the stabilisation of HIF-2α protein, which was also 
observed in all cell lines tested (Bracken et al, 2006). Maximal expression of HIF-2α was 
35 
 
detected following exposure to 1% oxygen and similar cell-specific differences were seen 
as with HIF-1α stabilisation. However, although a 4 hour hypoxia treatment was sufficient 
for HIF-1α detection, this was insufficient to stabilise HIF-2α and a prolonged exposure of 
16 hours was required (Bracken et al, 2006). This suggests that although HIF-1α and HIF-
2α are stabilised under similar conditions, the kinetics of their response differs.   
Little is known regarding the functions of lesser known HIF-3 although several 
splice variants have been described. HIF-1 and HIF-2 both contain two transactivation 
domains (NTAD and CTAD, as described earlier) (Kaelin & Ratcliffe, 2008). However, some 
splice variants of HIF-3 are lacking transactivation domains are and thought to act as 
dominant-inhibitory factors in the transcriptional activity of HIF-1 and HIF-2 (Kaelin & 
Ratcliffe, 2008). An alternative splice product of HIF-3 termed iPAS, has been seen to bind 
and inactivate HIF-1 (Makino et al, 2002). iPAS is a target of HIF-1, suggesting a negative 
feedback loop that helps regulate HIF responses (Makino et al, 2002).  
 
1.3.4 Non-hypoxic roles of HIF  
Although HIF is best known for its role in hypoxic adaptation, it has been 
associated with the activation of several major signalling pathways including the Notch 
(Gustafsson et al, 2005), Wnt (Kaidi et al, 2007) and Myc pathways (Koshiji et al, 2004). 
Studies have shown that HREs can interact with Myc binding sites. HIF-1, but not HIF-2, 
has also been to shown to bind Myc directly, preventing it from binding certain promoters 
(Gordan et al, 2007; Koshiji et al, 2004). This leads to Myc-dependent genes such as those 
encoding cyclin D2 and E2F being down regulated, and Myc-repressed genes p21 and p27 
being upregulated. These genes are important factors in the regulation of the cell cycle, 
which implies a regulatory role for HIF in the cell cycle. Non-hypoxic roles of HIF-2 have 
also been identified. HIF-2 has been shown to repress transcription of cyclin D1 and TGFα, 
which are essential for cell growth (Kim & Kaelin, 2006). HIF may also have a role in 
differentiation. HIF-1 is shown to interact with Notch in hypoxic muscle cells to help 
maintain an undifferentiated phenotype (Gustafsson et al, 2005). HIF-2 is shown to 
repress Oct4, an essential gene in cell differentiation (Covello et al, 2006). Oct4 is one of 
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four factors used in the generation of induced pluripotent stem (iPS) cells. The role of HIF 
in the differentiation of stem cells and the reversion of mature cells to a more stem-like 
state is currently being investigated. 
The requirement for HIF during development has been investigated in studies 
using C.elegans and drosophila as model organisms (Centanin et al, 2005; Jiang et al, 
2001). Inactivation of HIF from these systems allowed the development to adult life, but 
with only a partially functional oxygen deliver system. However in mammalian 
development, hypoxia and hypoxia signalling is considered a signal in the developmental 
process and the deletion of HIF can cause severe developmental abnormalities (lyer et al, 
1998; Ryan et al, 1998). Mouse embryos are known to contain regions of severe hypoxia 
(Lee et al, 2001). Differences in HIF-2 activity are seen during development. In studies 
using mouse embryonic stem cells, HIF-2 appeared to bind HREs but did not transactivate 
them (Hu et al, 2006). Interestingly, when HIF-2 was overexpressed in these cells, 
transcription of target genes was achieved. This suggests that HIF-2 is being repressed, 
where HIF-1 transactivation of target genes is preferential (Hu et al, 2006). 
 
1.3.5 Multiple isoforms of PHD 
PHD was first discovered as a single isoform that was identified in drosophila and 
C.elegans, namely dHPH in drosophila and EGLN or EGLN-9 in C.elegans (Fong & Takeda, 
2008). However, in mammalian cells, four isoforms of the PHD has been discovered - 
PHD1, PHD2, PHD3 and PHD4. Belonging to the same gene family as EGLN-9, these 
mammalian isoforms are also sometimes referred to as EGLN1, EGLN2, EGLN3 and HPH-4 
(Metzen et al, 2002). Few studies have been published regarding the specific functions of 
PHD4, however it is reported to play a role in the regulation of HIF (Bruik et al, 2001). 
However, PHD1, PHD2 and PHD3 have been more fully characterised and many studies 
have been concluded, reporting multiple biological roles of each isoform, each with 
distinct functions and specificities for HIF, although all three isoforms are reported to play 
a role in hypoxia signalling regulation (Takeda et al, 2008; Nytko et al, 2011). PHD1 and 
PHD3 are known to be more active in the regulation of HIF-2α, whereas PHD2 is best 
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known for its role in the regulation of HIF-1α and is often considered to be the most 
critical regulator of hypoxia signalling (Appelhoff et al, 2004). In cell based studies by 
Takeda et al, it was seen that PHD2 deficiency in the liver and kidney of mice, resulted in 
the accumulation of HIF-1α but not HIF-2α (Takeda et al, 2007). Further studies by this 
group also showed that an accumulation of HIF-2α was seen in the kidneys of mice that 
were deficient in both PHD1 and PHD3 (Takeda et al, 2008). However, it is unclear as to 
whether PHD isoforms can compensate for each other. A study by Berra et al recently 
gave some insight into compensatory functions of PHD in hypoxic regulation. This study 
used siRNA to ablate each PHD isoform individually, in order to assess the effect of HIF 
expression and function, based on luciferase activity. The study showed that ablation of 
PHD2 allowed the accumulation of HIF-1α, which remained fully functional, suggesting 
that PHD1 and PHD3 were not able to compensate for the hypoxic regulation of PHD2 
(Berra et al, 2003). Furthermore, ablation of PHD1 and PHD3 did not affect the 
degradation of HIF-1α or the mRNA levels of PHD2, further suggesting that only PHD2 is 
essential for hypoxic regulation of HIF-1α (Berra et al, 2003). However, this study did not 
investigate the effect of PHD ablation on HIF-2α, which is thought to be preferentially 
regulated by PHD1 and PHD3. Differential regulation of specific HIF isoforms may also be 
linked to the sensitivity of PHDs to oxygen levels. As previously discussed, many of the 
factors regulating the activity of PHD are related to the availability of oxygen and the 
induction of hypoxia signalling. However, PHD isoforms have been shown to have 
different tolerances to hypoxia and may even have some activity under hypoxic 
conditions. In a study by Metzen et al, PHD2 and PHD3 were both seen to be induced 
following exposure to hypoxia. The mRNA levels of PHD isoforms were measured 
following exposure to hypoxia, suggesting that both PHD2 and PHD3 may limit the activity 
of HIF in both normoxic and hypoxic conditions (Metzen et al 2002). 
PHD isoforms are also seen to have differences in their expression patterns of the 
three isoforms. The study conducted by Metzen et al also identified the localization of 
PHD isoforms by fusing GFP tags to PHD proteins. PHD2 was seen to be mainly localised in 
the cytoplasm, whereas PHD1 was seen to be exclusively nuclear. PHD3 was found to be 
expressed in both the cytoplasm and the nucleus but at very low levels (Metzen et al 
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2002). However, in a separate study by Huang et al, PHD3 was seen to localise 
predominantly in the cytoplasm (Huang et al, 2012). The disagreement between these 
studies may be reflected in the observation that the expression levels of PHD are also 
known to differ between cell types. Although PHDs are known to be widely expressed, 
some cell types have higher levels of expression and may produce different results in cell 
based experiments. For example, the study by Metzen showed that expression levels of 
PHD3 were barely detectable in HeLa cells by qPCR, whereas, PHD3 is known to be 
expressed at high levels in the heart (Kaelin & Ratcliffe, 2008). PHD1 mRNA levels are also 
reported to be more highly expressed in the testes. It is likely that the higher expression 
seen in these cells types may be related to the non-hypoxic functions of these proteins. 
 
1.3.6 Non-hypoxic roles of PHD 
PHDs are also known to function in a HIF-independent manner, where they can 
regulate the expression of target proteins, with or without hydroxylation (Hiwatashi et al, 
2011). As well as hypoxia signalling, PHDs have been linked to several cellular functions 
including proliferation, metabolic regulation and angiogenesis (Hiwatashi et al, 2011), 
although much more work needs to be done in this area to define the functions of these 
proteins.  
PHD1 and PHD3 have been seen to regulate ATF-4 (Koditz et al, 2007). ATF-4 is 
known to be induced following ER stress, oxidative stress and amino acid deprivation 
(Hiwatashi et al, 2011). ATF-4 induces transcription of many genes involved in apoptosis, 
mitochondrial function and redox balance and its regulation by PHD creates a possible 
role for PHD in these processes. Studies conducted by Koditz et al utilized a yeast-2-hybrid 
system to identify novel interactions of PHD proteins. Their results showed an interaction 
between PHD1 and ATF-4 and PHD3 and ATF-4, a member of the ATF/CREB family of 
transcription factors which are known to induce transcription of stress response genes 
(Koditz et al, 2007). Koditz et al also reported that HeLa cells which were treated with 
dimethyloxaloylglycine or DMOG, a PHD inhibitor, or exposed to hypoxia, showed an 
increase in ATF-4 activity, suggesting that PHD negatively regulates ATF-4. In support of 
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this finding, they also showed that when cells exposed to hypoxia were reoxygenated, 
ATF-4 was quickly degraded. Hiwatashi et al confirmed the interaction between PHD3 and 
ATF-4 by performing an immunoprecipitation assay using tagged AFT-4. They showed that 
PHD3 co-precipitated with ATF-4, suggesting a direct interaction between the two 
proteins (Hiwatshi et al, 2011). Furthermore, they also showed an interaction between 
PHD1 and ATF-4 through co-precipitation. However, this study showed that ATF-4 did not 
act as a substrate for PHD. They proposed that ATF-4 regulation did not involve direct 
hydroxylation and that it was possible that another unidentified molecule was involved 
(Hiwatshi et al, 2011). It has recently been suggested that ATF-4 may play a role in cancer 
progression. A recent study showed that blocking ATF-4 expression blocked tumour 
growth, suggesting a possible role for PHD in cancer (Kumanoua et al, 2010). 
PHD has also been associated with the NF-κβ pathway which is known to play a 
role many biological processes, proposing a possible role for PHD in apoptosis, 
differentiation, proliferation and immune responses (Fu & Taubman, 2010). PHD3 is seen 
to be upregulated during myogenic differentiation and its expression is thought to 
promote skeletal muscle differentiation by negatively regulating NF-κβ (Fu & Taubman, 
2010). Studies by Fu et al have shown that cells treated with DMOG PHD inhibitor had 
enhanced activation of the NF-κβ signalling pathway. The induced expression of NF-κβ 
target genes YY1 and Cyclin D1 was also seen (Fu et al, 2007).  The induction of Cyclin D1 
has been proposed as a possible mechanism by which NF-κβ negatively regulates 
myogenesis. PHD1 has also been reported to bind and inhibit Iκκβ, which is known to 
regulate NF-κβ activity (Cummins et al, 2006).PHD3 has been seen to be a negative 
regulator of NF-κβ in colon adenocarcinoma cells. It is suspected that PHD3 mediates 
apoptosis in neutrophils at least partially through the NF-κβ signalling pathway (Fu et al, 
2007; Fu & Taubman, 2010). 
PHD3 is well known to play a role in the regulation of cell death (Lee et al, 2005).  
In studies using synthetic neurons, PHD3 expression is seen to be upregulated during the 
stress-induced response of cells, following the withdrawal of nerve growth factor (NGF) 
(Lipscomb et al, 1999). Lipscomb et al also showed that PHD3 is required for neural 
apoptosis during development. Studies using a catalytically inactive mutant of PHD3 also 
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showed that cell death is dependent on the hydroxylation activity of PHD (Lipscomb et al, 
1999). The mechanism by which PHD3 regulates apoptosis is not fully understood. 
Although, it has been proposed that this may involve the regulation of kinesin family 
member 1B-β (KIF1B-β), which is involved in apoptosis (Schlisio et al, 2008). However, 
under hypoxic conditions PHD3 may play a contradictory role in regulating apoptosis in 
other cell types. Walmsley et al showed that apoptosis was increased in neutrophils 
under hypoxic conditions in PHD3-/- mice. An increase in pro-apoptotic factor Siva-1 and a 
down regulation of anti-apoptotic factor Bcl-xl was also seen (Walmsley et al, 2011).  
PHD2 has also been linked to the regulation of cell death in cardiac cells. 
Natarajan et al performed ischemia-reperfusion in murine hearts, which resulted in large 
infarcts forming due to extensive cell death. The study showed that PHD2 knockdown in 
cardiac cells reduced infarct sizes, suggesting that PHD2 may promote cell death in the 
heart (Natarajan et al, 2006). 
A role for PHD3 in proliferation has also been proposed. Hogel et al showed that 
PHD3 deficiency in several different cell lines including HeLa cells and primary squamous 
carcinoma cell lines, resulted in the inhibition of cell growth under hypoxic conditions. 
Cell cycle arrest at G1 was seen in cells, as well as an upregulation of negative cell cycle 
regulator p27/Kip (CDKN1B) (Hogel et al, 2011). Interestingly, PHD3 ablation did not 
appear to affect cell growth under normoxic conditions. 
 
1.3.7 The requirement of hypoxia signalling in HSCs 
It has long been believed that HSCs reside in hypoxia and therefore, hypoxia 
adaptation and HIF expression are essential. However, recent studies by Nombela-Arrieta 
et al showed that HSCs do not always reside in hypoxic regions but do express HIF-1α 
(Nombela-Arrieta et al, 2013). This suggests that although the role of hypoxia in HSC 
maintenance has been challenged, the expression of HIF-1α in HSCs throughout the bone 
marrow does suggest an important role for HIF-1α in HSC maintenance. In accordance 
with this, a study by Takubo et al provided evidence that HIF-1α is essential for the 
maintenance of HSCs (Takubo et al, 2012). This study analysed the mRNA expression of 
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HIF-1α, HIF-2α and HIF-3α in different populations within the stem cell compartment. 
They found that all 3 isoforms of HIF-α were highly expressed in LT-HSCs compared to 
other haemopoietic populations. Next the study aimed to identify the role of HIF-1α in 
the maintenance of HSCs through the conditional deletion of HIF-1α in the haemopoietic 
system. A bone marrow reconstitution assay was used to determine the effect of HIF-1α 
deletion on reconstitution ability. Upon initial analysis, HIF-1α-/- cells appeared to have 
improved chimerism, as determined by the frequency of donor derived cells in the 
peripheral blood, compared to host cells. A significant increase in the transcription of 
Ink4a, a marker for senescent stem cells, indicated that this may be attributed to 
increased proliferation although a correlation between these factors was not examined. 
Analysis at 4 months post transplantation indicated that HSC levels had decreased, 
suggesting that HSCs are not able to sustain long-term maintenance in the absence of 
HIF-1α due to senescence-induced exhaustion. Furthermore, upon secondary 
transplantation of LSK cells, HIF-1α-/- cells were unable to reconstitute the haemopoietic 
system. To analyse the impact of Ink4a upregulation on HSC maintenance, cells were 
transduced with Bmi retrovirus which causes repression of Ink4a. This restored the ability 
of HIF-1α-/- cells to reconstitute the bone marrow, suggesting that HIF-1α plays a role in 
protecting HSCs from exhaustion by mediating Ink4a gene products. Interestingly, Takubo 
et al also showed that HIF-1α overexpression, through the deletion of negative regulator 
VHL, caused a loss of stem cell capacity in vivo, suggesting that a tight regulation of HIF-
1α is required for the maintenance of HSCs.  
However, recent studies by Guitart et al have suggested that HIF-2α may not be 
required for HSC maintenance. Mice lacking expression of HIF-2α in the haemopoietic 
system were used to determine if HIF ablation affects the HSCs ability to maintain multi-
lineage haemopoiesis. Bone marrow was analysed by flow cytometry to identify the 
frequency of mature lineage cells such as T cells, B cells and erythroctyes. Results showed 
that ablation of HIF-2α or both HIF-1α and HIF-2α had no effect on the generation of 
progenitor cells. Furthermore, frequencies of LT-HSCs and ST-HSCs were unaffected, 
suggesting that HIF-2α is not required for HSC maintenance or function (Guitart et al, 
2013). However, in this model, HIF-2α deletion was only in haemopoietic cells and 
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remained functional within the bone marrow niche, posing the question if HIF-2α 
expression within the niche is required for HSC maintenance. In another mouse model, 
HIF-2α is conditionally deleted in all cells following injection with Poly(I) Poly(C) which 
induces deletion of the target gene. Bone marrow from HIF-2αfl/fl mice was transplanted 
to recipient mice to assess the ability of HSCs to reconstitute the haemopoietic system. 
Results showed that mice injected with bone marrow lacking HIF-2α expression in the 
entire bone marrow had a significant reduction of LT-HSCs, suggesting that HIF-2α is 
required for long term maintenance of HSCs in a non-cell autonomous manner 
(Unpublished by Guitart et al). 
The requirement of PHD in HSC maintenance is unclear. It has recently been 
published that PHD2 has an essential role in the maintenance of HSCs (Singh et al, 2013). 
Singh et al utilized a mouse model in which PHD2 was conditionally deleted throughout 
the haemopoietic system. They reported that conditional knockout (cKO) mice had almost 
50% more LSK cells in the bone marrow compared to WT mice. Similarly, they found a 
significant increase in the frequencies of MPPs. Singh et al also investigated the 
proliferation rate of LSKs and found that cKO LSKs showed a higher rate of actively cycling 
cells compared to WT LSKs. Following analysis of apoptotic frequencies, no differences 
were seen between the genotypes. They also found a significant induction of SMAD7, 
which promotes cell cycle progression through inhibition of TGF-β. Next the group 
examined if this phenotype was dependent of HIF by generating a mouse model deficient 
for both PHD2 and HIF-1α. They found that the ablation of HIF-1α abolished the 
phenotype seen in cKO mice and LSK and MPP frequencies were similar to WT 
counterparts. This study also examined the effect of PHD2 ablation under stressful 
conditions. Competitive bone marrow transplantation was performed in which, cKO or 
WT LSK cells (CD45.2) are transplanted alongside CD45.1 competitor cells, to lethally 
irradiated mice. Recipient bone marrow was analysed 4 weeks after transplantation. cKO 
donor cells showed significantly lower chimerism compared to WT cells, showing that 
PHD2 deficient LSKs had a diminished ability to repopulate. These data show that PHD 
ablation leads to increased proliferation under steady state conditions and a diminished 
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reconstitution ability under stressful conditions. This suggests that PHD2 does play a role 
in maintaining the stem cell compartment in a HIF-1α dependent manner. 
However, work conducted by Guitart et al have not been able to confirm these 
results, casting uncertainty on the reliability of this study and on the requirement of PHD 
in HSC maintenance. Unpublished studies by Guitart et al analysed the stem cell 
compartment of mice lacking PHD2 within the haemopoietic system to identify if PHD2 
had a role in haemopoiesis. Results showed that mice lacking PHD2 had frequencies of LT-
HSCs, ST-HSCs and MPPs which were comparable to WT mice, suggesting that PHD2 is not 
required for the maintenance of the stem cell compartment. Competitive bone marrow 
transplantation assays were also conducted where PHD2fl/fl bone marrow was 
transplanted to recipient mice. PHD2fl/fl bone marrow was seen to successfully 
reconstitute the bone marrow of the recipient mice suggesting that the reconstitution 
ability of HSCs is unaffected by PHD2 ablation (Unpublished by Guitart et al). The 
contradictory results seen in these 2 studies means that the role of PHD2 in HSC 
maintenance is still unclear and that more work needs to be undertaken in order to 
confirm this. 
 
1.3.8 Hypoxia signalling in disease 
The mammalian system must have the ability to adapt to hypoxic conditions by 
increasing the efficiency of oxygen delivery and reducing the consumption of oxygen, in 
order for cells to survive in low oxygen conditions. Hypoxic adaptation induces various 
biological processes that help cells to adapt including angiogenesis, glycolysis and 
erythropoiesis. These are tightly regulated processes and it stands to reason that a defect 
in the regulation of hypoxia signalling, such as up or down regulation of PHD, could have 
effects on these hypoxia-sensitive functions. This is particularly crucial when there has 
been significant tissue damage, or in organs where large, constant supplies of oxygen as 
required, for example, the heart. It is for this reason that PHD and HIF isoforms have 
received much attention for their potential as therapeutic targets.  
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As previously discussed, erythropoiesis is a tightly regulated process which 
produces red blood cells, through stimulation by EPO (Rankin et al, 2007). EPO is a well-
known HIF target gene suggesting that the regulation of erythropoiesis is closely linked to 
the regulation of hypoxia signalling. A defect in the regulation of erythropoiesis can cause 
a decrease in the production of red blood cells in conditions such as anaemia. 
Overexpression of PHD has also been reported in anaemia, likely caused by over-
degradation of HIF and a decreased production of EPO (Minamishima & Kaelin, 2010). 
Polycythaemia is a condition that results in the overproduction of red blood cells 
and which has been associated with the overexpression of HIF, resulting from the ablation 
of PHD genes. Studies by Takeda et al investigated the role of PHD1, PHD2 and PHD3 
individually in the regulation of erythrocytosis, an increase in red cell mass. They found 
that mice lacking PHD1 and PHD3 together had significantly increased numbers of RBCs. 
Interestingly, mice lacking single isoforms of either PHD1 or PHD3 had no apparent 
differences in blood production. However, mice lacking PHD2 (PHD2 cKO) showed signs of 
severe polycythaemia with increased blood counts and dramatically increased levels of 
EPO and HIF-1α (Takeda et al, 2008). In a separate study conducted by Rankin et al, mice 
were treated with PHD inhibitor DMOG to assess the effect on erythropoiesis. The study 
also showed that HIF was stabilized following treatment with DMOG and EPO production 
was increased. However, this same result was seen in mice lacking VHL, suggesting that 
HIF stabilisation, rather than PHD ablation, is responsible for increased EPO production 
(Rankin et al 2012). It has also been reported that PHD2 mutations have been identified in 
patients with increased erythropoiesis and polycythaemia (Percy et al, 2007). This was 
also confirmed by studies using mice. However, in a study by Minamishima et al, they 
found that the mice that had increased red blood cell production due to inactivation of 
PHD2, died prematurely following the development of cardiomyopathy (Minamishima et 
al, 2008). 
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1.4 Leukaemic Development 
 
1.4.1 Acute myeloid leukaemia 
AML (Acute Myeloid Leukaemia) is a heterogeneous disease with over 100 genetic 
aberrations being linked to its development (Zuber et al, 2009). AML can be separated 
into subtypes which are based on morphological features of the disease as determined by 
the French-British classification method which was proposed by Bennett et al in 1976 (See 
Table 1). However, a more recent model proposed by the World Health Organisation uses 
more up to date techniques such as flow cytometry and molecular analysis to classify 
AML based on the identification of genetic aberrations through (See Table 2).  
AML emerges through the overgrowth of immature progenitors and haemopoietic 
cells in the bone marrow and peripheral blood known as blast cells. Current treatment for 
AML patients involves induction chemotherapy followed by further cycles of 
chemotherapy and stem cell transplantation (Zuber et al, 2009; Wunderlich et al, 2013; 
Pardee, 2012). However, patients show varied responses to treatment and in some 
subsets of AML, relapse is more common. Many AML patients achieve complete 
remission but relapse in this disease reduces mortality to a five year survival in just 50% 
of patients (Guinn et al, 2007). The median age of AML patients is 63 years old. This 
creates a further complication of many patients being ineligible for stem cell 
transplantation due to their age and the risks associated with surgery, reducing the rate 
of remission to just  11% (Guinn et al, 2007).  
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FAB 
classification 
Morphological features 
M1 Predominance of myeloblasts with <10% granulocytic differentiation 
M2 More than 30% myeloblasts with >10% differentiating granulocytes, NSE <20% 
M3a Hypergranular promyelocytes with numerous Auer rods on Wright-stain or CAE 
M3b A variant form showing cells with bilobed, multibed or reniform nuclei (NSE-
negative) and relative scarcity of hypergranular promyelocytes or of primitive 
cells with multiple Auer rods 
M4 Monocytic cells with >20% but <80% NSE-butyrate positivity 
M5 Monocytic cells with >80% NSE positivity 
M5a Monoblastic, poorly differentiated 
M5b Monoblastic, differentiated 
M6 More than 50% erythroblasts with >30% myeloblasts excluding the 
erythrothroid cells 
 
 (Table adapted from Neame et al,1986) 
 
Table 1.1. French-American-British classification of AML subtypes.  
The French-American-British (FAB) classification model was proposed in order to standardise the 
way that AML is classified to make it easier for results in different institutes to be compared. The 
FAB system classifies AML into subtypes based on morphological and cytochemical features of the 
disease. 
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WHO classification of AML 
AML with recurrent genetic abnormalities 
          AML with t(8;21)(q22;q22), (AML1/ETO) 
          AML with abnormal bone marrow eosinophils and inv(16)(p13.1q22) or  
……….t(16;16)(p13.1;q22), (CBFβ-MYH11) 
          Acute promyelocytic leukaemia with t(15;17)(q22;q12), (PML/RARα) and varients 
          AML with 11q23 (MLL) abnormalities 
AML with with multilineage dysplasia 
          Following MDS or MDS/MPD 
          Without antecedent MDS or MDS/MPD, but with dysplasia in at least 50% of 
……….cells in 2 or more myeloid lineages 
Acute myeloid leukaemia and myelodysplastic syndromes, therapy related 
          Alkylating agent/radiation–related type 
          Topoisomerase II inhibitor–related type (some may be lymphoid) 
          Others 
Acute myeloid leukaemia, not otherwise categorized 
     Classify as: 
          Acute myeloid leukaemia, minimally differentiated 
          Acute myeloid leukaemia without maturation 
          Acute myeloid leukaemia with maturation 
          Acute myelomonocytic leukaemia 
          Acute monoblastic/acute monocytic leukaemia 
          Acute erythroid leukaemia (erythroid/myeloid and pure erythroleukaemia) 
          Acute megakaryoblastic leukaemia 
          Acute basophilic leukaemia 
          Acute panmyelosis with myelofibrosis 
          Myeloid sarcoma 
 
(Table adapted from Vardiman et al, 2002) 
 
Table 1.2. World Health Organisation classification of AML subtypes.  
The World Health Organisation (WHO) classification method was proposed to categorise AML 
based on the genetic abnormalities found in various subgroups. Many of the criteria used in the 
FAB classification system is incorporated into the WHO method. However, this system also 
considers more recent advances in the identification of genetic changes through advancement of 
medical diagnostic techniques. 
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1.4.2 Cancer stem cells 
The existence of cancer stem cells (CSCs) is constantly debated but is well 
documented in AML. The cancer stem cell theory encompasses the idea that not all 
tumour cells are capable of initiating disease when transplanted. Rather, that there is a 
rare population of self renewing stem cell-like cells which are responsible for initiating 
disease. This was first seen when a single human AML cells was transplanted into SCID 
mice. Mice developed leukaemic disease that recapitulated human AML. The primitive 
cell that was responsible for initiating disease was termed the SCID leukaemia-initiating 
cell (SL-IC). Purification of these cells confirmed that SL-ICs were exclusively CD34+CD38-. 
(Lapidot et al, 1994). Further studies by this group also showed that SL-ICs are capable of 
differentiating in vivo to recapitulate the original disease, whilst maintaining self renewal 
capacity (Dick & Bonnet, 1997). Histochemical and flow cytometric analysis was 
performed to determine the differentiation of transplanted cells. NOD/SCID mice were 
transplanted with either sorted CD34+CD38- SL-ICs or unfractionated samples from AML 
patients. Bone marrow of mice transplanted with unfractionated cells showed 
undifferentiated leukaemic cells. However, bone marrow transplanted with CD34+CD38- 
SL-IC showed myeloblastic and monoblastic differentiation (Dick & Bonnet, 1997). 
Furthermore, upon serial transplantation to secondary recipients, CD34+CD38- SL-ICs 
successfully engrafted recipient bone marrow showing that cells had retained their self 
renewal capacity.  
 
1.4.3 Leukaemic stem cells 
As previously discussed, LSCs are responsible for initiating leukaemia. The self 
renewal capacity of LSCs, as well as similarities in phenotype, suggest that early leukemic 
mutations may arise in self renewing HSCs (Al-Hajj et al, 2004). The similar properties 
between HSCs and LSCs would mean that fewer mutations would be needed for the cell 
to achieve LSC status and leukaemic potential. The self renewal capacity of LSCs is an 
important characteristic of these cells which is not seen in non-LSCs. Much like the 
haemopoietic stem cell compartment, leukaemia is also considered to be organised into a 
hierarchy with LSCs having the potential to self renew and to generate leukaemic cells 
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(Bonnet & Dick, 1997). This difference in properties between LSCs and leukaemic blast 
cells has led to further studies, investigating if these differing properties have clinical 
relevance in diagnosis and may be potential therapeutic targets (Eppert et al, 2011). 
Studies by Eppert et al have identified an LSC-specific genetic signature that has been 
shown to be negatively correlated to patient outcome. This LSC-signature will be 
important in future work to identify novel therapies that can target LSC-specific genes, 
many of which are involved in the regulation of self renewal (Eppert et al, 2011). 
Furthermore, many mutations implicated in carcinogenesis have also been seen to be 
involved in the regulation of self-renewal including Wnt, Bmi-1, Notch and Sonic 
hedgehog signalling pathways (Al-Hajj et al, 2004).  However, the HSC origin of LSCs has 
been challenged by more recent genetic profiling of LSCs which has suggested that the 
transcriptional program expressed by LSCs is closer to that of embryonic stem cells (ESCs) 
rather than HSCs (Somervaille et al, 2009). The expression of ESC programs is seen in 
more mature progenitor cells suggesting that LSCs may arise from progenitors, rather 
than HSCs, (Somervaille et al, 2009). Furthermore, the immunophenotypic analysis of 
LSCs has also shown that this may be closer to the immunophenotype of granulocyte-
macrophage progenitors (GMP) rather than that of stem cells, leaving the cell of origin for 
LSCs widely debated (Goardon et al, 2011). It is possible, and generally accepted that pre-
LSCs may arise from haemopoietic stem and progenitor cells residing within the hypoxic 
niche in the bone marrow. Studies have indicated that LSCs may also interact with the 
same niche environment adopted by HSCs, in order to sustain their ability to self-renew 
(Lane et al, 2011). Studies following the localisation of transplanted human AML LSCs 
(CD34+CD38-) showed that LSCs preferentially home to the endosteal region, which is 
commonly thought of as hypoxic and is considered the prefer site for normal HSCs (Zhang 
et all, 2003; Calvi et al, 2003). Furthermore, LSCs were seen to continue residence within 
this region for up to 4 months following transplantation and during AML development 
within the bone marrow (Ishikawa et al, 2007). 
50 
 
                
                                                                                    
Figure 1.8. The origin of leukaemic stem cells from haemopoietic stem cells. 
Leukaemic stem cells (LSCs) are capable of initiating leukaemia. LSCs share many functional and 
immunophenotypical properties with HSCs. It has also been proposed that LSCs share properties 
with early progenitor cells and they are believed to originate from either stem cells or early 
progenitor cells. LSCs are responsible for the generation of leukaemic blast cells in the same way 
that HSCs are responsible for the generation of blood cells.  
 
1.4.4 Genetic factors in the development of AML 
Mixed lineage leukaemia (MLL) gene encodes a histone methyltransferase which is 
essential in embryonic development and haemopoiesis (Wang et al, 2011). Human AML is 
often associated with chromosomal translocations of MLL, which results in various MLL 
fusions that are often associated with poor survival rates and a higher risk of patient 
relapse following treatment (Glaser et al, 2011; Wang et al, 2011). Previous studies have 
identified 64 translocation partner genes, with which, MLL can fuse with to form fusion 
products such as MLLT3/AF9, MLLT1/ENL and MLLT10/AF10, all of which have been 
identified in human samples (Meyer et al, 2009). The fusion proteins that result from MLL 
translocations are known to induce AML development by acquiring novel biological 
functions. This often involves the constitutive activation of target genes, including 
Figure adapted from Reya et al, 2001. 
 
 
Mature blood 
cells 
Leukaemic 
cells 
51 
 
transcription factors, leading to dysregulation of gene expression. MLL fusions can result 
in the overexpression of multiple genes that are associated with AML including Meis1 and 
Hoxa9.  
 
1.4.5 Hoxa9 and Meis1 in AML development 
Hox genes are well known for the role they play in the development of AML and 
are reportedly upregulated in human AML (Eklund, 2011). Hoxa9 has been described as 1 
of 20 genes that distinguish AML from acute lymphoid leukaemia (ALL) (Dorsam et al, 
2004). Several Hox genes, including Hoxa9, are known to be target genes of MLL and the 
induction of Hoxa9 is common in MLL-induced leukaemia (Dorsam et al, 2004). In 
addition, MLL has been seen to bind to the promoter region of multiple Hox proteins 
(Eklund, 2011). The expression of Hoxa9 has been shown to correlate closely with 
treatment outcome and is associated with poor prognosis in AML patients (Hu et al, 2009; 
Dorsam et al, 2004). Hox genes are frequently overexpressed in MLL-leukaemias and are 
also involved in the self renewal of normal stem cells, making their dysregulation an 
advantageous target for leukaemic development (Wong et al, 2007). Numerous studies 
have shown that several Hox family members are dysregulated in cancers including lung, 
breast, colon, prostate and ovarian cancer (Kelly et al, 2011).  
The mechanism through which Meis1 and Hoxa9 induce leukaemia is unclear. 
However, studies have indicated that Meis1 may form complexes with other leukaemic 
factors such as Pbx1/2 (Wang et al, 2006). Meis1 and Pbx1/2 are also known to form 
complexes that help regulate the expansion of progenitors in normal haemopoiesis.  
These leukaemia-inducing complexes are thought to bind and activate promoters that are 
required for leukaemogenesis. The exact nature by which Meis1 and Hoxa9 interact is 
also unclear. However, Hox proteins are known to induce transcription of genes that are 
also regulated by Meis1. It is believed that Hoxa9 directly interacts with Meis1, forming 
complexes that regulate normal haemopoiesis and possibly leukaemogenesis (Wang et al, 
2006). 
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Meis1 and Hoxa9 are often used as tools to study the development of AML in 
mice. Bone marrow cells collected from mice can be transduced with Meis1 and Hoxa9 
oncogenic viruses, resulting in the over expression of these genes in bone marrow cells 
(Kroon et al, 1998; Wang et al, 2006). Bone marrow cells over expressing Meis1 and 
Hoxa9 can then be transplanted to lethally irradiated recipient mice. Transplanted 
recipient mice are known to develop AML that is similar to human AML within 2-6 months 
(Kroon et al, 1998; Wang et al, 2006; Gibbs et al, 2012). This allows a fast and efficient 
system in which to study the development of AML as well as the role of Meis1 and Hoxa9 
in leukaemogenesis. 
However in previous models, Hox dysregulation alone does not recapitulate MLL 
leukaemia (Wong et al, 2007). Studies by Wong et al showed that co-expression of Hoxa9 
with a known binding partner Meis1, significantly shortens the latency period of the 
disease as well as recapitulating many of the same features seen in MLL-AML (Wong et al, 
2007).  Similarly, Thorsteinsdottir et al showed corresponding results that show that 
Meis1 and Hoxa9 cooperate to induce disease similar to human MLL-AML and with a 
short latency (Thorsteinsdottir et al, 2001). Meis1 and Hoxa9 are frequently shown to be 
expressed together in patients with MLL-induced (Imamura et al, 2002; Huang et al, 
2012). Studies by Hu et al examined human leukaemia bone marrow samples. They found 
correlated expression of Meis1 and Hoxa9 in all 21 leukaemic samples. These studies have 
shown that overexpression of Hoxa9 and Meis1 may produce a useful system for studying 
MLL-AML.  
 
 
1.5 The Role of Hypoxia Signalling in Cancer 
 
1.5.1 HIF proteins in cancer development 
Solid tumours are well known to contain hypoxic regions which are thought to 
influence the survival of cancer cells. In response to hypoxic conditions, tumour cells have 
been seen to adapt pro-survival changes in gene expression, allowing tumour cells to 
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grow within the hypoxic environment. These pro-survival changes have led to them being 
considered hypoxic tumour cells which are often considered to have a more aggressive 
phenotype and are often associated with metastasis and resistance to conventional 
chemotherapy (Poon et al, 2009). Hypoxia in tumours has been seen to enhance tumour 
angiogenesis, vasculogenesis and metastasis whilst repressing apoptosis and immune 
response (Wilson & Hay, 2011). Hypoxia signalling is also frequently linked to cancer and 
both HIF and PHD have been implicated in various forms of cancer. However, much like 
their normal biological functions, the exact role of each isoform appears to be cancer-
specific. 
HIF proteins have been implicated in melanoma, lung cancer, breast cancer, 
colorectal cancer, neuroblastoma and leukaemia (Noguera et al, 2009; Ryan et al, 2000; 
Acker et al, 2005; Carmeliet et al, 1998; Koh et al, 2011). Studies by Ryan et al adopted 
the cre/loxP system to create HIF-1α null cell lines, which were used to investigate the 
role of HIF-1α in tumours derived from ES cells. HIF-1α null cell lines were transformed 
and transplanted in to immunocompromised mice which developed solid tumours. 
Results showed that the absence of HIF-1α resulted in a significant decrease in tumour 
mass, suggesting a role for HIF-1α in regulating tumour growth and implicating HIF-1α as 
a tumour promoter in solid tumours (Ryan et al, 2000). However, a separate study by 
Carmeliet et al showed contradictory results (Carmeliet et al, 1998). Carmeliet et al 
showed that HIF-1α-deficient tumours had impaired vascular function with a decreased 
ability to form new blood vessels, resulting in tumours with large areas of hypoxia 
(Carmeliet et al, 1998). This study also showed that tumours lacking HIF-1α showed 
accelerated growth which was attributed to a decrease in hypoxia-induced apoptosis and 
an increase in stress-induced proliferation. These findings imply that HIF-1α may play a 
negative role in tumour development acting as tumour suppressor. 
 
1.5.2 HIF in leukaemic development 
 HIF expression has also been implicated in leukaemia (Martin et al, 2011; Wang et 
al, 2011; Matsunaga et al, 2012; Zhang et al, 2012; He et al, 2013). The factors involved in 
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LSC maintenance and leukaemogenesis are largely unknown. However, the requirement 
of HIF and hypoxia signalling in HSC maintenance provides a possible link between HIF 
and leukaemogenesis. Several studies have reported a role for HIF in the development of 
various subsets of leukaemia.  
A possible role for HIF-1α in the development of chronic myeloid leukaemia (CML) 
has also been identified (Zhang et al, 2012). Zhang et al showed that HIF-1α target genes 
were highly upregulated in CML LSCs carrying the BCR-ABL mutation, a product of the 
causative chromosomal translocation of CML. HIF-1α target genes were upregulated in 
HSCs transformed with BCR-ABL when compared to normal HSCs, suggesting that the 
presence of BCR-ABL may upregulate HIF-1α. This study also aimed to identify the 
requirement of HIF-1α in CML by using HIF-1αfl/fl mice, where HIF-1α is deleted in the 
haemopoietic system. HIF-1αfl/fl BM cells were transformed using BCR-ABL retrovirus, 
before being transplanted to lethally irradiated mice, in order to develop CML. Following 
development of CML, leukaemic cells were used to conduct a secondary transplantation. 
Following the secondary transplant, HIF-1αfl/fl CML cells failed to induce CML in recipient 
mice, although WT CML cells did induce disease. This suggests that HIF-1α may be 
required for the development of CML (Zhang et al, 2011). 
 Matsunaga et al investigated the role of HIF-1α in resistance to chemotherapy 
(Matsunaga et al, 2012). AML LSCs have been reported to localise within hypoxic regions 
in the bone marrow. Hypoxic treatment of solid cancers has been seen to induce cell cycle 
arrest and it is this mechanism that is suspected to convey chemoresistance in hypoxic 
AML LSCs. Considering this, AML cell lines were subjected to hypoxic conditions. Cells 
were then treated with common leukaemia agent Ara-C. Cells subjected to hypoxia were 
seen to express high levels of HIF-1α and were seen to be significantly less sensitive to 
treatment compared to normoxic LSCs. This suggests that the hypoxic induction of HIF-1α 
in AML may contribute to chemoresistance that is often seen in AML (Matsunaga et al, 
2012). 
Recently, Wang et al conducted a study providing evidence that HIF-1α expression 
is required for the maintenance of CSCs in haematological malignancy (Wang et al, 2011). 
Cultured lymphoma cells were transplanted to immunocompromised mice in order for 
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lymphoma tumours to develop in recipient mice. Selected tumour-bearing mice were 
then treated with HIF-1α inhibitor echinomycin. Untreated mice all developed disease 
and survived just 6-10 weeks. Mice treated with echinomycin were euthanized at 134 or 
252 days with no sign of tumour development. A significant upregulation of Notch1 target 
Hes1 was also seen, suggesting that HIF-1α may be involved in the development of 
lymphoma by mediating Notch1 signalling.  
 
1.5.3 PHD in cancer development 
  PHD2 is frequently associated with cancer and a high incidence of PHD2 
mutations are reported in endometrial cancers (Kato et al, 2006). Chan et al performed 
studies to determine the role of PHD in colorectal cancer and whether this role is 
dependant of HIF (Chan et al, 2009). Studies show that PHD2 expression was decreased in 
colorectal tumours compared to surrounding colon tissue, suggesting that PHD2 may 
regulate tumour development. Chan et al used colorectal carcinoma cells in which, HIF-
1α, PHD2 or both HIF-1α and PHD2 were silenced. Transplantation of cells to SCID mice 
resulted in a significant increase in tumour growth in absence of PHD2. Tumours lacking 
PHD2 also showed increased blood vessel formation, suggesting that PHD2 functions as a 
tumour suppressor by negatively regulating angiogenesis. Tumours lacking both HIF-1α 
and PHD2 grew faster than tumour lacking only HIF-1α. This suggests that the mechanism 
by which PHD2 influences tumour growth is not dependent on HIF expression (Chan et al, 
2009). 
 Studies by Lee et al also suggest a role for PHD2 as a tumour suppressor (Lee et al, 
2008). Human fibroblast cell lines that have acquired malignant characteristics and 
become fully transformed following the acquisition of a further random genetic mutation, 
were used to assess the level of transformation in cells, based on the production of 
colonies in an in vitro colony formation assay. This study showed that an overexpression 
of PHD2 altered the transformed phenotype of the cells and several samples lost the 
ability to form colonies altogether. Furthermore, PHD2 expression was reported to 
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negatively correlate with transformation of cell lines, suggesting a tumour suppressor role 
for PHD2 (Lee et al, 2008).  
PHD2 has also been suggested to play a role in the response to chemotherapy. 
Leite de Oliveira et al investigated the role of PHD2 by transplanting B16 melanoma cells 
to WT and PHD2+/- mice, which developed melanoma tumours. Mice were then treated 
with chemotherapeutic agent cisplatin. Platinum accumulation was measured to assess 
the effect of treatment. Intratumoural platinum levels and drug diffusion within the 
tumour was higher in PHD2+/- mice, suggesting that PHD2 deletion increases the efficiency 
of drug delivery. Furthermore, following treatment with suboptimal doses of cisplatin, WT 
tumours were unaffected. However, PHD2+/- tumours were reduced by more than 70%, 
suggesting that PHD2 ablation increased the response to chemotherapy. Interestingly, 
PHD2 deletion also conveyed a protective role in organs that are often affected by the 
side effects of chemotherapy. The level of apoptotic cells in the kidneys of treated mice 
were high in WT mice but were barely detectable in PHD2+/- mice. The effect of cardiac 
output was also assessed and was seen to be reduced by 22.3% in WT mice but was 
unaffected in PHD2+/- mice. These interesting results not only support a role for PHD2 in 
tumour response to chemotherapy but also the response of distant organs to the side 
effects of chemotherapy (Leite de Oliveira et al, 2012). 
Several studies have also indicated a role for PHD3 as a tumour suppressor. PHD3 
expression has been seen in a variety of human cancers such as pancreatic cancer, lung 
cancer, colorectal cancer, breast cancer and gastric cancer (Su et al, 2012; Anderson et al, 
2011). The expression of PHD3 has been associated with well differentiated tumours and 
is considered a prognosticator for good survival rates in gastric cancer (Su et al, 2012). 
Tennant and Gottlieb investigated the role of PHD in tumour growth by treating tumours 
with α-ketoglutarate, which is known to activate PHD (Tennant & Gottlieb, 2010). Various 
cancer cell lines were used to develop xenograph tumours in mice. Following treatment 
with α-ketoglutarate and subsequent activation of PHDs, tumour growth was inhibited. 
Furthermore, increased apoptosis was seen, suggesting that the reduction in tumour 
growth was attributed to increased cell death. shRNAs targeting PHD1, PHD2 and PHD3 
were used to determine which isoform was responsible for the reduced tumour growth. 
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Results showed that xenograph tumours lacking PHD3 expression showed no effect on 
growth, following treatment with α-ketoglutarate. These findings suggest that PHD3 plays 
a tumour suppressor role by influencing tumour growth through increased apoptosis 
(Tennant & Gottlieb, 2010). 
The overexpression of PHD1, PHD2 and PHD3 has been seen in non-small cell lung 
cancer (NSCLC) and are associated with poor survival rates (Anderson et al, 2011). PHD1 
and PHD2 expression is also seen in pancreatic cancer and are correlated to negative 
outcome. These studies implicate PHDs are tumour promoters. However, there are 
numerous studies indicating a tumour suppressor role for PHD. Much like their normal 
biological functions, the exact role of each isoform appears to be cancer specific, making 
it difficult to speculate their roles in cancers that have not been directly studied. 
 
1.5.4 PHD in leukaemic development 
 To date, the role of PHD in leukaemia has not been identified. The cancer and cell 
specific functions of PHD, as well as the existence of both HIF-dependent and HIF-
independent functions, make it difficult to speculate the role of PHD in leukaemia. 
However, several studies assessing the role of isocitrate dehydrogenases (IDH) mutations 
in leukaemia have provided some insight. IDH mutations are seen in 20% of AML (Xu et al, 
2011). IDH1 and IDH2 are metabolic enzymes that convert isocitrate to α-ketoglutarate 
which is known to regulate PHD. Therefore, a dysregulation in IDH activity may disrupt 
the regulation of PHD. IDH mutations in cancer are seen to convert 2-OG to (R)-
enantiomer of 2-hydroxyglutarate ((R)-2HG), which is known to stimulate PHD activity 
(Koivunen et al, 2012; Losman et al, 2013). Studies by Losman et al showed that cells 
passaged in the presence of (R)-2HG displayed two hallmarks of leukaemia; enhanced 
proliferation and impaired differentiation. Following the suggestion that this may be 
attributed to the inhibition of 2-OG-dependent enzymes, such as PHD, the study 
investigated the role of PHD in transformation. shRNA was used to knockdown PHD 
activity. PHD inhibition abrogated the transformed phenotype of the cells, suggesting that 
PHD may be required for leukaemic transformation (Losman et al, 2013). Other studies 
have shown that cells containing tumour-derived mutant IDH1 (IDH1 R132H), had 
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enhanced proliferation, along with increased levels of (R)-2HG (Koivunen et al, 2012). 
Koivunen et al showed that (R)-2HG expression promoted the activity of PHD1 and PHD2. 
These results suggest that PHD may influence transformation of IDH-mutated cells and it 
is possible that PHD may be involved in the transformation of IDH-associated leukaemia. 
However, this study also showed a downregulation of HIF-1α, which is seen to be 
required for leukaemic transformation, suggesting a more complicated role for hypoxia 
signalling in leukaemogenesis that requires much further investigation. 
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1.6 Thesis Aims 
 
The overall aim of this study is to investigate the role of PHD isoforms in the 
transformation and function of leukaemic stem cells. This aim can be broken down as 
follows: 
 
1. To optimise an in vitro assay which can be used to retrovirally transduce HSPCs in 
the generation of pre-LSCs, which can be used in further studies 
 
A previously published methylcellulose-based in vitro assay will be adapted in order to 
achieve the generation of transformed pre-LSCs. HSPCs will be retrovirally transduced 
with Meis1 and Hoxa9 viruses and seeded into methylcellulose, to allow cells to become 
transformed over several passages. Transformed pre-LSCs developed in this assay can 
then be used to achieve the further objectives of this study. 
 
2. To assess the self renewal capacity and transformation of HSPCs in the absence of 
PHD genes. 
 
The in vitro assay utilized in the transformation of HSPCs can be used to assess the self 
renewal capacity of cells, and in addition, can give an indication of the transformed status 
of cells. Transduced HSPCs are seeded into methylcellulose cultures, in which, self 
renewing cells will generate colonies, which can be quantified in order to give a measure 
of self renewal. Comparison of colony production between WT HSPCs and HSPCs lacking 
PHD genes (PHD KO) can indicate if PHD plays a role in self renewal. Transformation is 
known to enhance self renewal capacity, therefore, measuring the self renewal of WT and 
PHD KO cells can also indicate is PHD ablation affects the transformation of HSPCs to pre-
LSCs. In addition, the immunophenotype of pre-LSCs can be assessed in order to 
determine if the phenotype of transformed cells is affected in the absence of PHD. 
 
3. To examine the role of PHD isoforms in the control of biological properties of pre-
LSCs. 
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 WT and PHD KO pre-LSCs generated in the in vitro transformation assay will be used to 
establish cell lines, which will then be used to perform various biochemical assays to 
assess the biological functions of pre-LSCs in the absence of PHD. Cell viability, cell cycle 
status, mitochondrial function and apoptosis will be examined and compared between 
WT and PHD KO cell lines to assess if PHD ablation affects the biological function of pre-
LSCs. 
 
4. To investigate the leukaemic potential of pre-LSCs lacking PHD isoforms. 
 
Similar studies utilizing the in vitro transformation assay have reported that pre-LSCs have 
the ability to generate leukaemia when transplanted to immunocompromised mice. The 
role of PHD in leukaemia is unknown. WT and PHD KO pre-LSCs will be transplanted in to 
lethally irradiated mice in order to examine if PHD ablation affects the leukaemic 
potential of pre-LSCs in vivo. 
 
5. To investigate the role of PHD in the resistance to chemotherapy. 
 
Hypoxia signalling has been implicated in the response to chemotherapy in other cancers; 
therefore, we sought to investigate if PHD plays a role in the response of leukaemic cells 
to chemotherapy. Pre-LSC cell lines will be used and treated with common leukaemia 
agents Ara-C and doxorubicin. Cell viability, cell growth and apoptosis will be compared 
between WT and PHD KO cells in order to determine if cells respond differently to 
chemotherapy treatment in the absence of PHD. 
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2 Materials & Methods 
 
2.1 Materials 
2.1.1. Mice 
Strain Genotype Sex Genotype Mouse ID 
PHD1/2/3Vav WT M Phd1+/+Phd2fl/flPhd3+/+Vav- 1659  
PHD1/2/3Vav WT  Not known 1961 
PHD1/2/3Vav WT M Phd1+/+Phd2fl/flPHD3+/+Vav- 2183 
PHD1/2/3Vav WT M Phd1+/+Phd2fl/flPhd3+/+Vav- 2603 
PHD1/2/3Vav WT F Phd1+/+Phd2fl/flPhd3+/+Vav- 2608 
PHD1/2/3Vav WT F Phd1+/+Phd2fl/flPhd3+/+Vav- 2609 
PHD1/2/3Vav WT M Phd1+/+Phd2fl/flPhd3+/+Vav- 2862 
PHD1floxVav WT M Phd1+/+Vav- 3389 
PHD1floxVav WT M Phd1+/+Vav+ 3390 
PHD1/2/3Vav WT M Phd1+/+Phd2+/+Phd3+/+Vav- 3408 
PHD1/2/3Vav WT M Phd1+/+Phd2+/+Phd3+/+Vav- 3492 
PHD1floxVav WT M Phd1+/flVav- 3814 
PHD1/2/3Vav WT M Phd1+/+Phd2fl/flPhd3+/+Vav- 3829 
PHD1/2/3Vav WT M Phd1+/+Phd2fl/flPhd3+/+Vav- 3830 
PHD1/2/3Vav WT F Phd1+/+Phd2fl/flPhd3+/+Vav- 4311 
PHD1/2/3Vav WT M Phd1+/+Phd2 fl/fl Phd3+/+Vav- 4310 
PHD1/2/3Vav WT F Phd1+/+Phd2+/flPhd3+/+Vav- 031380 
PHD1floxVav WT M Vav-   4734 
PHD1/2/3Vav PHD1 KO M Phd1-/-Phd2+/+Phd3+/+Vav- 1666 
PHD1/2/3Vav PHD1 KO  Not known 2003 
PHD1floxVav PHD1 KO M Phd1fl/flVav+ 3388 
PHD1floxVav PHD1 KO F Phd1fl/flVav+ 3392 
PHD1/2/3Vav PHD1 KO M Phd1-/-Phd2fl/flPhd3+/+Vav- 3588 
PHD1/2/3Vav PHD1 KO M Phd1-/-Phd2+/flPhd3+/+Vav- 3589 
PHD1floxVav PHD1 KO F Phd1fl/flVav+ 3817 
PHD1floxVav PHD1 KO F Phd1fl/flVav+ 3819 
PHD1floxVav PHD1 KO F Phd1fl/flVav+ 3820 
PHD1/2/3Vav PHD1 KO M Phd1-/-Phd2fl/flPhd3+/+Vav- 4165 
PHD1/2/3Vav PHD1 KO M Phd1-/-Phd2fl/flPhd3+/+Vav- 4171 
PHD1/2/3Vav PHD1 KO F Phd1-/-Phd2+/+Phd3+/+Vav+ 4175 
PHD1/2/3Vav PHD1 KO M Phd1-/-Phd2+/+Phd3+/+Vav+ 4342 
PHD1/2/3Vav PHD1 KO M Phd1-/-Phd2+/+Phd3+/+Vav- 4619 
PHD1/2/3Vav PHD1 KO M Phd1-/-Phd2+/flPhd3+/+Vav- 4620 
PHD1/2/3Vav PHD2 KO  Not known 1960 
PHD1/2/3Vav PHD2 KO M Phd1+/+Phd2fl/flPhd3+/+Vav+ 2184 
PHD1/2/3Vav PHD2 KO F Phd1+/+Phd2fl/flPhd3+/+Vav+ 2190 
PHD1/2/3Vav PHD2 KO F Phd1+/+Phd2fl/flPhd3+/+Vav+ 2191 
PHD1/2/3Vav PHD2 KO M Phd1+/+Phd2fl/flPhd3+/+Vav+ 2602 
PHD1/2/3Vav PHD2 KO F Phd1+/+Phd2fl/flPhd3+/+Vav+ 2607 
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PHD1/2/3Vav PHD2 KO F Phd1+/+Phd2fl/flPhd3+/+Vav+ 2610 
PHD1/2/3Vav PHD2 KO M Phd1+/+Phd2fl/flPhd3+/+Vav+ 2863 
PHD1/2/3Vav PHD3 KO M Phd1+/+Phd2fl/flPhd3-/-Vav- 3989 
PHD3floxVav PHD3 KO F Phd3fl/flVav+ 4655 
PHD3floxVav PHD3 KO F Phd3fl/flVav+ 4656 
PHD1/2/3Vav PHD3 KO F Phd1+/+Phd2+/+Phd3-/-Vav- 031385 
PHD1/2/3Vav PHD3 KO F Phd1+/+Phd2+/+Phd3-/-Vav- 031386 
PHD1/2/3Vav PHD3 KO F Phd1+/+Phd2+/+Phd3-/-Vav- 031387 
PHD1/2/3Vav PHD3 KO F Phd1+/+Phd2+/+Phd3-/-Vav- 031388 
PHD1/2/3Vav PHD3 KO F Phd1+/+Phd2+/+Phd3-/-Vav- 031389 
PHD1/2/3Vav PHD1/2 KO  Not known 2000 
PHD1/2/3Vav PHD1/2 KO M Phd1-/-Phd2fl/flPhd3+/+Vav+ 2871 
PHD1/2/3Vav PHD1/2 KO M Phd1-/-Phd2fl/flPhd3+/+Vav+ 2872 
PHD1/2/3Vav PHD1/2 KO M Phd1-/-Phd2fl/flPhd3+/+Vav+ 4174 
PHD1/2/3Vav PHD1/2 KO M Phd1-/-Phd2fl/flPhd3+/+Vav+ 4621 
PHD1/2/3Vav PHD1/3 KO M Phd1-/-Phd2fl/flPhd3-/-Vav- 2874 
PHD1/2/3Vav PHD1/3 KO M Phd1-/-Phd2fl/flPhd3-/-Vav- 2876 
PHD1/2/3Vav PHD1/3 KO M Phd1+/+Phd2+/flPhd3-/-Vav- 3351 
PHD1/2/3Vav PHD1/3 KO M Phd1-/-Phd2fl/flPhd3-/-Vav- 3352 
PHD1/2/3Vav PHD1/3 KO F Phd1-/-Phd2+/flPhd3-/-Vav- 3354 
PHD1/2/3Vav PHD1/3 KO M Phd1-/-Phd2fl/flPhd3-/-Vav- 3591 
PHD1/2/3Vav PHD1/3 KO M Phd1-/-Phd2fl/flPhd3-/-Vav- 3594 
PHD1/2/3Vav PHD1/3 KO M Phd1-/-Phd2fl/flPhd3-/-Vav- 3620 
PHD1/2/3Vav PHD1/3 KO F Phd1-/-Phd2+/flPhd3-/-Vav- 3854 
PHD1/2/3Vav PHD1/3 KO M Phd1-/-Phd2+/+Phd3-/-Vav- 3826 
PHD1/2/3Vav PHD1/3 KO M Phd1-/-Phd2+/flPhd3-/-Vav- 3984 
PHD1/2/3Vav PHD1/3 KO M Phd1-/-Phd2+/+Phd3-/-Vav+ 4027 
PHD1/2/3Vav PHD1/3 KO M Phd1-/-Phd2+/flPhd3-/-Vav- 4219 
PHD1/2/3Vav PHD1/3 KO F Phd1-/-Phd2fl/flPhd3-/-Vav- 4340 
PHD1/2/3Vav PHD1/3 KO F Phd1-/-Phd2+/flPhd3-/-Vav- 4451 
PHD1/2/3Vav PHD1/3 KO F Phd1-/-Phd2+/flPhd2-/-Vav- 4452 
PHD1/2/3Vav PHD1/2/3 KO F Phd1-/-Phd2fl/flPhd3-/-Vav+ 3992 
PHD1/2/3Vav PHD1/2/3 KO M Phd1-/-Phd2fl/flPhd3-/-Vav+ 4337 
 
Table 2.1. Details of mice used for in vitro analysis 
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2.1.2 Cell lines 
 
2.1.2.1 Commercial cell lines 
 
Cell line Origin 
NIH3T3 Mouse Fibroblasts 
Plat-E Commercially generated, available from Cell 
Biolabs Inc. 
 
Table 2.2. Details of commercial cell lines 
Details of commercially available cell lines used in this study, along with their origin, are 
listed in table 2.2. NIH3T3 cells are commonly used and were available ‘in house’. NIH3T3 
cells were chosen to test efficiency of retroviral production and transfection due to their 
murine origin and accessibility. Commercially available Platinum-E (Plat-E) retroviral 
packaging cell line was chosen for the production of virus. Plat-E cells are specially 
designed for rapid production of high-titre ecotropic retrovirus.  
 
2.1.1.2 Established murine cell lines 
 
Cell line Original Mouse Genotype Mouse ID 
WT Phd1+/+Phd2fl/flPhd3+/+Vav- 1659 
WT Phd1+/+Phd2fl/flPhd3+/+Vav- 2609 
WT Phd1+/+Phd2+/+Phd3+/+Vav- 3408 
WT Phd1+/+Phd2fl/flPhd3+/+Vav- 3829 
WT Phd1+/+Phd2fl/flPhd3+/+Vav- 4310 
PHD1 KO Phd1-/-Phd2+/+Phd3+/+Vav- 1666 
PHD1 KO Phd1fl/flVav+ 3817 
PHD1 KO Phd1fl/flVav+ 3820 
PHD1 KO Phd1fl/flVav+ 3819 
PHD1 KO Phd1-/-Phd2+/+Phd3+/+Vav- 4619 
PHD1 KO Phd1-/-Phd2+/flPhd3+/+Vav- 4620 
PHD2 KO Phd1+/+Phd2fl/flPhd3+/+Vav+ 2190 
PHD2 KO Phd1+/+Phd2fl/flPhd3+/+Vav+ 2863 
PHD2 KO Phd1+/+Phd2fl/flPhd3+/+Vav+ 2607 
PHD2 KO Phd1+/+Phd2fl/flPhd3+/+Vav+ 2191 
PHD2 KO Phd1+/+Phd2fl/flPhd3+/+Vav+ 2610 
PHD12 KO  Phd1-/-Phd2fl/flPhd3+/+Vav+ 4621 
 
Table 2.3. Details of mice used to establish cell lines for in vitro analysis.   
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Details of cell lines established during the study, along with details of mice used to collect cells, 
are listed in table 2.3. The methods by which cell lines were established are detailed in section 
2.3.5.5. 
 
2.1.3 Plasmids 
Plasmids were used in this study to overexpress genes known to have a role in 
leukaemogenesis. Meis1 and Hoxa9 plasmids were constructed using an MSCV backbone 
and were a kind gift from Tim Somervaille, (Paterson Institute for Cancer Research, 
Manchester). Meis1 plasmid contained a puromycin resistance cassette allowing 
successfully transfected cells to be selected using puromycin antibiotic. Hoxa9 plasmid 
contained a neomycin resistance cassette and successfully transfected cells were selected 
using neomycin. A packaging plasmid VSV-G was also used to provide the necessary 
enveloping proteins. Addition of VSV-G plasmid is known to increase efficiency of 
retroviral transfection (Okimoto et al, 2001). VSV-G plasmid was available ‘in house’. 
MSCVneo and MSCVpuro plasmids were used to generate control viruses lacking Meis1 
and Hoxa9 inserts. 
 
                    
 
Figure 2.1. Restriction map of pMSCV plasmid.  
MSCV based plasmid containing Meis1 gene and puromycin resistance cassette (A) or Hoxa9 gene 
and neomycin resistance cassette (B). 
puror 
 
Hoxa9 Meis1 
neor 
A B 
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2.1.4 Tissue culture supplies 
Supplier Product 
Baxter Healthcare, Nottingham, UK Sterile water 
Biolegend, London, UK Mouse recombinant Interleukin-3 (IL-3) 
 Mouse recombinant Interleukin-6 (IL-6) 
 Mouse recombinant Stem Cell Factor (SCF) 
 Mouse recombinant Granulocyte-Macrophage 
Colony Stimulating Factor (GM-CSF) 
Gilson, Bedfordshire, UK P1000 & P200 plastic pipette tips 
Greiner, Bio-One, Gloucestershire, UK  Cryotubes 
 Pipettes (5mL, 10mL & 25mL) 
 Tissue culture flasks (25cm2, 75cm2, 175cm2) 
 Tissue culture plates (6-well, 12-well, 24-well, 
48-well & 96-well) 
Invitrogen, Paisley, UK 2-mercaptoethanol (2-ME) 
 Dulbecco’s Modified Eagle Medium (DMEM) 
 Iscove’s Modifided Dulbecco Medium (IMDM) 
 Dulbecco’s Phosphate Buffered Saline (PBS) 
 Foetal Calf Serum (FCS) 
 L-glutamine (200mM) 
Miltenyi Biotec, Bisley, UK c-Kit microBead™ kit mouse  
Nalgene Labware, Roskilde, Denmark  25cm2 and 75cm2 tissue culture flasks  
Sartorius, Hannover, Germany  Minisart 0.2μM sterile filters  
 Minisart 0.45μM sterile filters  
Sigma-Aldrich, Dorset, UK  Bovine serum albumin (BSA)  
 DMSO  
 Gelatin  
 Hank’s buffered salt solution (HBSS) 
 Hydrochloric acid (HCl) 
 Magnesium chloride (MgCl2)  
 Polybrene® 
 Sodium azide 
 Trypan blue  
 Trypsin-EDTA 
StemCell™ Technologies, Grenoble, France Ammonium chloride solution (NH4Cl) 
 Methocult™ M3231 
Sterilin Ltd, Hounslow, UK  Disposable pipettes (5mL, 10mL, 25mL) 
 Pastettes 
 Sterile plastic falcon tubes (15mL & 50mL) 
 
Table 2.4. Details of tissue culture supplies.   
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2.1.5 Molecular biology supplies 
Supplier Product 
Abcam, Cambridge, UK Anti-GAPDH 
Bioline, London, UK Crystal 5X DNA loading buffer, blue 
  HyperPAGE prestained protein marker 
 ISOLATE II Genomic DNA kit 
 MangoMixTM  
 α-select competent cells (silver efficiency) 
Bio-Rad Laboratories Ltd, Sussex, UK Gel combs 
 Gel casting trays 
 Immuno-Blot™ polyvinylidene fluoride (PVDF) 
membrane 
Cell Signalling Technology, New England 
Biolabs, UK 
1kiloBP DNA ladder 
Chemical store, University of Glasgow Ethanol 
 Isopropanol 
 Methanol 
Eurofins MWG Operon, Wolverhampton, UK PCR primers 
Life Technologies Ltd, Paisley, UK SYBR®safe 
 Tris EDTA (TE) buffer 
 XCell Surelock Mini-Cell system 
 NuPAGE® LDS Sample Buffer (4X) 
 NuPAGE® Novex® 4-12% Bis-Tris Protein Gels 
Marvel Originals Dried skimmed milk 
Novus Biologicals, Cambridge, UK Anti-HIF-1α 
 Anti-HIF-2α 
Qiagen, West Sussex, UK HiSpeed ® Plasmid Maxi kit 
Sigma-Aldrich, Dorset, UK 4-(2-hydroxyethyl)-1-piperazinethanesulfonic 
acid (HEPES)  
 Agarose 
 Calcium chloride (CaCl2)  
 EDTA  
 Sodium docedyl sulphate (SDS) 
 Tris base  
 TWEEN 20 for electrophoresis 
Thermo Scientific Inc. (Pierce), Hempstead, UK Bicinchoninic acid (BCA)™ protein assay kit  
 RIPA buffer 
 DTT powder 
 10X Tris-Glycine-SDS Buffer (transfer buffer) 
 10X Tris-Glycine Buffer (running buffer) 
 Supersignal West Dura chemiluminescent 
substrate 
 CL-XPosure film 
Roche Applied Sciences, West Sussex, UK PhosSTOP; Phosphatase Inhibitor Cocktail 
Tablets 
 cOmplete Protease Inhibitor Cocktail Tablet 
Table 2.5. Details of molecular biology supplies.   
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2.1.6 Flow cytometry supplies 
Supplier Product 
BD Biosciences, Oxford, UK Annexin-V Allophycocyanin 
(APC)/Phycoerithrin (PE) 
 Fluorescein isothiocyanate (FITC)Anti- Ki67 
Kit  
 Fluorescence Activated Cell Sorter (FACS) 
 Flow/FACS Clean 
 BDTM CompBeads Anti-mouse Ig ĸ 
Biolegend UK, London, UK Anti-mouse CD11b/Mac-1 (PE) 
 Anti-mouse CD11b/Mac-1 (APC) 
 Anti-mouse Gr-1 (PE) 
 Anti-mouse Gr-1 (APC-Cy7) 
 Anti-mouse c-Kit (APC) 
 Anti-mouse c-Kit (APC-Cy7) 
 Anti-mouse CD45.1 (FITC) 
 Anti-mouse CD45.2 (Pacific BlueTM) 
 Purified Anti-H2A.X-Phosphorylated (Ser139) 
Life Technologies Ltd, Paisley, UK Alexa Fluor® 488 goat anti-rabbit IgG  
 MitoTracker® Red CMXRos 
 MitoTracker® Green FM 
Sigma-Aldrich, Dorset UK 4’6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) 
Table 2.6. Details of flow cytometry supplies.   
 
 
2.1.7 PCR primer sequences 
Primer Sequence 
Mouse Vav iCre Forward CCGAGGGGCCAAGTGAGAGG  
Mouse Vav iCre Reverse GGAGGGCAGGCAGGTTTTGGTTTTGGTG 
Mouse Phd1 flox Forward GAGGCTCCTTGAGTCTG 
Mouse Phd1 flox Reverse ATTTAGTTCAGTTCTCAG 
Mouse Phd2 flox Forward TTGCAGTGTGCAACAGTCAG 
Mouse Phd2 flox Reverse CACGGGGAACTCTGATTCAT 
Mouse Phd2 flox (excised band) CCAAAATCACCAATCTAGAATAACTTC 
Mouse Phd3 flox Forward AGTCTCAAAAGCATCAGG 
Mouse Phd3 flox Reverse ACTACATGCAATGGCACA 
Mouse Phd1 Multiplex Forward (WT) GAAGGAGGACAAAGGTCTCTTGG 
Mouse Phd1 Multiplex Forward (KO) CCTATATTCACGGGACAGATCCTG 
Mouse Phd1 Multiplex Reverse (WT) GGGCCCACAGTCAGCTAAAG 
Mouse Phd1 Multiplex Reverse (KO) AGAGGCCACTTGTGTAGCGC 
Mouse Phd3 Multiplex Forward GAGCACCCTTATAAAAAGCAAGTGA 
Mouse Phd3 Multiplex Reverse (WT) TGCAGAAACACCCCAGATGA 
Mouse Phd3 Multiplex Reverse (KO) GGAAAAGCGCCTCCCCTA 
Table 2.7. Details of PCR primer sequences.   
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2.2 Media & Solutions 
2.2.1. Tissue culture 
 
2.2.1.1 DMEM 
 
DMEM    440mL 
FCS    50mL 
L-glutamine (200mM)  5mL 
Penicillin/Streptomycin 5mL 
(10,000UmL-1/10,000gmL-1) 
 
 
2.2.1.2 IMDM base 
 
IMDM    445mL 
FCS    50mL 
Penicillin/Streptomycin 5mL 
(10,000UmL-1/10,000gmL-1) 
 
 
2.2.1.3 IMDM 40/20/20 
 
IMDM base*   50mL 
Mouse SCF (100μg/mL)  20μl (40ng/mL)  
Mouse IL-3 (100μg/mL)  10μl (20ng/mL)  
Mouse IL-6 (100μg/mL) 10μl (20ng/mL) 
 
 
2.2.1.4 IMDM Intermediate 
 
IMDM base*   50mL 
Mouse SCF (100μg/mL)  10μl (20ng/mL)  
Mouse IL-3 (100μg/mL)  5μl (10ng/mL)  
Mouse IL-6 (100μg/mL) 5μl (10ng/mL) 
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2.2.1.5 IMDM IL-3 
 
IMDM base*   50mL 
Mouse IL-3 (100μg/mL)  5μl (10ng/mL)  
 
*IMDM base prepared as detailed in section 2.2.1.2. 
 
 
2.2.1.6 Methylcellulose 
 
Methocult™ 3231  80mL 
IMDM    20mL 
Mouse SCF (100μg/mL)  10μl (20ng/mL)  
Mouse IL-3 (100μg/mL)  5μl (10ng/mL)  
Mouse IL-6 (100μg/mL 5μl (10ng/mL) 
Mouse GM-CSF (100μg/mL) 5μl (10ng/mL) 
 
 
2.2.1.7 PBS / 2% FCS  
 
PBS     490mL  
FCS     10mL 
 
 
2.2.1.8 Freezing media 10% DMSO FCS  
 
DMSO     5mL  
FCS     45mL 
 
 
2.2.2 Western blotting 
 
2.2.2.1 RIPA buffer  
 
Per mL 
DTT (1mM)   1µL 
Protease Inhibitor (25X) 40µL 
Phosphatase Inhibitor (10X) 100µL 
RIPA buffer   859µL 
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2.2.2.2 10X TBS buffer* 
 
NaCl     876.6g  
Tris     121.1g  
dH20     10L  
 
 
*1X solution was made using 100mL of the 10X solution with the addition of 900mL of 
dH20 supplemented with 10mL of Tween-20. 
 
 
2.2.2.3 1X Transfer buffer 
 
10X Tris-Glycine-SDS Buffer 100mL 
dH2O    900mL 
 
 
2.2.2.4 Running buffer 
 
10X Tris-Glycine Buffer 100mL 
dH2O    900mL 
 
 
2.2.2.5 5% (w/v) Milk/TBST blocking solution  
 
1X TBST    50mL  
Powdered Milk  2.5g 
 
 
 
2.2.3 Flow cytometry 
 
2.2.3.1 DAPI (1X)* 
 
DAPI (1000X)   50mg 
PBS    1mL 
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*DAPI stock solution was diluted at a ratio of 1:50 in PBS to give 1000X solution which was 
stored at -20oC. Prior to use, 1000X DAPI stock was further diluted in PBS to give a 1X 
solution with a concentration of 1µg/mL. 
 
 
2.2.3.2 Annexin V 
 
Annexin V APC/PE   5µL 
HBSS supplemented with 1X DAPI 95µL 
 
 
 
2.2.3.4 Fixation/Permeabilisation buffer  
 
Paraformaldahyde (4%)  100µL  = 0.4% 
HEPES (0.05mM)   20µL = 10mM 
Saponin (1%)    20µL  = 0.02% 
ddH2O     840µL 
 
 
2.2.3.5 Wash Buffer 
 
FBS       50µL = 5% 
Sodium azide     5µL = 0.05% 
Saponin (1%)    10µL = 0.02% 
EDTA (11mg/L)   0.375µL = 55mg/L 
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2.2.4 PCR 
 
2.2.4.2 PCR Mix 
 
PHD1 Flox µL PHD2 Flox µL PHD3 Flox µL 
PHD1 Fw Primer        
PHD1 Rv Primer    
MangoMix™ 
Nuclease free H2O   
0.1 
0.1 
12.5 
8.3 
PHD2 WT FL Fw Primer       
PHD2 WT FL Rv Primer  
PHD2 FL excised Primer 
MangoMix™ 
Nuclease free H2O 
 
0.1 
0.1 
0.1 
12.5 
8.2 
AF Fw Primer 
BR Rv Primer       
MangoMix™ 
Nuclease free H2O 
 
0.1 
0.1 
12.5 
8.3 
PHD1 Muliplex µL PHD3 Muliplex µL Vav µL 
PHD13 Fw Primer 
PHD14 Rv Primer 
PHD KO Fw Primer 
PHD KO Rv Primer  
MangoMix™  
Nuclease free H2O 
 
0.1 
0.1 
0.1 
0.1 
12.5 
8.1 
PHD3 WT KO Fw Primer 
PHD3 WT Rv Primer 
PHD3 KO Rv Primer      
MangoMix™ 
Nuclease free H2O 
 
0.15 
0.1 
0.1 
12.5 
10.15 
Vav Fw Primer 
Vav Rv Primer 
MangoMix™ 
Nuclease free H2O 
 
 
0.1 
0.1 
12.5 
10.3 
 
Table 2.8. Details of PCR primer mixes.   
 
 
2.2.4.1 2% (w/v) Agarose TBE 
 
1X TBE     125mL 
Agarose    2.5g 
 
*Preparation of 2% agarose gel is described as an example. However, different genes required 
different concentrations of agarose and gels were also prepared at concentrations appropriate to 
the gene, which was decided during optimisation of assay. 
 
Gene Agarose concentration 
Vav 2% 
PHD1 Multiplex 2.5% 
PHD2 Flox 2% 
PHD3 Multiplex 2% 
PHD1 Flox 3% 
PHD3 Flox 2% 
 
Table 2.9. Details of agarose gel concentration used for individual primers.   
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2.2.5 Transfection 
 
2.2.5.1 2X HEPES-buffered saline (HBSS)  
 
NaCl     8g  
KCl     0.37g  
Na2HP042H20    106.5mg  
Dextrose    1g  
HEPES     5g  
dH20     to 500mL  
pH 7.05 to 7.1 
2.2.5.2 2M CaCl2  
 
CaCl2     147g  
dH20     to 500mL 
 
 
2.2.5.3 Transfection Solution/10cm2 plates 
 
dH20     437.5μl  
2 X HBSS    500μl  
2M CaCl2    62.5μl  
VSV-G    3μg  
Plasmid (Meis1 or Hoxa9)  10μg 
 
 
2.2.5.4 0.1% (w/v) Gelatin solution 
 
Gelatin powder  1g 
dH2O    1L 
 
 
2.2.6 Plasmid preparation 
2.2.6.1 Ampicillin (100mg/mL) 
 
Ampicillin sodium salt  5g  
dH20     50mL 
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2.2.6.2 LB broth  
 
Miller’s LB base®   20g  
dH20     up to 1L  
Ampicillin (100mg/mL)* 1mL  
 
*Solution was autoclaved immediately following preparation and prior to 
supplementation with Ampicillin. 
 
 
2.2.6.3 LB agar plates  
 
Miller’s LB base®   20g  
Microagar    7g  
Ampicillin (100mg/mL)* 1mL  
 
*Solution was autoclaved and cooled in a waterbath at 50oC. Cooled solution was 
supplemented with ampicillin and added to sterile petri dished. Dished were stored at 4oC. 
 
 
2.3 Methods 
 
2.3.1 Animal work 
2.3.1.1 Ethics 
All animal work was in accordance with the Animals Scientific Procedures Act 1986 
and UK Home Office regulations. Animals were housed at the Beatson Institute for Cancer 
Research or at the Veterinary Research Facility at the University of Glasgow.  
 
2.3.1.2 Mouse models 
PHD knockout mice were obtained from Peter Ratcliffe (University of Oxford). 
Gene targeting of PHD1 and PHD3 were used to delete a single exon, resulting in a non-
functional mutant allele (Takeda et al, 2006). A mutant band is detectable by PCR using 
PHD1 and PHD3 primers. The detection of a mutant or WT band is used to determine the 
75 
 
genotype of the mice. PHD1+/- and PHD3+/- were crossed to generate PHD1-/- and PHD3-/- 
mice. 
PHD2 or PHD1 gene is flanked by loxP sites which are recognised as excision sites 
by Cre recombinase. Activation of Cre will allow the gene to be excised conditionally. 
VavCre is expressed in haemopoietic cells only, allowing floxed genes to be deleted only 
in the haematopoietic system. PHD2+/flox and PHD1+/flox mice were crossed to VavCre+ 
mice to create PHD1flox/floxVavCre and PHD2flox/floxVavCre mice.  
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Illustration demonstrating mating strategy.  
PHD1+/flox mice were crossed to PHD1+/flox mice to generate PHD1flox/flox mice. PHD1flox/flox mice were 
crossed to Vav+ mice to generate PHD1flox/floxVav+ mice. Similarly, PHD2+/flox mice were crossed to 
PHD2+/flox mice to generate PHD2flox/flox mice. PHD2flox/flox mice were crossed to Vav+ mice to 
generate PHD2flox/floxVav+ mice. Double knock-out mice were obtained by crossing PHD1flox/floxVav+ 
and PHD2flox/floxVav+ mice, generating PHD1flox/floxPHD2flox/floxVav+ mice. 
 
 
PHD1+/flox 
OR 
PHD2+/flox 
 
PHD1+/flox 
OR 
PHD2+/flox 
 
PHD1flox/flox 
OR 
PHD2flox/flox 
 
Vav+ 
PHD1flox/floxVav+ 
X X 
PHD2flox/floxVav- 
X 
PHD1flox/floxPHD2flox/floxVav+ 
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2.3.2 Cell culture 
2.3.2.1 General technique 
Tissue culture was conducted in an aseptic manner in which all materials were 
autoclaved and sterilised with 70% ethanol prior to use. All tissue culture technique was 
carried out within a laminar air flow hood to ensure aseptic working conditions.  
 
2.3.2.2 Cryopreservation of samples 
Primary cells and cell lines were stored at -80oC for future use. Cells were washed 
several times with ice cold PBS/FBS to remove any residual media. Cells were counted 
and resuspended at concentrations of no more than 2x106/mL. Cells were pelleted and 
resuspended in ice cold FBS with 10% DMSO and dispensed into cryotubes. Cryotubes 
were placed in a freezing container (“Mr Frosty”) containing neat isopropyl to allow 
gradual freezing of the samples, which were incubated at -80oC overnight. After 24 hours, 
samples were moved to storage boxes at -80oC.  
 
 
2.3.1.3 Recovery of frozen samples  
In order to ensure maximum recover rates from frozen samples, cells were 
thawed with care. On removal from -80oC, cells were thawed immediately in a water bath 
of 37oC. Thawed samples were then moved to 15mL Falcon tubes and 10mL of pre-
warmed IMDM supplemented with 10% FBS, was added drop wise to the cell suspension 
to slowly dilute the freezing medium. Cell solution was centrifuged for 10mins at 400 x g. 
Cells were then washed with PBS/FBS to remove any residual freezing media. Cells were 
cultured in IMDM 40/20/20 overnight. Media was changed the following day to remove 
dead cells or debris after thawing. Cells were passaged as required until re-established. 
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2.3.3 PCR 
Polymerase chain reaction (PCR) is a common technique used in molecular biology 
to amplify the number of copies of a gene within a sample, allowing that gene to be 
detected. Primers are designed to anneal to complementary DNA sequences within a 
target gene. Taq polymerase is also used to allow DNA synthesis of the gene, allowing 
amplification of the gene of interest. In this study, PCR has been used to determine the 
genotype of mice and the resulting cell lines that have been derived from them. 
 
2.3.3.1 Primer design  
NCBI software was used to design primers using the DNA sequence of the gene of 
interest. Primers were synthesised commercially by Eurofins MWG Operon. Primers were 
reconstituted in nuclease-free H2O to a stock concentration of 100µM and stored 
aliquoted at -20oC. Working concentration of primers and PCR reagents, along with PCR 
conditions, were optimised to each primer set. Conditions for primers used in this study 
are detailed in section 2.2.4.2. 
 
2.3.3.2 Generation of DNA  
Mouse ear/tail samples were collected and incubated for several hours or 
overnight at 55oC in DNA lysis buffer containing Proteinase-K. DNA was extracted from 
animal samples using a Bioline DNA extraction kit as per manufacturer’s instructions. 
 
2.3.3.3 Standard PCR  
PCR was used to detect the presence or absence of a gene to determine the 
genotype of the sample. In this study, the cre-lox system was used as a means to 
conditionally knock out target genes. PCR was used to distinguish floxed genes from wild 
type genes, based on the size of DNA fragment that is amplified. 
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Positive controls were used to determine the success of the reaction. PCR reaction 
mix without DNA was used to assess contamination of PCR reagents. PCR conditions were 
optimised for each primer set. DNA fragments produced during the PCR reaction can be 
analysed using an agarose gel, through which DNA fragments migrate, allowing them to 
be separated by size. Agarose gels are prepared containing SybrSafe™, which is used to 
visualise DNA by UV exposure. DNA ladders of known size were run with each gel to help 
determine the size of DNA fragments and as a control that the DNA had migrated through 
the gel appropriately. 
Agarose gels were prepared to an appropriate concentration, which was 
optimised for each PCR product. The percentage of agarose used reflects the porosity of 
the gel. Therefore, larger DNA fragments may require a lower percentage of gel with a 
higher porosity in order to move efficiently through the gel. Optimisation of this assay 
found that some genes being analysed achieved clearer results when the percentage of 
agarose used was altered. Agarose powder was dissolved in 1X TBE which was heated in a 
microwave. Agarose solution was allowed to cool before SybrSafe™ was added and gel 
was poured into a gel tray containing combs. Once the gel had solidified, combs were 
removed, forming wells that were used to load samples into the gel. The gel was placed 
into an electrophoresis tank containing 1X TBE solution. PCR samples were loaded into 
the gel and an electric current passed through the tank, causing the DNA to migrate 
through the gel, separating the fragments by size. Smaller fragments are able to move 
through the pores in the gel easier that larger one and therefore, are able to migrate 
further. Following electrophoresis, DNA within the gel can be visualised as bands using UV 
illumination using the molecular imager Chemidoc™ XRS visualisation system. 
 
2.3.4 Transfection 
2.3.4.1 Plasmid production 
Plasmid DNA was concentrated and purified using a Qiagen MaxiPrep kit. Agar 
plates were prepared as detailed in section 2.2.6.3. Plasmid DNA was added to competent 
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bacteria and streaked onto agar plates. Plates were incubated overnight at 37oC to allow 
bacterial colony growth. LB broth was prepared as per section 2.2.6.2 and autoclaved to 
ensure no bacterial growth. A single bacteria colony was picked from the agar plate and 
added to the LB both. LB broth was placed on a shaker and incubated at 37oC overnight to 
allow growth of the bacterial culture. Plasmid DNA within the bacterial culture was 
isolated using a MaxiPrep kit according to manufacturer’s instructions. DNA was eluted in 
nuclease free H2O and stored at -20
oC. DNA was quantified using a NanoDrop™ 
spectrophotometer Nd-1000. 
 
2.3.4.2 Retroviral production 
Retroviral transfection was used to introduce the overexpression of Meis1 and 
Hoxa9, which are known to play a role in leukaemic development. Genes of interest can 
be cloned into plasmid DNA structures which can be transfected into packaging cell lines 
such as commercially available Plat-E cells. Following transfection with plasmid DNA, Plat-
E cells package the retroviral DNA into viral particles which are released into the 
supernatant. Supernatant can then be collected and added to target cells, such as 
Haemopoietic stem and progenitor cells (HSPCs), in order to transfect these cells with the 
virus. Retroviral DNA can then integrate into the DNA of the host cell which overexpresses 
the target gene, in this case, Meis1 and Hoxa9. 
10cm2 culture dishes were pre-coated with 0.1% (w/v) gelatin. Plat-E cells were 
counted and seeded at a density of 1.8x106cells/plate and allowed to adhere for 24 hours 
at 37oC prior to transfection. Transfection solution was prepared as described in section 
2.2.5.3 and incubated for 30 mins at room temperature. Fresh, pre-warmed DMEM media 
was added to cells. Transfection solution was then added drop-wise to the plates which 
were mixed gently and incubated at 37oC overnight. Following overnight incubation with 
transfection solution, media was removed and replaced with fresh, pre-warmed IMDM 
supplemented with 10% FBS, in which viral particles will be collected. Plates were 
incubated for a further 48 hours to allow cells to produce viral particles into the 
supernatant. At 48 hours, supernatant was collected and filtered using a 0.44µM sterile 
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filter. Filtered supernatant containing viral particles was immediately collected on dry ice 
to ensure that maximum half-life of the virus is preserved in the frozen stock. Virus was 
stored at -80oC. 
 
2.3.4.3 Testing efficiency of retrovirus 
Mouse fibroblast NIH3T3 cells were used to test each batch of virus produced 
prior to infection of HSPCs. NIH3T3 cells were seeded in 6-well plates at a density of 1 x 
105 cells/well in 2mL of DMEM media. Cells were cultured for 24 hours at 37oC to allow 
cells to adhere. Once cells had adhered, media was removed and replaced with 500µL of 
freshly thawed viral supernatant containing 2µg/mL Polybrene and incubated at 37oC 
overnight. The following day, media was replaced with fresh DMEM. Forty-eight hours 
following infection, cells were centrifuged and resuspended in media containing selection 
antibiotics 1.5mg/mL neomycin and 1.5µg/mL puromycin. Cells that have been 
successfully transfected with both viruses will express resistance cassettes for the 
selection antibiotics and will be positively selected. Cells remained in the selection media 
for 72 hours before selection was complete. At 72 hours, cells were imaged by 
microscopy to assess if cells had grown in the presence of the antibiotics. Cells that were 
not infected with any virus were used as a control to ensure that antibiotics successfully 
prevented the growth of non-transfected cells.  
The concentration of neomycin and puromycin were determined through titration 
experiments in which, NIH3T3 cells were grown in the presence of different 
concentrations of drug to determine the most efficient dose for selection. The growth of 
NIH3T3 cells was compared against the growth of NIH3T3 cells that were transfected with 
virus. Infected cells that grew in the selection media were considered transfected and the 
virus deemed efficient.  
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2.3.5 Isolation and culture of HSPCs and pre-LSCs 
2.3.5.1 Collection of mouse bone marrow cells 
Hips, femur and tibia were extracted from mice following their humane sacrifice 
by schedule 1 method according to Home Office licence. Bones were crushed using 
mortar and pestle in PBS containing 2% FBS. Cells were washed several times in PBS/FBS 
in order to deplete tissue contamination in the bone marrow sample. Bone marrow cells 
were filtered using a sterile 0.2μM filter to create a single cell suspension. Bone marrow 
cells were treated with NH4Cl to lyse any remaining red blood cells to purify the white 
blood cell population. 
2.3.5.2 Isolation of HSPCs by c-Kit enrichment 
HSPCs were isolated based on the expression of haemopoietic marker c-Kit, which 
is expressed on haemopoietic stem cells and early progenitors but not committed 
progenitors. A c-Kit magnetic bead kit was used to enrich the c-Kit+ population through a 
column separation method. Bone marrow cell suspension was prepared as in section 
2.3.5.1 and counted to ensure an efficient concentration of beads against mouse c-Kit IgG 
was mixed with the cell suspension. Cells were filtered using a sterile 0.2µM filter to 
ensure a single cell suspension and added to a magnetic column, to which anti- c-Kit 
beads coupled to c-Kit+ cells attached. The column was washed several times with 
PBS/FBS to remove any negative cells. c-Kit+ cells which were selected by the magnetic 
column were collected and washed. To ensure that the enrichment had worked 
effectively, selected cells were stained with an antibody for c-Kit and the frequency of c-
Kit+ cells determined by flow cytometry. 
 
2.3.5.3 Transduction of primary mouse samples  
Primary mouse bone marrow samples were enriched for stem and progenitor 
marker c-Kit to ensure a primitive population of HSPCs. 1 x 106 c-Kit cells were cultured 
overnight in IMDM 40/20/20 prepared as per section 2.2.1.3. The following day, cells 
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were collected in 50mL falcon tubes. Frozen viral supernatant was thawed and added to 
cells along with 2µg/mL Polybrene which increases the efficiency of transfection by 
neutralising the cell surface and allowing viral particles to bind more efficiently to 
receptors. Cells underwent spinoculation where tubes were centrifuged at 800 x g for 2 
hours at 4oC, maximising the contact of the cells with the viral particles and increasing the 
chances of infection. Viral media was removed and cells were resuspended in fresh IMDM 
40/20/20 and returned to culture at 37oC overnight. The following day, spinoculation was 
repeated. 48 hours following the initial infection, cells were centrifuged and resuspended 
in fresh IMDM 40/20/20 containing 1.5mg/mL neomycin and 1.5µg/mL puromycin.  
 
2.3.5.4 CFC assay 
The colony forming cell or CFC assay is a common assay in haemopoietic studies 
and is widely used as a measure of self renewal ability and ‘stemness’ of bone marrow 
populations in an in vitro setting. Cells are seeded into a semisolid medium where their 
self renewal capacity allows them to produce colonies. Colonies are replated several 
times and can be counted at each round to measure the frequency of colony forming cells 
which possess self renewal capacities. Variations of this assay can be used to monitor 
proliferative potential of cells in response to drug treatments or genetic manipulation. 
Furthermore, this technique can be used to evaluate the differentiation of 
haematopoietic progenitors by characterising colonies of different phenotypes produced 
in culture. 
Cytokines can be added to the culture to support the growth of particular 
populations and to drive the differentiation of a particular phenotype. In this study, IL-3, 
IL-6 and GM-CSF mouse recombinant cytokines were added to culture to drive the culture 
towards a macrophage-granulocyte progenitor population as this is the cell type that is 
seen to be abnormal within AML.  
Primary mouse bone marrow cells were c-Kit enriched and transfected with 
Meis1/Hoxa9 retroviruses according to section 2.3.5.3. Methylcellulose was prepared as 
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per section 2.2.1.6. Cells were then added to methylcellulose and vortexed thoroughly to 
ensure homogenous mixing prior to plating. Cell/methylcellulose mix was distributed into 
duplicate wells in a 6-well plate using a sterile needle and syringe. Sterile water was 
dispersed to empty wells within the plate to increase humidity. Furthermore, plates were 
incubated within a humidifying box to ensure constant humidity and to prevent the 
media from drying out. Cultures were incubated for a period of 5-8 days (based on 
growth) at 37oC, 5% CO2. Colonies were counted and images recorded using standard 
light microscopy. Colonies were then harvested and resuspended in IMDM. Cells were 
counted and added to fresh methylcellulose at a density of 1 x 104 cells/mL before 
returning to culture for a second round of replating. This density of cells was chosen as 
plating with lower densities failed to produce colonies. Procedure was repeated every 5-8 
days for up to 5 rounds of replating, with colonies being assessed at each round. A sample 
was also taken at each round and cells were analysed by flow cytometry to determine 
their immunophenotype. This assay often generated large numbers of cells and surplus 
cells were used to generate cell lines or were frozen down for future use as per section 
2.3.2.2. 
 
 
 
 
 
 
Figure 2.3 Illustration demonstrating preparation of cells by CFC assay.  
Bone marrow cells are extracted from mice, which are plated into methylcellulose in a CFC assay. 
Colonies developed can be transferred to liquid culture to establish new cell lines. 
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2.3.5.5 Single cell cloning assay 
A single cell cloning assay was used to estimate the self renewal capacity and 
leukaemic potential of cells generated in the CFC assay. Cells were allowed to produce 3 
generations of colonies, at which point they were considered fully transformed. Cells 
from CFC3 were harvested from methylcellulose and washed several times. Cells were 
stained with fluorescently labelled antibodies against specific LSC cell markers as 
described in section 2.3.6.2. Cells were analysed by flow cytometry to visualise the pre-
LSC population based on the expression of cell markers. Single pre-LSCs were then sorted 
directly into individual wells of a 96-well plate containing 80μL of methylcellulose 
(prepared as described in section 2.2.1.6). Single cells for each biological sample were 
plated in 96 replicates. Plates were spun down to place the cell in the centre of the well. 
Plates were incubated at 37°C for approximately 10 days to allow colonies to develop. 
After 10 days, each well was scored for the presence or absence of a colony. Scores were 
used to determine the frequency of cells within each sample that had self renewal 
capacity. 
 
2.3.5.6 Culture and expansion of murine cell lines 
Cells generated during the CFC assay were used to establish a cell line of 
transformed pre-LSCs. Cells were replated several times before considered fully 
transformed so only cells that had formed colonies three times (CFC3) were used to 
generate cell lines. A minimum of 1 x 105 cells were seeded into a liquid culture 
containing high concentrations of cytokines (IMDM 40/20/20 as detailed in section 
2.2.1.3).  Media was replaced after 24 hours to remove any dead cells or debris carried 
over from the colonies, which also contained some dead cells. After a further 24-48 hours 
(dependent on growth), cells were passaged and resuspended in media containing a 
lower concentration of cytokines (IMDM 20/10/10 as detailed in section 2.2.1.4). In order 
to wean cells off higher concentrations of cytokines, cells were passaged several times in 
IMDM 20/10/10. Once cells appeared to be stabilised, cells were passaged and added to a 
media containing only IL-3 (IMDM IL-3 as detailed in section 2.2.1.5). Once stabilised, cells 
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were grown in IMDM IL-3 and passaged every 2-3 days dependent on growth, and 
resuspended in pre-warmed, fresh media to expand culture. Cell lines were maintained at 
a density of 2.5 x 104cells/mL. Cell lines were frozen at early passages in multiple aliquots, 
creating a reserve that was used for future experiments.  
 
2.3.5.7 Assessment of viability and cell growth 
Counting of the cells and assessment of viability were determined by trypan blue 
exclusion using a counting chamber or haemocytometer. Trypan blue is incorporated by 
dead cells that do not have an intact membrane, causing dead cells to appear blue in 
colour under the microscope. Viable cells with an intact membrane do not incorporate 
trypan blue and do not take on the blue colour, allowing them to be discriminated against 
dead cells. Viable cells can be counted in order to determine the cell number and growth 
of the culture. In order to determine viability, dead cells are counted separately from 
living cells to calculate the ratio of living/dead cells. 
Trypan blue stock solution was diluted 1 in 10 in PBS to give a working solution. 
Cell suspension was diluted 1 in 2 in trypan blue solution. Cell suspension mixed with 
trypan blue solution was added to the chamber of a haemocytometer and cells counted 
under the microscope. To ensure an accurate count, four squares within the chamber 
were counted and an average of the four squares was used to give the cell count. Cell 
count was then multiplied by the dilution factor (i.e. 2) and 1 x 104 to give the 
concentration of the cell suspension per mL. 
 
2.3.5.8 Drug treatment of cell lines 
Common leukaemia treatment chemotherapeutic agents Doxorubicin and AraC 
were used to treat cell lines. Doxorubicin (Dox) was available at 2mg/mL and was diluted 
to give a stock solution of 200ng/mL before use. Dox was diluted 1 in 100 to give a 
20,000ng/mL solution. 20,000ng/mL drug solution underwent a further dilution of 1 in 
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100 to give a 200ng/mL solution, which was distributed into 1ml aliquots and stored at -
20oC. Dox was diluted in 0.9% NaCl/H2O as directed by product datasheet.  
AraC was available at 1g/10mL and was diluted to give a stock solution of 24ng/mL 
before use. AraC stock solutions were determined in a similar manner to solutions of Dox; 
a 100x solution was made from the original stock and this was then used to make a 1x 
solution which was used to generate concentrations needed in future experiments. 
However, as the concentration of AraC is expressed in g/mL, calculations were first done 
to determine the volume of solution required to generate a 100x solution. 24.32µL of 
neat drug stock was added to 975.68µL of ddH2O to give a solution of 2,400ng/mL. 
2,400ng/mL solution was then diluted 1 in 100 to give a solution of 24ng/mL (100nM). 
The concentration of both drugs was determined based on similar studies published in 
the literature (Pardee et al, 2011). Within this study, AraC concentration is expressed in 
nM notation and all working solutions have been calculated to be in accordance with the 
concentrations used in other studies. However, as a comparison between the two drugs 
used, the concentration of AraC has been expressed as ng/mL, as with Dox. AraC was 
diluted in ddH2O as directed by the product datasheet. 
1X stock solutions of AraC and Dox underwent serial dilutions to give a range of 
concentrations which were used to treat cell lines. Cells were counted and viability 
assessed as per section 2.3.5.6. Only cell lines with good viability for that particular 
genotype (as determined by previous experiments) were used in the assay. Cells were 
seeded into 96-well plates at a density of 5 x 105/mL with 1 x 105 cells being seeded to 
each well in a total volume of 200µL per well. WT and KO cell lines were tested and each 
biological replicate was plated in duplicate. The volume required of Dox and AraC solution 
to make the desired concentrations within a 200µL final volume was calculated and the 
correct volume of drug stock was added to each well. Plates were incubated at 37oC for 
24 or 48 hours without disruption. Cell response was assessed at 24 and 48 hours. Cell 
growth was assessed by trypan blue exclusion method as detailed in section 2.3.5.7. 
Apoptosis was also assessed by flow cytometry, as detailed in section 2.3.6.4. 
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2.3.5.9 Radiation treatment of cell lines 
Cell lines were counted and plated at a density of 5 x 105/mL in IMDM IL-3. Plates 
were sealed using parafilm to ensure cells remain in sterile conditions during 
transportation. Plates were put on ice and transported to The Beatson Institute for 
Cancer Research in order to use the radiation facilities. Plates were subjected to various 
doses of gamma radiation. The length of exposure was calculated based on the strength 
of the machine which decreases over time. Cells were analysed immediately or returned 
to culture depending on the time points being examined during the experiment. 
 
2.3.5.10 Hypoxia treatment of cell lines 
Cell lines were counted and plated at a density of 5 x 105/mL in IMDM IL-3. Plates 
were transported to a specialised hypoxia chamber which allows cells to be cultured at 
37oC in an environment with a set concentration of Oxygen. Cells were subjected to 1% 
Oxygen for 24 hours before being analysed by flow cytometry. 
 
2.3.6 Flow cytometry and cell sorting  
2.3.6.1 Flow cytometry  
Flow cytometry is a laser-based technology which allows cells to be counted, 
sorted or detected based on the presence of biomarkers. Flow cytometry has been used 
throughout this study to detect frequencies of specific cell populations based on the 
expression of surface markers. In addition, many other biochemical processes can be 
analysed in this way including apoptosis and cell cycle progression. Flow cytometry can 
detect the size and granularity of the cells which is used to discriminate different cell 
types within a heterogeneous population based on these parameters, which is displayed 
as forward scatter and side scatter, respectively. This can also be used to exclude dead 
cells from viable populations, as dead cells appear much smaller and denser than larger 
living cells. Prior to analysis by flow cytometry, cells can be incubated with fluorescently 
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labelled antibodies which will bind to specific antigens present on the cell. Cells are then 
passed through lasers which allow fluorescent signals to be emitted by labelled cells, 
allowing for the quantification of cells that are positive for the particular antigen, based 
on the fluorescent signal detected by the flow cytometer.   
All antibodies and reagents used for this technique have been listed in section 
2.1.6. A FACSCanto™ II or LSRFortessa™ cell analyser (both from BD Biosciences) were 
used for flow cytometry analysis and a FACSAria (BD Biosciences) was used for single cell 
sorting. Unstained cells, compensation beads and single colour controls were used to 
compensate for all fluorescent overlap and to optimize gating strategy prior to analysis. 
All data was acquired using BD FACSDiva (BD Biosciences) and analysis was performed 
using FlowJo (Tree Star Inc., Ashland, USA) software.  
 
2.3.6.2 Assessment of immunophenotype 
The immunophenotype of cells was determined by the simultaneous expression of 
cell surface markers c-Kit, Mac-1 and Gr-1. An appropriate number of cells were washed 
in PBS/FBS and incubated in appropriate concentrations of antibody mix on ice and away 
from light to reduce fading of fluorescence. Cells were washed to remove any unbound 
antibody and resuspended in PBS/FBS containing DAPI. DAPI is a DNA stain that can be 
used to distinguish living and dead cells based on the permeabilisation of the dye by dying 
or dead cells with compromised cellular membranes. Unstained cells and compensation 
beads were also prepared and kept on ice prior to analysis. 
 
2.3.6.3 Assessment of cell cycle frequencies 
Ki67 and DAPI staining was used to determine the frequency of cells in the 
different stages of the cell cycle. Ki67 is known to be expressed by cycling cells but it is 
not detectable in non-cycling cells (Endl et al, 1997). Therefore, cells in G0 can be 
distinguished based on the lack of Ki67 expression. Cells that are positive for Ki67 
expression are considered to be actively proliferating. Simultaneous staining with DAPI 
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allows the other phases of the cell cycle to be identified based on the DNA content of the 
cells. For example, cells that have completed DNA synthesis during S phase will have a 
higher concentration of DNA and therefore, a higher incorporation of DAPI and higher 
fluorescent intensity on flow cyotometry. 
Cells were counted and approximately 4 x 104 cells were seeded into a round-
bottomed 96-well plate. Plates were centrifuged and washed to remove residual media. 
Cells were resuspended in fixation/permeabilisation buffer as detailed in section 2.2.3.4 
and incubated at room temperature for 30 mins. Cells were then washed several times 
using wash buffer as detailed in section 2.2.3.5. Anti-Ki67 antibody was added to the 
residual wash buffer within each well and vortexed gently to resuspend cells within the 
solution. Plates were incubated at room temperature in the dark for 30 mins. Following 
antibody incubation, plates were centrifuged and cells washed several times before being 
resuspended in PBS supplemented with DAPI. Samples were kept away from light until 
analysed by flow cytometry. Unstained cells and an isotype control were used to 
distinguish a positive result from background fluorescent signal. 
 
 
 
 
 
 
Figure 2.4. Representative plot of cell cycle analysis by Ki67 staining.   
DAPI and Ki67 staining is visualised on the X and Y axes respectively. Gates are determines using 
an FITC isotype control and an unstained control. Ki67+ positive cells are considered as cycling 
cells and can be further categorised based on the DNA content of the cells as measured by DAPI 
staining.  
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2.3.6.4 Assessment of apoptosis 
The frequency of apoptotic cells was determined by the detection of Annexin V 
binding and incorporation of DAPI. During the process of apoptosis, phosphatidylserine 
(PS) is expressed on the outer membrane of the cell. Annexin V is known to bind strongly 
with PS and is commonly used to measure apoptosis. Annexin V can be labelled with 
fluorescent epitopes that can be detected by flow cyotmetry. Annexin V-DAPI- cells were 
considered viable as these cells did not incorporate DAPI or bind to apoptosis marker 
Annexin V. Annexin V+ cells were considered to be undergoing apoptosis. However, these 
can be further discriminated into early and late apoptosis by using DAPI. Cells that were 
Annexin V+ but DAPI- were considered to be in early apoptosis as DAPI was not able to 
penetrate the cell, suggesting that the cell had an intact membrane. Cells that were 
Annexin V+ which were also DAPI+ were considered to be in late phase apoptosis as these 
cells had lost membrane integrity. 
Cells were washed several times and incubated in a solution of HBSS and Annexin 
V and kept in the dark for 15 mins at room temperature according to manufacturer’s 
protocol. Immediately prior to analysis, cells were further diluted with HBSS containing 
DAPI. Unstained cells and cells stained with single colours were used to set up gating 
strategy, allowing for the detection of viable cells and cells undergoing early and late 
apoptosis. 
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Figure 2.5 Representative plot of Annexin V and DAPI staining to analyse apoptosis.  
Annexin V and DAPI can be visualised on the X and Y axes respectively. Viable cells which are 
negative for both Annexin V and DAPI can be seen in Q4 of the plot. Q3 shows cells that are 
Annexin V+ but negative for DAPI, which are considered in the early phases of apoptosis. Q2 
contains cells positive for both Annexin V and DAPI, which are considered to be in the late stages 
of apoptosis. Unstained controls and cells stained with single colours were used to determine the 
gates. 
 
2.3.6.5 Assessment of functional mitochondria 
MitoTracker Green is a fluorescent mitochondrial stain which stains mitochondria 
within the cell regardless of membrane potential. That is, MitoTracker Green stains 
mitochondria in both healthy and dying cells. This technique can be used to visualise the 
number of mitochondria in cells through analysis by flow cytometry.  MitoTracker Red 
works in a similar way but stains intact mitochondria in living cells only and is dependent 
on membrane potential. Cells can be stained with both MitoTracker Red and MitoTracker 
Green to distinguish the total number of mitochondria against respiring mitochondria to 
give the frequency of functional and dysfunctional mitochondria.  
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1 x 105 cells were plated into round-bottomed 96-well plates. Plates were 
centrifuged and cells washed in PBS. MitoTracker Green and MitoTracker Red stains were 
diluted in prewarmed IMDM to give a final concentration of 100nM for each stain. 
MitoTracker Red/Green mix was added to cells and incubated at 37oC for 30 mins 
according to manufacturer’s protocol. Following incubation, cells were washed in PBS to 
remove excess antibody. Stained cells were resuspended in PBS/2% FBS and analysed by 
flow cytometry. 
 
 
 
Figure 2.6. Assessment of functional and dysfunctional mitochondria.  
MitoTracker Green mitochondrial stain can be used in conjunction with MitoTracker Red stain in 
order to distinguish functional and dysfunctional mitochondria. MitoTracker Red stains only 
respiring mitochondria whereas MitoTracker Green stains total mitochondria. A population that 
stains positive for both colours is considered to be functional mitochondria. However, cells that 
stain positive for MitoTracker Green only contain dysfunctional mitochondria.  
 
2.3.6.6 Assessment of DNA damage 
Cells were fixed and permeabilised following the protocol detailed in section 
2.3.6.3. After cells were washed, anti-H2AX antibody was added to the residual wash 
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buffer within each well and vortexed gently to resuspend cells within the solution. Plates 
were incubated at room temperature in the dark for 60 mins. Following antibody 
incubation, plates were centrifuged and cells washed several times before being 
resuspended in FITC anti-mouse secondary antibody for a further 30 mins. Cells were 
then washed several times in PBS and resuspended in PBS supplemented with DAPI. 
Samples were kept away from light until analysed by flow cyotmetry. Unstained cells and 
an isotype control were used to distinguish a positive result from background fluorescent 
signal. 
 
2.3.6.7 Flow cytometry cell sorting  
Cells to be seeded into the single cell cloning assay (as detailed in section 2.3.5.4) 
sorted were stained with appropriate antibodies, washed and resuspended in PBS/FBS. 
Cells were filtered using a sterile nylon filter and samples were kept on ice prior to sorting 
by FACSAria (BD Biosciences).  
 
2.3.7 Western blotting 
2.3.7.1 Preparation of protein lysates  
RIPA buffer was used to lyse cells and was prepared on ice as described in section 
2.2.2.1 immediately prior to use. Cells were washed twice in ice cold PBS and 
resuspended in RIPA buffer. Cells in RIPA buffer were incubated on ice and placed on a 
shaker for 30 mins. Cells were centrifuged at for 30 mins at maximum speed at 4oC to 
separate the DNA and cellular debris from the supernatant containing denatured 
proteins. Supernatant was collected and immediately stored at -20oC for short term 
storage or -80oC for long term storage.   
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2.3.7.2 Protein quantification  
The proteins contained in each supernatant samples were quantified using the 
BCA™ protein assay kit in accordance with the manufacturer’s protocol. Appropriate 
reagents were added to samples which were incubated at room temperature for 30 mins. 
A colour change occurred in samples containing protein; the intensity of the colour 
correlating with the concentration of protein in the sample. The intensity of the resulting 
colour can then be measured using a spectrometer, which measures the UV absorbance 
within the sample. Standards, which are included in the BCA assay kit, contain known 
concentrations of protein. These were used to generate a standard curve which was used 
to determine the concentration of protein in the unknown samples, based on the 
absorbance of each sample. The concentrations of protein within the samples were used 
to determine the volume of sample needed for the western blot and to ensure that an 
equal amount of protein was loaded for each sample. 
 
2.3.7.3 Gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) is a widely used technique 
used to separate proteins by size. SDS is a negatively charged detergent that linearises 
proteins and coats them with an uniform negative charge masking the intrinsic charge of 
the residues such that when an electric current is applied, the proteins to move towards 
the positive electrode. Proteins migrate through the gel at different speeds, according to 
their molecular weight. This results in smaller proteins migrating further through the 
matrix than large ones. A protein marker can be used to mark the position of known sizes 
of proteins, which appear as bands along the gel. This marker can be used to judge the 
sizes of proteins that appear in the unknown samples.  A protein of interest can be 
identified based on the presence of a band of the correct size. 
Protein samples were prepared in 1X SDS buffer and heated at 95oC for 5 mins. 
Samples were then loaded into separate wells of the gel alongside a pre-stained protein 
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ladder. Running buffer (as detailed in section 2.2.2.4) was added to the gel to prevent it 
from drying out. Samples were run at 120 volts for 1.5 hours. 
 
2.3.7.4 Membrane transfer 
Following gel separation, proteins were transferred to PVDF membrane which 
would allow proteins to be visualised through immunoblotting. The hydrophobicity of 
PVDF membrane means it must first be soaked in methanol for approximately 30 
seconds. The gel containing the separated proteins and the PVDF membrane were 
pressed together tightly using several layers of sponges and paper which were soaked in 
transfer buffer (section 2.2.2.3) Layers were compressed in a transfer cassette which was 
loaded into the electrophoresis tank containing ddH2O to prevent the system from 
overheating. The tank was then placed on ice or in a cold room and the transfer was run 
at 30 volts for 3 hours. Successful transfer was determined by the printing of the protein 
ladder from the gel onto the membrane. The membrane was kept in TBST solution at all 
times following the transfer to prevent it from drying out. 
 
2.3.7.5 Immunolabelling  
Following transfer of the proteins to the membrane, the membrane was 
transferred to a blocking solution of 5% (w/v) Milk in TBST to try and minimise non-
specific binding. Membrane was incubated overnight at 4oC with gentle rotation to allow 
constant motion and to ensure the entire membrane was blocked. The following morning, 
the membrane was transferred to fresh blocking solution containing the appropriate a 
primary antibody which will bind specifically to the protein of interest. Membrane was 
incubated in the primary antibody with gentle shaking for a minimum of 1 hour. Following 
antibody incubation, membrane was washed several times in TBST to remove unbound 
antibody. The membrane was then incubated in the appropriate secondary antibody 
which is used to detect the presence of protein-bound primary antibody for 1 hour at 
room temperature with gentle shaking. Blot was washed several times before an ECL 
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detection method was used to visualise the bound antibody and therefore identify the 
presence of the target protein. Supersignal West Dura ECL kit was used according to 
manufacturer’s instructions. The blot was kept in the dark to avoid loss of luminescent 
signal. Blots were pressed onto x-ray film, which was developed in a dark room using an 
x-ray developing machine.  
 
2.3.8 In vivo studies 
2.3.8.1 Overview 
A transplantation assay was used to assess the leukaemic potential of the 
Meis1/Hoxa9 transformed pre-LSCs which were generated in the CFC assay. Cells used in 
the CFC assay were harvested from WT and PHD KO mice which were originally bred with 
B6-Ly5.2 mice which have a CD45.2+ background. The transfer of CD45.2+ cells to 
recipient mice with a different CD45 background, allows the prevalence of CD45.2+ cells in 
the bone marrow of recipient mice to be monitored by flow cytometry and distinguished 
from the bone marrow cells of the recipient. As it is unclear as to whether these cells will 
have the ability to reconstitute the bone marrow, and due to the difficulty and expense of 
generating high concentrations of pre-LSCs, support bone marrow can be transplanted 
simultaneously to ensure the adequate reconstitution of the bone marrow and survival of 
the recipient mice. Mice can be monitored long term for signs of leukaemic development 
to determine if genetic differences between the samples injected affect the leukaemic 
potential of the cells. 
 
2.3.8.2 Cell preparation 
The CFC assay as detailed in section 2.3.5.3, was used to generate pre-LSCs which 
were used in transplantation assays. Samples were plated into the CFC assay as normal 
but several replicate plates were incubated on the third round of replating to ensure that 
an adequate number of cells were available for harvest at CFC3. Cells were washed 
several times in PBS supplemented with 2% FBS to remove any residual media. Cells were 
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then c-Kit enriched according to section 2.3.5.2 to ensure a population of pre-LSCs. The 
genotype of each sample was confirmed by PCR prior to transplantation. 
During this assay, support bone marrow was harvested from mice with a CD45.1 
background. Using mice with a different CD45 background allows both the pre-LSCs and 
support bone marrow to be tracked simultaneously by flow cytometry following 
transplantation. Bones were harvested and crushed and red blood cells lysed as detailed 
in section 2.3.5.1. White blood cells were filtered using a 0.2µM sterile filter and counted 
using an automated Hemavet 950FS (Drew Scientific) cell counter. Pre-LSCs and support 
bone marrow was mixed at a ratio of 1 x 105 per-LSCs to 2 x 105 support bone marrow 
cells per recipient mouse.  Samples were kept in sealed sterile tubes on ice until the time 
of injection. Samples were analysed by flow cytometry to determine that the frequency of 
pre-LSCs, as well as the ratio between CD45.2 and CD45.1 cells was similar in each 
sample. 
 
 
 
 
 
Figure 2.7. Illustration demonstrating cell preparation for transplantation.  
Cells are extracted from mice and entered into a CFC assay. Cells produced in the CFC assay are c-
Kit enriched and transplanted to lethally irradiated recipient mice. 
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2.3.8.3 Preparation of recipient mice 
Ly5.1/Ly5.2 F1 (first filial generation) hybrid mice, which result from crossing Ly5.1 
and Ly5.2 mice, were supplied by University of Edinburgh Biological Services and used as 
recipient mice. Ly5.1/Ly5.2 F1 hybrid mice are heterogeneous for CD45.1 and CD45.2 and 
are referred to in this report as CD45het. CD45het cells can be positively stained for both 
CD45.1 and CD45.2 allowing this cell population to be visualised in the double positive 
quadrant when analysed by flow cytometry. Recipient mice were subjected to 10Gy lethal 
radiation 24 hours prior to injection to deplete the bone marrow of the mice. Radiation 
treatment causes the mice to be immunocompromised following bone marrow depletion. 
Mice were kept in sterile filter-top cages and treated with anti-inflammatory drugs for 4 
weeks from the date of radiation, to reduce the chance of infection until the bone 
marrow was reconstituted by the transplanted bone marrow.  
 
2.3.8.4 Transplantation 
Injection to recipients was carried out as soon as possible following cell 
preparation. Recipient mice received tail vein injections of 200µL of cell suspension under 
sterile conditions. Mice were closely observed following transplantation and were 
sacrificed if considered moribund. Following 4 weeks in sterile conditions, mice were 
transferred to open-top cages and kept in non-sterile conditions. 
 
2.3.8.5 Analysis 
Four weeks following injection, peripheral blood samples were taken from the tail 
vein to assess the background of the cells derived from the reconstituted bone marrow. 
Blood samples were taken every 2 weeks and analysed by FACS to determine the 
frequency of CD45.2+ cells as an indication of leukaemia. When mice appeared to have a 
high frequency of CD45.2+ cells within the blood, they were considered leukaemic and 
were sacrificed to prevent suffering of the animal. At this point, mice usually had some 
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physical symptoms of leukaemia including swelling around the face or torso and lethargic 
behaviour. Blood, bone marrow, spleen and thymuses were harvested from leukaemic 
mice for analysis. 
 
2.3.8.5.1 Blood 
Blood samples were collected in heparin-coated collection tubes and kept at room 
temperature to minimise coagulation. Neat blood samples were used to assess cellularity 
and WBC concentration which was determined by automated cell counter. 10µL of blood 
was added to 400µL of NH4Cl to lyse red blood cells and to allow white blood cells to be 
analysed. Lysed cells were incubated with antibodies against CD45.1 and CD45.2 to 
determine the frequency of CD45.2 cells. In addition, antibodies against c-Kit, Mac-1 and 
Gr-1 were used to determine the frequency of cells with a LSC phenotype. Cells were 
washed and resuspended in PBS before being analysed by FACS. 
Ten microlitres of whole blood was also used to create blood smears by spreading 
the sample onto a microscope slide and fixing the cells in ethanol. Slides were then 
treated with Giemsa-Wright staining solution which allows cells to be differentiated when 
analysed under a light microscope. Images were collected from several blood samples to 
assess the presence of blast-like cells within the blood.   
 
2.3.8.5.2 Bone marrow 
Femur and tibia were collected with care from leukaemic mice and bone marrow 
cells extracted as per section 2.3.5.1. The WBC concentration of the bone marrow cell 
suspension was counted by automated cell counter. Bone marrow cells were stained with 
antibodies against CD45.1, CD45.2, c-Kit, Mac-1 and Gr-1 as described in section 2.3.6.2. 
Bone marrow cells of leukaemic mice were also further analysed to determine 
apoptotic frequencies as detailed in section 2.3.6.4. 
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2.3.8.5.3 Spleen & Thymus 
Spleens collected from leukaemic mice were weighed, measured and 
photographed to evaluate the enlargement of the spleen which is characteristic of 
leukaemic disease.  
Spleens and thymuses were mashed in 12mL & 7mL PBS/2% FBS, respectively, 
using a sterile plunger and filtered to give a single cell suspension. Cellularity and 
frequency of CD45.2+ LSCs were determined as described in section 2.3.6.2. 
 
2.3.9 Statistical analysis 
The results included in this report are shown as the means of samples including 
both biological and technical replicates. Error was calculated based on standard deviation. 
All statistical analyses were performed using the student’s unpaired t-test for two sample 
analysis using Microsoft Excel. A t-test value of p <0.05 was considered significant. 
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3 Results 
 
3.1 Establishment of Pre-LSCs Lacking PHD Isoforms and the Investigation 
into Self Renewal Capacity 
3.1.1 Optimisation of antibiotic concentration required for selection of transduced cells 
In order to investigate the role of PHD in leukaemia, an in vitro transformation 
assay which is well established in the literature was utilised (Kroon et al, 1998; 
Somervaille & Cleary, 2006; Zeisig & So, 2009; Yeung et al, 2010). This assay facilitates the 
in vitro transformation of haemopoietic cells through retroviral transduction with 
leukaemia-inducing oncogenes, for example Meis1 and Hoxa9. The successful 
transduction of cells with oncogene containing retroviruses can be confirmed using 
appropriate selection antibiotics, based on the presence of antibiotic resistance cassettes 
carried by the plasmids (as detailed in Chapter 2).  
The viruses used for transformation had not previously been assessed in 
haemopoietic cells, and therefore the assay required optimisation. Puromycin and 
neomycin antibiotic treatments were used to verify Meis1 and Hoxa9 retroviral 
transduction, respectively. A concentration-effect assay was conducted to determine the 
optimal dose of these antibiotics to be used for selection, that is, the concentration which 
killed non-transduced cells lacking the antibiotic resistance cassette. However, as normal 
HSPCs are unable to survive in in vitro culture for long periods, a commonly used mouse 
fibroblast cell line (NIH3T3) was chosen for the initial antibiotic sensitivity assay. It should 
be noted that there are some differences between NIH3T3 cells and HSPCs and that 
NIH3T3 cells may not be the best representative of HSPC sensitivity. The main differences 
between these cells are that where HSPCs are primary cells that grow in suspension 
culture, NIH3T3 cells are adherent cell lines. Despite these differences, NIH3T3 cells were 
chosen for this assay as they are of mouse origin. Unfortunately, murine suspension cells 
were unavailable for this assay. NIH3T3 cells were seeded into 6 well plates and allowed 
to adhere for 24 hours. Puromycin or neomycin was then added to cells in increasing 
concentrations. NIH3T3 cells were then grown in the presence of antibiotics for 72 hours 
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to determine which concentration effectively killed non-transduced NIH3T3 cells. The 
addition of 0.5ng/mL puromycin failed to effectively kill parental, non-transduced NIH3T3 
cells (Fig. 3.1.1). However, non-transduced NIH3T3 cells did not survive following addition 
of 1ng/mL puromycin. Similarly, the addition of 0.5µg/mL neomycin was ineffective; 
however, 1µg/mL neomycin successfully killed non-transduced NIH3T3 cells.     
The drug sensitivity assay was conducted in order to determine the drug 
concentrations needed to effectively select transduced NIH3T3 cells. NIH3T3 cells were 
used to test the efficiency of each batch of virus produced and the concentrations used 
during this selection process were determined by the results of the sensitivity assay. The 
results of the sensitivity assay were also used to determine an approximate concentration 
to use for selecting transduced HSPCs. However, as the exact sensitivity of HSPCs to either 
puromycin or neomycin was unclear, it was decided to use a slightly higher concentration 
for these cells to reduce the possibility of non-transduced cells evading selection. Based 
on the results of the NIH3T3 selection assay, it was concluded that 1.5ng/mL puromycin 
and 1.5µg/mL neomycin were the most effective concentrations to be used to select 
transformed HSPCs. 
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Figure 3.1.1. Antibiotic titration for retroviral selection.  
Meis1 and Hoxa9-transduced NIH3T3 cells were cultured in the presence of different concentrations 
of puromycin and neomycin in order to determine the most effective concentration of antibiotic that 
would kill the majority of cells, allowing the surviving cells to be positively selected, based on the 
expression of antibiotic resistance genes. In brief, mouse fibroblast NIH3T3 cells were seeded and 
cultured overnight in DMEM media to allow adhesion. Adherent cells were cultured in media 
containing viral particles for 24 hours, allowing cells to be transduced with Meis1 and Hoxa9 
oncogenic viruses. Meis1 and Hoxa9-transduced NIH3T3 cells were cultured with antibiotics for 72 
hours before survival of the cells was assessed. Cells undergoing selection were imaged and assessed 
by standard light microscopy.  
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3.1.2 Verification of successful transduction by Meis1 and Hoxa9 retroviruses 
Efficiency of Meis1 and Hoxa9 retroviral transduction was assessed using NIH3T3 
cells. NIH3T3 cells were transduced with retroviruses and grown in the presence of 
selection antibiotics. Their response to the antibiotic was assessed after 72 hours (Fig. 
3.1.2). NIH3T3 cells which survived the selection were considered to be fully transduced 
and so the virus production was verified as successful. Every batch of retrovirus produced 
was tested in this manner and only virus batches that were confirmed as effective in 
NIH3T3 transduction were used to transform HSPCs.  
 
3.1.3 Self renewal as a read out for transformation 
Self renewal capacity is known to be significantly enhanced in transformed cells 
and so investigating self renewal in cells lacking PHD would also indicate the requirement 
of PHD in the transformation of LSCs. In order to assess self renewal, femurs and tibias 
were first harvested from mice. Bones were crushed to release bone marrow cells, which 
included the HSPCs, and these were collected in PBS suspension. HSPCs were enriched 
based on the expression of c-Kit. HSPCs extracted from wild-type (WT) mice were used as 
controls. HSPCs were also collected from mice lacking individual or multiple PHD 
isoforms, referred to collectively as PHD knock-out (KO). Following viral transduction, 
transformation was assayed in the colony-forming cell (CFC) assay that is commonly used 
in the literature to determine the self renewal capacity of cells in vitro. WT and PHD KO 
cells were each analysed and compared so that the role of PHD in the self renewal 
capacity of pre-LSCs could be determined.  
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Figure 3.1.2. Retroviral selection for Meis1 and Hoxa9 transduction.  
NIH3T3 cells were used to test the efficiency of transduction for each batch of virus produced. NIH3T3 
cells were seeded and cultured overnight in IMDM to allow cells to adhere. Cells were cultured for 24 
hours in media contain Meis1, Hoxa9 or both Meis1 and Hoxa9 viral particles to allow transduction of 
NIH3T3 cells. Following transduction, cells were cultured in fresh media containing puromycin or 
neomycin at concentrations determine by the optimisation experiment, in order to select fully 
transduced cells based on the expression of resistance cassettes carried by the retroviruses. This 
method was used to test efficiency of each batch of virus produced to ensure efficient transduction of 
cells. A. As a control, non-transduced NIH3T3 cells were treated with puromycin or neomycin to 
ensure selection was efficient and that non-transduced cells do not grow following selection. B. 
NIH3T3 cells retrovirally transduced with Meis1, Hoxa9 or both Meis1 and Hoxa9 were considered to 
be successfully transformed based on their resistance to puromycin or neomycin. 
NIH3T3 transduced with Hoxa9 
and selected with 1.5mg/mL 
neomycin 
NIH3T3 transduced with Meis1 
and selected with 1.5µg/mL 
puromycin 
A 
B 
NIH3T3 transduced with Meis1 
and Hoxa9 and selected with 
1.5µg/mL puromycin and 
1.5mg/mL neomycin 
Non-transduced NIH3T3 treated 
with 1.5mg/mL neomycin 
Non-transduced NIH3T3 treated 
with 1.5µg/mL puromycin 
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A non-transforming control virus was used to determine the survival and self 
renewal capacity of non-transformed HSPCs. HSPCs were infected with empty vector 
retrovirus Mouse Stem Cell Virus (MSCV). MSCV-transduced cells produced colonies that 
were well-spread with a distinct morphology as compared to colonies produced by 
Meis1/Hoxa9-transduced cells. Colonies produced by MSCV-transduced cells appeared to 
have a similar phenotype regardless of genotype, which is WT or KO background (Fig. 
3.1.3). MSCV-transduced cells also produced colonies on the second round of replating. 
Colony frequency of MSCV-transduced cells was similar regardless of genotype with no 
significant differences seen. This result suggested that the absence of PHD isoforms did 
not affect the self renewal capacity of non-transformed HSPCs in vitro. All MSCV-
transduced cells failed to produce colonies on the third round of replating, suggesting 
that non-transformed HSPCs have a limited self renewal capacity in vitro, as was 
expected.  
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Figure 3.1.3. Transduction of HSPCs with MSCV-neo and MSCV-puro.  
Bone marrow cells were extracted from WT and PHD KO mice. White blood cell population was purified 
by lysing red blood cells. Cells were enriched for c-Kit expression to enrich a HSPC starting population. 
HSPCs were transduced with MSCV control virus to assess the colony forming abilities of non-
transformed HSPCs. Freshly thawed media containing MSCV-neo and MSCV-puro viral particles were 
added to 1 x 106 cells. Cells were centrifuged at 800 x g for 2 hours before being resuspended in fresh 
media and cultured overnight. Procedure was repeated after 24 hours. 48 hours following infection with 
virus, cells were cultured in media containing neomycin or puromycin for 72 hours to select fully 
transduced cells. Following selection, cells were counted and seeded into methylcellulose at 
10,000cells/mL. Cells were cultured for 5-7 days and cells with self renewal ability produced colonies. 
Colonies numbers were recorded before cells were harvested, counted and seeded into fresh 
methylcellulose for a further 5-7 days. Replating procedure was repeated every 5-7 days until cells 
expired.  A. Images are representative of colonies produced by WT, PHD1 KO and PHD2 KO HSPCs. B. 
Data presented are the mean total number of colonies produced by MSCV-neo/MSCV-puro-
transduced cells during serial replating assay. The number of biological replicates for each genotype 
seeded into CFC1 is annotated above each data point. Mean colony numbers for CFC2 and CFC3 were 
based only on plates that produced colonies. The number of plates that produced colonies in CFC2 and 
CFC3 is annotated in the graph. 
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Following selection with puromycin or neomycin, WT and PHD KO HSPCs 
successfully transduced with Meis1 and Hoxa9 all formed dense colonies that had a 
distinctly different phenotype from cells transduced with MSCV (Fig. 3.1.4). Colonies 
produced by Meis1/Hoxa9-transduced cells were similar to those detailed in the 
literature, which are described as hyper-cellular and immature (Takacova et al, 2012). The 
morphology of the colonies suggested that cells may have had enhanced proliferation and 
reduced differentiation as a result of Meis1/Hoxa9 transduction.  
Colonies produced by Meis1/Hoxa9-transduced cells were counted after one 
week. Cells were serially replated, with colonies being counted at each replating. In 
contrast to MSCV-transduced cells, which did not survive after two rounds of replating, 
Meis1/Hoxa9-transduced cells formed colonies after multiple rounds and were 
considered fully transformed after three passages (Fig. 3.1.5). Colony frequency can be 
used to indicate self renewal capacity of the cells. Colony production was comparable 
across all genotypes and no significant differences were seen. However, this assay proved 
to be highly variable. In order to overcome this variability, multiple biological replicates 
were accrued over several experiments. However, it is appreciated that the number of 
biological replicates completed was insufficient for some of the genotypes analysed and 
so further work needs to be carried out in order to gain statistical power and significance. 
Only one biological replicate was available for PHD1/2/3 triple KO, therefore the 
calculated error was based on intra-experimental technical replicates. Therefore, no solid 
conclusion could be drawn on these data. Further data collection for this genotype in 
particular would be very interesting. The functions and interactions of individual PHD 
isoforms are unclear, but it is possible that there may be some redundancy between 
them. It would be interesting to address if in the absence of all three PHD isoforms, a 
situation in which compensation is not possible, self renewal and transformation would 
be affected. Unfortunately, the lack of availability for this genotype made this impossible. 
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Figure 3.1.4. Colony production of pre-LSCs transduced with Meis1 and Hoxa9.  
HSPCs were extracted and purified from mouse bone marrow. Freshly thawed media containing 
Meis1 and Hoxa9 viral particles were added to 1 x 106 cells. Cells were centrifuged at 800 x g for 2 
hours before being resuspended in fresh media and cultured overnight. Procedure was repeated 
after 24 hours. 48 hours following infection with virus, cells were cultured in media containing 
neomycin or puromycin for 72 hours to select fully transduced cells. Following selection, cells 
were counted and seeded into methylcellulose at 10,000cells/mL. Cells were cultured for 5-7 days 
and cells with self renewal ability produced colonies. Colonies numbers were recorded before 
cells were harvested, counted and seeded into fresh methylcellulose for a further 5-7 days. 
Replating procedure was repeated every 5-7 days until cells expired.  A. Images are representative 
of colonies produced by WT, PHD1 KO, PHD2 KO and PHD1/2 KO HSPCs transduced with Meis1 
and Hoxa9.  
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Figure 3.1.5. Colony frequency of Meis1/Hoxa9 transformed pre-LSCs.  
HSPCs were extracted from mouse bone marrow, purified, transduced with both Meis1 and Hoxa9 
retroviruses and seeded into a methylcellulose serial replating assay as previously described. Colonies 
were counted at each round of replating. Data presented are the mean total number of colonies 
produced by Meis1/Hoxa9-transduced cells during serial replating assay. The number of biological 
replicates for each genotype is annotated within each graph. 
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Meis1 and Hoxa9 are both known to be associated with the development of AML 
and are downstream targets of MLL fusion products. Transduction of HSPCs with these 
oncogenes has been reported in the literature to successfully transform cells in vitro, 
which upon transplantation, have the ability to generate murine leukaemia that is 
comparable to human AML. These cells are referred to as pre-LSCs. It is believed that 
although pre-LSCs have leukaemic potential upon transplantation, they require an 
additional mutational hit in vivo, in order to become fully transformed LSCs. Transduction 
of cells with MLL fusion products is also widely used experimentally. However, the 
overexpression of Meis1 and Hoxa9 simultaneously is known to induce AML in murine 
models which is similar to AML induced by MLL transduction, but with a much shorter 
latency (60 days compared to 200 days), making this a more efficient experimental model 
(Wang et al, 2006). Since transduction by downstream targets of MLL fusions, such as 
Meis1 and Hoxa9, provides a more direct and rapid route to disease development, it is 
possible that this may result in a more aggressive phenotype. Studies by Kroon et al 
showed that cells transformed with Hoxa9 alone induced AML with a long latency (8 
months). Cells transformed with Meis1 alone, were not capable of generating leukaemia. 
However, cells transformed with both Meis1 and Hoxa9 simultaneously, are known to 
initiate leukaemic disease within 2-6 months (Kroon et al, 1998; Wang et al, 2006; Gibbs 
et al, 2012). Furthermore, Meis1 is a known to have a role in HSCs and has been reported 
to regulate HIF-1α (Simsek et al, 2010; Unnisa et al, 2012). HIF-1α is reported to have a 
role in leukaemia (Wang et al, 2011; He et al, 2013; Zhang et al, 2012), and it stands to 
reason that up-regulation of HIF-1α, through overexpression of Meis1, may lead to the 
enhanced leukaemogenesis seen in this model. The link between Meis1 and HIF-1α makes 
this an interesting model in which to study the role of hypoxia signalling in leukaemia. As 
PHD isoforms function to destabilise HIF-1α, it is possible that HIF1-α proteins are 
stabilised in cells lacking various PHD isoforms, either single or multiple isoforms. 
Transducing PHD KO cells with Meis1 would cause HIF-1α to be stabilised through both 
pathways, that is, through PHD ablation and Meis1 overexpression, resulting in a higher 
expression of HIF-1α in PHD KO cells. A higher expression of HIF-1α may in turn lead to an 
enhanced Leukaemic phenotype. Therefore, it was interesting to see if PHD KO cells had 
enhanced leukaemogenesis compared to WT cells. 
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It has been hypothesised, although not confirmed, that cells transduced with 
Meis1/Hoxa9 in vitro are pre-disposed to leukaemic transformation, but require a second 
mutational hit in vivo, fully transforming them to LSCs which are capable of generating 
leukaemia (Wang et al, 2005; Chen et al, 2008).  In vitro, these cells are not considered to 
be fully capable of leukaemogenesis and are considered to be in a pre-leukaemic state 
and are therefore referred to as pre-LSCs. Cells generated in vivo that are able to induce 
leukaemia upon transplantation to secondary recipients are referred to as LSCs (So et al, 
2010). 
Considering the known leukaemic potential of cells transformed with Meis1 and 
Hoxa9, along with the putative link to hypoxia signalling, these oncogenes were chosen 
for study in order to transform HSPCs to pre-LSCs.  
  
 
3.1.4 The expression of LSC markers on Meis1/Hoxa9 transduced pre-LSCs 
The simultaneous expression of Mac-1, Gr-1 and c-Kit is unique to LSCs and is 
commonly used to isolate this population by flow cytometry (Somervaille & Cleary, 2006; 
Somervaille & Cleary, 2009; Soh et al, 2010). The expression of LSC markers is also seen in 
pre-LSCs generated in vitro in similar studies. These ‘LSC-like’ cells are suspected to be the 
population that is capable of generating leukaemia in vivo. However, there have been 
some discrepancies in the requirement for Gr-1 as a pre-LSC marker. Gibbs et al recently 
performed an in depth study which aimed to identify the cell population responsible for 
initiating leukaemia in vivo. An in vitro transformation assay was used to establish a 
culture of pre-LSCs. Different combinations of LSC markers were then used to isolate 
populations which were prepared and transplanted to recipient mice. The study 
concluded that the Gr-1+ c-Kit+ cell population had low colony forming ability, (1%) and 
reduced leukaemic potential. However, they further concluded that populations lacking 
expression of Gr-1 were still capable of initiation of leukaemia. In contradiction to this 
study, Somervaille & Cleary found that AML cells that were sorted for Gr-1+ expression 
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had full leukaemic capabilities and cells were able to initiate disease upon transplantation 
(Somervaille & Cleary, 2006). 
However, it was observed that cells which were Mac-1+ were also Gr-1+. 
Therefore, in this study, the definition of ‘LSC-like’ cell is based on the simultaneous 
expression of c-Kit, Mac-1 and Gr-1. Flow cytometry was used to identify expression of 
these LSC markers and the frequency of ‘LSC-like’ cells was assessed. The frequency of 
‘LSC-like’ cells was used to indicate if this population is increased following 
transformation with leukaemia-inducing oncogenes and if it is altered by the ablation of 
PHD genes.   
The expression of the LSC markers c-Kit, Mac-1 and Gr-1 by harvested CFC was 
assessed by flow cytometry. HSPCs transduced with MSCV were used as a control to 
identify the frequency of cells with an LSC phenotype within the non-transformed cell 
population. The first analysis was for c-Kit+ cells as a single marker. c-Kit expression alone 
was assessed as this is a marker of primitive populations. The expression of c-Kit was used 
to determine if the cells had differentiated or remained primitive. This was assessed in 
WT cells and PHD KO cells to examine if PHD ablation affects the differentiation of HSPCs. 
Before cells were plated into methylcellulose (pre-CFC), MSCV-transduced cells showed 
considerable c-Kit+ expression (range 28.8-62.8%), suggesting that a large fraction of the 
cells analysed had not differentiated and had remained primitive (Fig. 3.1.6). Colonies 
formed at each round of the assay were also analysed by flow cytometry for the 
expression of c-Kit. Colonies analysed following the first round of the assay (CFC1) were 
seen to have a higher percentage of c-Kit+ cells. It is likely that c-Kit- cells had already 
expired at this point. c-Kit+ cells however are more primitive and have increased self 
renewal capacity and it is possible that this population does not expire as quickly as c-Kit- 
cells, allowing the c-Kit+ population to become enriched. As MSCV-transduced cells 
expired after the second round of replating, very few cells were available for analysis at 
this point and not all genotypes were available. PHD2 KO and PHD1/2 KO CFC cells were 
analysed and showed a very low percentage of c-Kit+ cells. This suggested that by this 
point, c-Kit+ cells had also begun to exhaust, along with c-Kit- cells. 
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Next, MSCV-transduced cells were analysed for simultaneous expression of LSC 
markers c-Kit, Mac-1 and Gr-1 as a measure for the frequency of LSCs. Cells analysed 
showed a low percentage of cells with an ‘LSC-like’ phenotype prior to the first round of 
the assay which increased following the first round of replating. This population 
diminished following the next round, at which point, cells were mostly expired. 
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Figure 3.1.6. Immunophenotype of MSCV- transduced HSPCs.  
MSCV-transduced cells were harvested from the colonies produced during the serial replating 
assay. Cells were washed in PBS and incubated in an antibody mix containing antibodies specific 
for c-Kit, Mac-1 and Gr-1 and analysed by flow cytometry. Cells were analysed for expression of c-
Kit (A) and LSC markers c-Kit, Mac-1 and Gr-1 (B) at each round of replating. Data presented 
represent the total mean of cell frequencies. The number of biological replicates for each 
genotype analysed at pre-CFC is annotated within the graph. Only one biological replicate was 
available for genotype presented at CFC1 and CFC2 and therefor data represents a single sample. 
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Meis1/Hoxa9-transduced pre-LSCs were also analysed at each round of replating 
and the frequency of cells with an immature phenotype (c-Kit+) as well as the frequency 
of ‘LSC-like’ cells were determined. The frequency of c-Kit+ cells remained high 
throughout multiple rounds of replating, suggesting that these cells had an increased self 
renewal capacity compared to MSCV-transduced cells, which expired at earlier stages of 
the assay (Fig. 3.1.7). No significant differences were seen between WT and PHD KO cells. 
LSC frequency was also investigated in Meis1/Hoxa9-transduced pre-LSCs, which was 
seen to be low during the first stage of the assay, that is, the first time the cells were 
harvested before replating. This might suggest that primitive cells are expiring as they 
have not been fully transformed by the viruses and do not have enhanced self renewal at 
this stage. However, after the first round of replating, the frequency of c-Kit+ cells 
increased significantly. This suggested that non-transformed cells have expired, enriching 
the population with fully transformed pre-LSCs. According to earlier data, cells transduced 
with MSCV virus (non-transformed) have expired at this point in the assay and so ‘LSC-
like’ cells that survive after this point were considered fully transformed pre-LSCs. After 
several rounds of replating, all cells had a significant frequency of pre-LSCs which had an 
‘LSC-like’ phenotype (40.6-73.1% between CFC2-CFC5). Statistical analysis preformed 
showed no significant differences between the genotypes tested. However, the 
frequencies of pre-LSCs were also highly variable and a larger number of biological 
replicates would be required before any firm conclusions could be made. 
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Figure 3.1.7. Immunophenotype of Meis1/Hoxa9 transformed pre-LSCs.  
Transduced cells were harvested from the colonies produced during the serial replating assay. Cells 
were stained with antibodies specific for c-Kit, Mac-1 and Gr-1 and analysed by flow cytometry. Cells 
were analysed for expression of c-Kit (A) and LSC markers c-Kit, Mac-1 and Gr-1 (B) at each round of 
replating. Data presented represent the total mean of cell frequencies. All genotypes consisted of at 
least three biological replicates unless otherwise stated. Genotypes with <3 biological replicates are 
indicated in the graph. 
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3.1.5 In vitro prediction of leukaemic potential and self renewal capacity 
A limiting dilution assay (LDA) is an in vitro assay that is used to quantify the 
frequency of a certain cell property such as self renewal ability. Variations of this assay 
are often used in conjunction with in vivo studies where limiting numbers of pre-LSCs are 
transplanted into recipients, in order to measure the frequency of leukaemia-initiating 
cells (LIC) based on the cells’ capabilities to generate leukaemia. LSCs are considered to 
have leukaemia-initiating potential and so this assay was used to calculate the frequency 
of LSCs. 
This assay was utilised to identify the leukaemic potential of cells lacking PHD 
genes, and as an alternative assay to quantify the frequency of cells with self renewal 
capacity within the pre-LSCs. Pre-LSCs established during CFC were sorted based on their 
expression of c-Kit, Mac-1 and Gr-1. WT, PHD1 KO, PHD2 KO, PHD3 KO and PHD1/3 KO 
cells were available for this experiment. Single pre-LSCs were seeded into methylcellulose 
and incubated for 10-14 days. Colony development was recorded and used to determine 
the frequency of cells that were capable of colony formation. Figure 3.1.8 depicts the 
frequencies of cells that produced colonies and that were therefore considered to be 
LSCs. Statistical analysis was performed and showed no significant difference between 
any of the genotypes assessed. However, not all genotypes analysed in CFC were available 
for this experiment and further work would need to be conducted to complete this study.  
Formal LDA and single cell plating have been used to determine the frequency of 
LSCs in vitro by assessing the cloning ability of single AML cells generated in vivo, which 
were sorted based on the expression of LSC markers (Somervaille & Cleary, 2006; Gibbs et 
al, 2012; Yeung et al, 2010). Following leukaemic development, AML cells were harvested 
from mice and seeded as single cells. AML cells that form colonies in vitro are considered 
to be LICs. LIC frequencies in Meis1/Hoxa9-induced AML are found to be relatively high at 
>10% (Gibbs et al, 2012). The cloning efficiencies of Meis1/Hoxa9-induced pre-LSCs have 
not been calculated. However, similar assays have shown that pre-LSCs transduced with 
MLL fusion proteins have a cloning efficiency of approximately 18-22% (So et al, 2010). 
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Figure 3.1.8. Cloning frequency of Meis1/Hoxa9 transformed pre-LSCs.  
Meis1/Hoxa9-transformed cells were harvested from colonies produced on the third round of 
plating during the serial replating assay. Cells were stained with antibodies specific for c-Kit, Mac-1 
and Gr-1 LSC markers. C-Kit+Mac-1+Gr-1+ cells were identified and sorted by flow cytometry as single 
cells into the wells of pre-prepared 96-well plates containing methylcellulose. Plates were cultured 
for 10-14 days and colonies were scored to determine the frequency of LSCs, which was based on 
the cells’ ability to form a colony. Data represent the total mean frequency of LSCs calculated from 
96 wells per biological sample from 3 independent experiments.  
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Taken together, these results suggest that the experimental model being used in 
this study is efficient in the transformation of HSPCs and establishment of pre-LSCs. 
Furthermore, these results suggest that PHD does not play a role in the transformation of 
pre-LSCs or their capacity for self renewal in vitro. 
 
 
3.2 Characterisation of Pre-LSCs Lacking PHD Isoforms  
3.2.1 Establishment of pre-LSC cell lines 
In order to fully characterise pre-LSCs, immortalised cell lines were established. 
Meis1/Hoxa9-transduced HSPCs were re-plated three times in the CFC assay, at which 
point, cells were considered fully transformed. Pre-LSCs were harvested and cultured in 
cytokine rich media. Cells were passaged several times to ensure stability before assays 
were performed. Cell lines were established for WT, PHD1 KO, PHD2 KO and PHD1/2 KO 
cells and all genotypes appeared to have a similar morphology (Fig. 3.2.1).  
Cell lines make ideal tools for in vitro characterisation as these can be grown 
indefinitely and large numbers of cells are available for analysis. The disadvantage to 
using cell lines is the emergence of randomly acquired mutations that cannot be 
controlled. For this reason, all analyses preformed on these cell lines were conducted at 
early passages to limit the possibility of random mutations. In addition, several biological 
replicates of each genotype were used to establish separate cell lines which were 
analysed individually in all experiments. However, it was not possible to analyse all 
biological replicates of all individual genotypes at one time and it was necessary to repeat 
cell line experiments several times, in order to accrue multiple biological replicates. Only 
one biological replicate was available for PHD1/2 KO so statistical analysis could not be 
performed on any of the cell line based experiments for this specific genotype and 
therefore no conclusions drawn. Any error bars shown for PHD1/2 KO cell line data have 
been based on standard deviation between technical replicates only.  
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Figure 3.2.1. Establishment of Meis1/Hoxa9-transduced pre-LSC cell lines.  
Meis1/Hoxa9-transformed cells were harvested from colonies produced on the third round of 
plating during the serial replating assay. Cells were seeded into a liquid culture of IMDM 
supplemented with cytokines and passaged several times until stable cell lines were established. 
Once cell lines were established, cells were grown in media containing reduced concentrations of 
cytokines. All cell lines appeared to have a similar morphology, regardless of genetic background, 
as assessed by standard phase microscopy.  Images of cell lines were acquired between passages 
8 to 16. 
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3.2.2 Pre-LSC cell lines show similar expression of LSC markers 
Cell lines were analysed for expression of LSC markers to ensure that changing the 
growth conditions of the cells from semi-solid methylcellulose to liquid culture, did not 
alter their phenotype. All genotypes of cell lines displayed a comparable expression 
profile with cells analysed at CFC3 during the serial replating assay, suggesting that the 
immunophenotype of cells was not dramatically changed following the change in growth 
conditions (Fig. 3.2.2).  In accordance with the immunophenotype seen in CFC3 cells (Fig. 
3.1.7), cells had some variability in the expression of c-Kit, although cells had a 
consistently high frequency of LSCs. Unfortunately PHD1/2 KO cells were not available for 
analysis.  
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Figure 3.2.2. Immunophenotype of immortalised pre-LSC cell lines.  
Pre-LSC cell lines were analysed by flow cytometry to determine the Immunophenotype of the 
CFC-derived cell lines. Images are representative of flow cytometry plots showing gating strategy 
for LSC phenotype. Cells were first gated based on c-Kit+ expression. c-Kit+ cells were then 
analysed for expression of Mac-1 and Gr-1. Frequencies of c-Kit+ cells were variable between 
samples but are in accordance with data collected from CFC3 cells (cf Fig 3.1.7). Frequency of c-Kit 
cells that were also Mac-1+Gr-1+, was similar for WT, PHD1 KO and PHD2 KO cells.  
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3.2.3 The expression of HIF-1α and HIF-2α in pre-LSC cell lines 
It was postulated that cells lacking PHD isoforms may overexpress HIF-1α, and as a 
result, have an enhanced leukaemic potential. Western blotting was used to identify the 
expression of HIF-1α and HIF-2α proteins in WT and in PHD KO cells.  As the exact 
relationship being HIF-1α and HIF-2α with PHD1 and PHD2 is unclear, both HIF-1α and 
HIF-2α expression were analysed in cells lacking PHD1 or PHD2 and both PHD1 and PHD2. 
Cobalt chloride is known to stabilise HIF proteins by inhibiting pVHL binding (Yuan et al, 
2003). NIH3T3 cells treated with cobalt chloride were used as a positive control. In the 
NIH3T3 cells, strong HIF-1α and HIF-2α bands were visible by western blotting. HIF-1α and 
HIF-2α proteins were undetectable in WT pre-LSC cell lines under normoxic conditions 
(Fig. 3.2.3). These results were as expected as HIF-1α and HIF-2α are both known to be 
degraded in the presence of oxygen. In the absence of either PHD1 or PHD2 isoforms, 
HIF-1α and HIF-2α both remained undetectable in normoxia. Interestingly, HIF-1α and 
HIF-2α were both strongly detected in cells lacking both PHD1 and PHD2. The stabilisation 
of HIF-1α and HIF-2α in cells lacking both PHD1 and PHD2, but not in cells lacking single 
isoforms, suggests that ablation of single PHD isoforms is not sufficient to stabilise HIF. 
The individual and overlapping functions of PHD isoforms are unclear in the literature. 
However, these data might indicate that PHD1 and PHD2 may be able to compensate for 
each other in certain cellular contexts. 
Furthermore, as HIF-1α was not stabilised in PHD1 KO or PHD2 KO cell lines, this 
suggested that the expression of Meis1 and the leukaemic potential of the cells would not 
be altered through up-regulation of HIf-1a. However, PHD is known to play a role in 
several other pathways and it is possible that altered regulation of an unidentified non-
hypoxia related pathway is involved. However, since HIF proteins were stabilised in 
PHD1/2 KO cells, it was possible that the leukaemia potential would be enhanced in these 
cells due to the over expression of HIF-1α. Unfortunately, PHD1/2 KO cells were not 
analysed for leukaemic potential by LDA as cells were limited, and were utilised for other 
experiments. However, PHD1/2 KO cells did not show any differences in self renewal 
capacity or LSC frequency which suggested that the leukaemic potential was not altered.  
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Figure 3.2.3. HIF-1α and HIF-2α protein expression in pre-LSC cell lines.  
Meis1/Hoxa9-transduced pre-LSC cell lines were used to investigate the expression of HIF 
proteins. Protein lysates were prepared from cell lines and the protein was quantified. Equal 
concentrations of protein were used for each sample which were analysed by western blotting. 
NIH3T3 cells were treated with CoCl2 for 24 hours and lysates used as a positive control for HIF 
protein accumulation. Strong bands were visible in both HIF-1α and HIF-2α western blots that 
were in accordance with band sizes of HIF-1α (approximately 92kDa) and HIF-2α (approximately 
100kDa). Bands were also visible in PHD1/2 KO cell lysates but were not seen in WT, PHD1 KO or 
PHD2 KO lysates. GAPDH was used as a loading control. Results were confirmed by two 
independent experiments.  
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3.2.4 Cell cycle distribution and proliferation rate of established pre-LSC cell lines 
One of the most fundamental properties of cancer cells is an increased rate of 
proliferation. Retroviral expression of Meis1 and Hoxa9 in HSPCs is known to stimulate 
proliferation. One of the aims of this study is to determine if there may be a difference in 
leukaemic potential between WT and PHD KO cells and this may be evident in the 
differential distribution of cell cycle phases.  Furthermore, PHD1, although not PHD2, has 
been linked to regulation of the cell cycle. PHD1 has been seen to up-regulate cyclin D1 
causing increased proliferation in breast, cervical and renal cancer cell lines (Zhang et al, 
2009). However, the role of PHD in the proliferative state of HSPCs or LSCs has not been 
determined. 
Pre-LSC cell lines derived from the CFC assay were used to investigate the 
frequency of pre-LSCs in different cell cycle phases. At first, the frequency of cycling cells 
based on the expression of the proliferation marker Ki67 (expressed from G1 through to 
the end of M phase) was assessed. Additional staining with DAPI allowed determination 
of the distribution of cells in the separate phases of the cell cycle, based on the DNA 
content. Figure 3.2.4 shows frequencies of cells in G0, G1 and G2/S/M phases as 
determined by flow cytometry. Data was collected at 8, 24 and 48 hours after passaging. 
Data collected at 24 hours was repeated to give three biological replicates (with the 
exception of PHD1/2 KO). Statistical analysis showed that there were no differences in cell 
cycle frequencies between WT, PHD1 KO and PHD2 KO cell lines. PHD functions are 
thought to be cell context specific and although differences were seen in breast, cervical 
and renal cancer cell lines lacking PHD1, it is possible that PHD1 does not perform this 
function in the context of the haemopoietic system, or more specifically pre-LSCs. In 
addition, the similar frequencies of cell cycle phases between WT and PHD KO cells 
suggested that Meis1 expression was unaffected by the absence of PHD and that Meis1 
and Hoxa9 expression were likely to be comparable across the different groups. 
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Figure 3.2.4. Cell cycle frequencies of pre-LSC cell lines.  
Pre-LSC cell lines were cultured for 8, 24 and 32 hours. 4 x 10 4 cells were fixed and permeabilised in 
96-well plates, then stained with an antibody specific for Ki-67, then washed, resuspended in DAPI 
and analysed by flow cytometry to determine the frequencies in different phases of the cell cycle. 
Data presented show mean frequencies of cells in G0, G1 and S/G2/M phases at (A) 8, (B) 24 and (C) 
32 hours.  
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Next, the growth rate of pre-LSCs was investigated. Cells were plated and counted 
after 24 and 48 hours. Dead cells were excluded using trypan blue staining and only live 
cells were counted. At 24 hours, WT cells had a higher growth rate than all cells lacking 
PHD isoforms (Fig. 3.2.5). Statistical analysis showed that PHD1 KO cells and PHD2 KO 
cells both had a significantly lower growth rate than WT cells. PHD1/2 KO cells also 
appeared to have a lower growth rate compared to WT cells, although no statistical 
analysis was performed. However, data collected at 48 hours showed that growth rates 
were highly comparable between WT, PHD1 KO and PHD2 KO. PHD1/2 KO continued to 
show a reduced growth rate at 48 hours, although the statistical significance is not known 
and biological meaning of this trend is unclear. Given that no differences were observed 
in proliferation, it was possible that the differences in cell growth were attributed to 
altered cell viability which was then examined.  
Dead cells that cannot exclude trypan blue were counted and used to calculate 
the overall viability of the cell population. At 24 hours, WT cells and PHD1 KO cells had 
comparable percentages of viable cells in the culture, with no significant differences seen 
between genotypes (Fig. 3.2.6). However, at 48 hours cell viability appeared higher in 
cells lacking PHD1, compared to that of WT cells (81% compared to 71%) and this 
difference was statistically significant. Considering that PHD1 KO cells did not show a 
difference in cell cycle distribution at 24 hours, yet, appeared to have a lower growth rate 
than WT cells which was statistically significant. It had been hypothesised that the lower 
growth rate seen in PHD1 KO cells may have been attributed to lower cell viability. 
Therefore, the observation that PHD1 KO cells had a higher viability than WT cells was 
unexpected. However, the balance between proliferation and cell death and their effect 
on overall cell growth is complicated and warrants further investigation. 
In contrast, PHD2 KO and PHD1/2 KO cells both had a lower viability (76.1% and 
72.5%) compared to WT cells (87.1%) at 24 hours. Statistical analysis preformed between 
WT and PHD2 KO confirmed that there was a statistically significant difference in cell 
viability (Fig. 3.2.6). At 48 hours however, this difference was not seen and WT, PHD2 KO 
and PHD1/2 KO cells had a similar viable cells.  
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Figure 3.2.5. Cell growth of pre-LSC cell lines.  
Pre-LSC cell lines were cultured for 24 and 48 hours at a starting density of 2.5 x 105/mL. Cells were 
harvested and counted by trypan blue dye exclusion method.  Data represent the mean cell 
concentration of biological replicates. (WT n=2, PHD1 KO n=2, PHD2 KO n=4, PHD1/2 KO n=1) 
Student t-test was performed to determine if the growth rate of PHD KO Pre-LSCs was significantly 
different to growth rates of WT cells at 24 and 48 hours. *p<0.05.  
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Figure 3.2.6. Cell viability of pre-LSC cell lines.  
Pre-LSC cell lines were cultured for 24 and 48 hours at a density of 2.5x105/mL. Cells were 
harvested and counted by trypan blue dye exclusion to assess the viability of each sample.  Data 
represent the mean percentage of viable cells of biological replicates. (WT n=2, PHD1 KO n=2, 
PHD2 KO n=4, PHD1/2 KO n=1) *p<0.05. 
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3.2.5 Apoptotic frequencies of pre-LSC cell lines 
Changes in cell viability are often attributed to changes in apoptosis. Much like the 
enhanced proliferative state, an altered apoptotic response is a common property of 
cancer cells. Cancer cells are often seen to be resistant to apoptosis, forming aggressive 
cells that are resistant to treatments.  
In order to further investigate the differences observed in pre-LSC cell viability, the 
apoptotic frequency of these cells was assessed. Cells that are Annexin V+DAPI- are 
considered to be in the early stages of apoptosis as they show Annexin V binding to cell 
surface phosphatidylserine, but have retained membrane potential. Cells that are 
Annexin V+DAPI+ are considered to be in the late phase of apoptosis as they show Annexin 
V binding and reduced membrane potential.   
Flow cytometry analysis preformed 24 hours after passage showed that WT and 
PHD1 KO cells had comparable frequencies of cells in the early and late phases of 
apoptosis, as well as overall apoptosis (Fig. 3.2.7). However, PHD2 KO cells showed an 
increase in early and late phase apoptosis as well as total apoptosis at 24 hours (Fig. 
3.2.7). Statistical analysis determined that the difference in early phase apoptosis 
between PHD2 KO and WT was not significant. However, differences in late phase 
apoptosis and overall apoptosis were highly significant (p=0.0002 & p=0.0009).  Cells 
lacking PHD2 also had a significant decrease in viability compared to WT at 24 hours 
(67.6% compared to 82.5%), which was concordant with the increased apoptosis. This is 
also corroborative with the reduced viability of PHD2 KO cells as determined by trypan 
blue exclusion (Fig. 3.2.7). 
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Figure 3.2.7. Apoptotic frequencies of pre-LSC cell lines at 24 hours.  
Annexin V binding and DAPI staining was used to determine the frequencies of viable and apoptotic 
Pre-LSC cells. Annexin V+DAPI- cells were considered to be in early apoptosis (A), Annexin V+DAPI+ 
cells were considered to be in late apoptosis (B). Total Annexin V+ cells (both DAPI+ and DAPI-) were 
used to measure total apoptosis (C). Cells that were Annexin V-DAPI- were considered viable cells 
(D).  Data shown represent the mean frequencies of apoptotic and viable cells. (WT n=6, PHD1 KO 
n=4, PHD2 KO n=5, PHD1/2 KO n=1.) Student t-test was performed to determine if PHD1 or PHD2 
KO genotypes have significantly different frequencies compared to WT Pre-LSCs. *p<0.05, 
**p<0.005, ***p<0.0005. 
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However, at 48 hours, PHD2 KO cells showed no differences in apoptosis 
compared to WT (Fig. 3.2.8), which was in accordance with the previous experiments 
showing no differences in growth or viability. It was interesting that differences in viability 
were evident at early but not later time points and it may be that that this difference was 
related to the density of the population. Interestingly, PHD1 KO cells analysed at 48 hours 
showed a lower frequency of apoptosis and a higher frequency of viable cells (Fig. 3.2.8). 
This is in line with previous experiments that also demonstrated a higher viability in PHD1 
KO cells at this time point. However, it should be noted that data collected at 48 hours for 
both trypan blue exclusion and Annexin binding assays consisted of only two biological 
replicates for both WT and PHD1 KO (n=2) and further replicates would be required in 
order to perform statistical analysis and verify these results. 
In terms of total apoptosis and viability, PHD1/2 KO cells showed frequencies that 
were comparable to PHD2 KO at both 24 and 48 hours (Fig. 3.2.7 & 3.2.8), yet the 
frequencies of cells within early and late phase apoptosis did appear to differ. However, 
this experiment would need to be repeated in order to make any firm conclusions. The 
similarities in overall apoptosis and viability between PHD1/2 KO and PHD2 KO might 
suggest that the apoptotic phenotype was due to the absence of PHD2 and was not 
abrogated further by the loss of PHD1. 
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Figure 3.2.8. Apoptotic frequencies of pre-LSC cell lines at 48 hours.  
Annexin V binding and DAPI staining was used to determine the frequencies of viable and apoptotic 
Pre-LSC cells. Annexin V+DAPI- cells were considered to be in early apoptosis (A), Annexin V+DAPI+ 
cells were considered to be in late apoptosis (B). Total Annexin V+ cells (both DAPI+ and DAPI-) were 
used to measure total apoptosis (C). Cells that were Annexin V-DAPI- were considered viable cells 
(D).   Data shown represent the mean frequencies of apoptotic and viable cells. (WT n=2, PHD1 KO 
n=2, PHD2 KO n=3, PHD1/2 KO n=1.)  *p<0.05.  
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3.2.6 Mitochondrial dysfunction and apoptosis in pre-LSC cell lines 
Apoptosis is often a response to mitochondrial dysfunction. PHD isoforms are 
closely linked to the energy production cycles within the cell. It is possible that the 
absence of PHD may cause the cellular metabolic processes to become dysregulated. 
Products of the energy production cycle, such as NO and ROS, are known to cause 
mitochondrial damage (Pieczenik & Neustadt, 2006), and are both known to inhibit PHD, 
suggesting a clear link between PHD activity and mitochondria dysfunction. Therefore, 
the frequency of functional and dysfunctional mitochondria within the cells was detected 
by flow cytometry. WT pre-LSCs had comparable frequencies of both functional and 
dysfunctional mitochondria compared to PHD KO pre-LSCs (Fig. 3.2.9). These results 
implied that the increase in apoptotic frequencies seen in PHD2 KO pre-LSCs was not 
attributed to mitochondrial dysfunction. Unfortunately, frequencies of 
functional/dysfunctional mitochondrial of PHD1/2 KO cells have not been analysed and 
further study would be required to detect changes in this cell line. 
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Figure 3.2.9. Mitochondrial function in pre-LSC cell lines.  
The frequency of functional and dysfunctional mitochondria was measured in Pre-LSC cell lines. 
Cells were stained with MitoTracker Green and MitoTracker Red mitochondria dyes which detect 
total or respiring mitochondria, respectively. Frequencies of functional and dysfunctional 
mitochondria were analysed by flow cytometry. A. Representative flow cytometry dot plots 
depicting the gating strategy for functional and dysfunctional mitochondria. Some variations in 
frequencies were seen between individual samples but no trend was seen between genotypes and 
no statistical difference was seen. B. Data presented show total mean frequencies of functional 
and dysfunction mitochondria. (WT n=4, PHD1 KO n=4, PHD2 KO n=3.) 
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3.2.7 Influence of the bone marrow niche on apoptosis of pre-LSC cell lines 
In vitro characterisation of cells lacking PHD isoforms had indicated that the 
absence of PHD2 may affect apoptosis. However, it was not clear if this was a property of 
transformed pre-LSCs or if this was a phenotype seen in normal haemopoietic cells within 
the bone marrow. In order to investigate the apoptotic frequencies of haemopoietic cells 
ex vivo, bone marrow cells were extracted from WT mice and mice lacking PHD isoforms. 
Cells were enriched for c-Kit expression to ensure that the population isolated was similar 
to the starting population of transformed cells. WT, PHD1 KO and PHD2 KO cells showed 
similar percentages of cells undergoing early and late apoptosis (Fig. 3.2.10). Similarly, the 
overall frequency of apoptotic cells was very low and comparable across all genotypes. 
The percentage of Annexin V- (viable) cells in the population was high for all genotypes 
and no differences were observed. 
Mitochondrial function of pre-LSCs ex vivo was also analysed by flow cytometry. 
Frequencies of functional mitochondria were similar across all genotypes (Fig. 3.2.11). 
Similarly, no differences were seen in the frequency of dysfunctional mitochondria. 
However, as with the in vitro results, data collected from this assay proved variable and 
would need further verification. 
As no differences were seen in apoptotic frequencies in c-Kit+ cells ex vivo, 
whether WT or PHD KO, this might suggest that the apoptotic phenotype seen in vitro in 
pre-LSCs lacking PHD isoforms was specific to Meis1/Hoxa9 transformed cells. However, it 
is also possible that this was an artefact of in vitro culture and further investigation into 
this phenotype would be required. 
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Figure 3.2.10. Frequency of apoptotic HSPCs in vivo.  
Bone marrow cells were extracted from WT and PHD KO mice. HSPCs were enriched following 
selection of c-Kit+ cells by column separation method. HSPCs were incubated with Annexin V and 
DAPI, which was used to determine the frequencies of viable and apoptotic cells within the HSPC 
population as determined by flow cytometry. Annexin V+DAPI- cells were considered to be in early 
apoptosis (A), Annexin V+DAPI+ cells were considered to be in late apoptosis (B). Total Annexin V+ 
cells (both DAPI+ and DAPI-) were used to measure total apoptosis (C). Cells that were Annexin V-
DAPI- were considered viable cells (D).  Data shown represent the mean frequencies of apoptotic 
and viable cells. (WT n=3, PHD1 KO n=1, PHD2 KO n=4). 
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Figure 3.2.11. Mitochondrial function of HSPCs in vivo.  
Bone marrow cells were extracted from WT and PHD KO mice. HSPCs were enriched following 
selection of c-Kit+ cells by column separation method. Cells were stained with MitoTracker Green 
and MitoTracker Red mitochondria dyes which detect total or respiring mitochondria, respectively. 
Frequencies of functional and dysfunctional mitochondria was analysed by flow cytometry.  Data 
shown represent the mean frequencies of functional and dysfunctional mitochondria. (WT n=3, 
PHD1 KO n=1, PHD2 KO n=4). 
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3.3 Investigation into the Leukaemic Potential of Pre-LSCs Lacking PHD 
Isoforms 
3.3.1 Transplantation of pre-LSCs to recipient mice 
The leukaemogenic potential of pre-LSCs generated in the CFC assay  were 
assessed, in a single preliminary experiment, using a well-established bone marrow 
transplantation model (Somervaille & Cleary; Weischenfeldt et al, 2008; So et al, 2010; 
Gibbs et al, 2012). Due to cost restraints and the desire to repeat this experiment, using 
larger cohorts of mice and with minor technical modifications, the experiment was 
terminated early, at 18 weeks, and full analyses on each and every mouse was not 
performed. Regardless the results were interesting and are therefore presented here.  
Pre-LSCs were originally derived in BM cells extracted from mice with a CD45.2+ 
background, which were then transformed with Meis1 and Hoxa9 retroviruses to produce 
pre-LSCs. Pre-LSCs were enriched for c-Kit expression to ensure a population of LIC, in 
accordance with the literature. WT, PHD1 KO, PHD2 KO or PHD1/2 KO c-Kit+ CD45.2+ pre-
LSCs were transplanted by tail vein injection to CD45.1/2het recipient mice which were 
lethally irradiated prior to transplantation. A full schematic diagram of the experimental 
procedure is depicted in figure 3.3.1.  
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Figure 3.3.1. In vivo Experimental Technique.  
A CFC assay as described in section 2.3.5.3, was used to produce a population of Meis1/Hoxa9 transformed 
pre-LSCs. Cells were harvested from B6-Ly5.2 mice with a CD45.2 background. Cells were then c-Kit 
enriched following incubation with anti-c-Kit magnetic beads and MACS separation technique as described 
in section 2.3.5.2. The genotype of each sample was confirmed by PCR prior to transplantation. Support 
bone marrow was harvested from B6-Ly5.1 mice with a CD45.1 background. Pre-LSCs and support bone 
marrow was mixed at a ratio of 1:2.  Ly5.1/Ly5.2 F1 hybrid mice or CD45het mice were used as recipient 
mice. Recipient mice were subjected to 10Gy lethal radiation to deplete recipient bone marrow. Pre-
LCS/support bone marrow cell suspension was then transplanted to recipient mice by tail vein injection. 
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The genotype of donor pre-LSCs prepared for transplantation was confirmed by PCR using 
genomic DNA extracted from cell samples. Each sample underwent a PCR reaction along 
with appropriate primers for PHD1 and PHD2 genes. The resulting DNA fragments were 
analysed by gel electrophoreses to determine if PHD genes were WT (normal PHD genes) 
or if genes had been genetically modified, based on the size of the DNA fragments 
produced. Two different systems were used to generate mice deficient in PHD genes. 
PHD1 KO cells (PHD1-/-) lack both alleles of the functional PHD1 gene. However, following 
a PCR reaction with PHD1 primers, a smaller DNA fragment can be detected on the gel 
which represents the mutated PHD1 gene. In this system, one exon of PHD1 has been 
deleted, resulting in a non-functional shorter gene that can still be detected using primers 
for PHD1. PHD2 KO cells (PHD2fl/fl), lack PHD2 following a conditional deletion using the 
Cre recombinase system. In this system, PHD2 has been flanked by loxP sites, which are 
recognised as excision sites by Cre recombinase, allowing the gene to be deleted under 
specific conditions. The pLox site within PHD2 results in a gene that is longer than WT 
PHD2 and which can still be detected by PHD2 primers. The band that is excised using this 
system can also be detected and is represented by a smaller band. This is also the case for 
PHD1 flox, where PHD1 can be deleted using the Cre system. Due to lethality of complete 
PHD2 deletion, PHD2 is only deleted in haematopoietic cells. This is achieved by fusing 
Cre (which is required for the gene excision) to Vav, a gene that is only expressed in the 
haematopoietic system. Specific VavCre primers are able to detect the presence of 
VavCre, resulting in a detectable band on a gel. Samples that do not contain VavCre will 
not produce a band. PHD1 KO, PHD2 KO and PHD1/2 KO cells were originally derived from 
mice with a PHD1+/-PHD2+/flVav+/- background so were genotyped using primers for PHD1, 
PHD2 flox and Vav. WT cells were derived from mice with a PHD1+/flPHD2+/flVav- 
background so were genotyped using primers for PHD1 flox, PHD2 flox and Vav (Fig. 
3.3.2). 
The phenotype of pre-LSCs was analysed by flow cytometry to ensure that the c-
Kit enrichment had been successful, and that populations consisted of a high percentage 
of LSCs, and that the immunophenotypic profile was comparable across all genotypes 
(Fig. 3.3.3). Within the pre-LSC culture, it was found that an extremely high percentage 
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(between 90-99%) of c-Kit+ cells were positive for both Mac-1 and Gr-1, therefore 
enrichment beyond c-Kit expression for LIC phenotype was considered unnecessary.  
Furthermore, the uncertainty within the literature concerning the requirement for Gr-1 
expression then became redundant, considering that cells which were positive for c-Kit 
and Mac-1 were also positive for Gr-1 expression.  
Bone marrow cells were also extracted from CD45.1+ mice and used as support 
bone marrow, which was mixed with CD45.2+ pre-LSCs before transplantation. Bone 
marrow transplantation requires a high number of transplantable cells. The number of 
pre-LSCs generated in vitro was limited and support bone marrow was used to ensure 
efficient reconstitution of the recipient mice following irradiation. The ratio of CD45.1+ 
support bone marrow to CD45.2+ pre-LSCs was analysed by flow cytometry for each 
genotype prior to transplantation to ensure equal populations (Fig. 3.3.3).   
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Figure 3.3.2. Confirmation of genotype of transplanted pre-LSCs by PCR using genomic DNA.  
A. Schematic diagram of PCR strategy used to confirm the genetic background of the mice used in 
experiments. DNA was extracted from cells and specific primers were used to amplify PHD and Vav 
genes in accordance with the initial genetic background of the mice, from which cells were derived. 
PCR products were separated by gel electrophoresis to confirm the presence of WT or mutated 
genes in each sample before transplantation. B. WT cells were extracted from mice with a 
PHD1+/flPHD2+/flVav+/- background and genotype was assessed based on PCR results following 
reactions containing primers for PHD1flox, PHD2flox and VavCre. C. PHD1 KO, PHD2 KO and PHD1/2 
KO cells were extracted from mice with a PHD1+/-PHD2+/flVav+/-background and genotype was 
assessed based on results of PCR reactions containing primers for PHD1, PHD2flox and Vav 
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Figure 3.3.3. Immunophenotype of transplanted pre-LSCs.  
Pre-LSCs (CD45.2+) and support bone marrow (CD45.1+) cells were prepared for transplantation 
under aseptic conditions. Pre-LSCs were enriched for c-Kit expression by column separation method. 
The expression of LSC markers was confirmed by flow cytometry prior to transplantation to ensure 
that LSC starting populations were similar between groups. A. Cells were analysed for c-Kit 
expression and c-Kit+ cells gated. B. c-Kit+ cells were further analysed for the expression of Mac-1 
and Gr-1. C. The ratio between CD45.1+ support bone marrow cells and CD45.2+ pre-LSCs was also 
confirmed by FACS prior to transplantation. 
 
146 
 
Following tail vein injection of CD45.1+ support bone marrow along with CD.45.2+ 
pre-LSCs, mice were monitored for signs of leukaemic development. The detection of 
CD45.2+ cells within the bone marrow is achievable through bone marrow aspiration. 
However, this procedure is technically challenging and particularly stressful for leukaemic 
mice which may be weak and immunodeficient. As an alternative, peripheral blood from 
recipient mice was analysed fortnightly and the presence of CD45.2+ leukaemic cells 
within the blood was considered a sign of leukaemic disease. Leukaemia develops initially 
within the bone marrow with cells eventually mobilising to the peripheral blood. As this is 
a later stage of re-establishment of the haemopoietic system, leukaemic cells were not 
detected immediately following transplantation. As mice are immunocompromised 
following radiation, blood samples were not taken until 4 weeks post transplantation, at 
which point, mice had recovered from radiation treatment and the haemopoietic system 
had been reconstituted. From the time of transplantation up to 4 weeks post 
transplantation, mice were monitored closely for signs of illness due to failed 
reconstitution, in which case, mice were sacrificed humanly in accordance with Home 
Office regulations.   
 
3.3.2 Detection of leukaemic disease and leukaemic frequency 
Flow cytometry analysis of blood samples showed the frequency of CD45.2+ pre-
LSCs, CD45.1+ support bone marrow derived cells and CD45.1/2het cells derived from 
residual recipient bone marrow (Fig. 3.3.4). This was continuously analysed over the 
course of the experiment and used to monitor the mice for the development of leukaemic 
disease. Figure 3.3.3 depicts the time course over which the experiment took place and 
the development of leukaemia over time. The frequency of CD45.2+ cells within the 
peripheral blood was plotted for individual transplanted mice and showed that overall, 
48% of mice developed detectable leukaemia within 18 weeks, which was within the time 
frame predicted in the literature (Kroon et al, 1998; Wang et al, 2006). This data also 
shows that the frequency of CD45.2+ in the blood increased over time as the disease 
developed.  
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Figure 3.3.4. Detection of CD45.2+ donor cells in peripheral blood. 
Peripheral blood samples were acquired from recipient mice 4 weeks following transplantation 
and every 2 weeks thereafter until the experiment was terminated at week 18. Blood was taken 
via tail vein. Red blood cells were lysed and white blood cells were stained with antibodies 
specific for CD45.1 and CD45.2.  A. Images show representative flow cytometry dot plots showing 
CD45.1+, CD45.2+ and CD.45het cells in peripheral blood of recipient mice. B. Data presented shows 
the frequency of CD45.2+ cells in the peripheral blood as detected by flow cytometry every 2 
weeks. Data show that CD45.2+ cells detected in recipient mice increase in frequency over the 
time course. Recipient mice that did not have any detectable CD45.2+ cells have not been 
included. (Recipient mice transplanted with pre-LSCs: WT n=12, PHD1 KO n=9, PHD2 KO n=11, 
PHD1/2 KO n=7). 
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The percentage of mice that were positive for CD45.2+ cells was calculated for 
each genotype. Of the 12 mice that received WT pre-LSCs, 10 developed leukaemia within 
18 weeks, resulting in 83% penetrance (Fig. 3.3.5). Of the mice that received PHD1 KO 
pre-LSCs, 56% of mice developed leukaemia. Of mice injected with PHD2 KO pre-LSCs, just 
9% of mice developed leukaemia. And of the mice that received PHD1/2 KO pre-LSCS, 
43% developed leukaemia.  Overall, the percentage of mice that developed leukaemia 
was significantly higher in mice transplanted with WT pre-LSCs compared to all other 
genotypes. This was particularly evident when mice were transplanted with PHD2 KO pre-
LSCs which had an extremely low penetrance of leukaemia (9%).  
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Figure 3.3.5. Leukaemic penetrance in transplanted mice.  
Penetrance of leukaemic disease was based on the detection of CD45.2+ leukaemic cells in the 
peripheral blood of the recipient mice. Data presented represent the frequency of recipient mice 
transplanted with WT, PHD1 KO, PHD2 KO and PHD1/2 KO pre-LSCs that had detectable CD45.2+ 
cells within the peripheral blood up to week 18 when the experiment ended. Recipient mice with 
detectable CD45.2+ cells were considered to be leukaemic. (WT n=12, PHD1 KO n=9, PHD2 KO 
n=11, PHD1/2 KO n=7). 
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This was recapitulated when the survival rate of recipient mice was examined. The 
survival rate of mice transplanted with WT pre-LSCs was 25% at 18 weeks (Fig. 3.3.6). 
However, one mouse (which appeared to be healthy) was seen to have a low frequency 
of CD45.2+ cells in the blood (2.34%); it is likely that this mouse would have succumbed to 
disease at a later time point. Unfortunately, it was not possible to continue the 
experiment past this point. The survival rate of mice injected with PHD1 KO pre-LSCs at 18 
weeks was 44.4%. At the end point of the experiment, several of the mice in this group 
had a negligible percentage of CD45.2+ cells (<0.1%) and it is therefore impossible to 
know whether these mice would ever have developed leukaemia.  Mice transplanted with 
PHD1/2 KO pre-LSCs had a significantly higher survival rate than WT (57%). Interestingly, 
mice that were transplanted with PHD2 KO pre-LSCs had a 100% survival rate at 18 
weeks. However, CD45.2+ cells were observed in one mouse in this group at a low 
percentage (4.99%), so it is possible that this mouse would have developed disease. 
Regardless of the premature termination of this experiment, the survival rates and 
penetrance of mice transplanted with pre-LSCs differed between the genotypes. A log-
rank test was used to compare the survival rates of the different groups. Mice 
transplanted with WT pre-LSCs were seen to have a lower survival rate compared to mice 
transplanted with PHD2 KO cells (p=0.0004). WT-transplanted mice also had a lower 
survival rate than PHD1/2 KO-transplanted mice which was also seen to be statistically 
significant (p=0.0354). WT-transplanted mice survival appeared lower than PHD1 KO-
transplanted mice, although this did not prove to be significant. Statistical significance 
was also seen when comparing PHD1-transplanted and PHD2 KO-transplanted mice 
(p=0.0047). However, these results were based on a single experiment that was 
terminated early and whilst interesting, it would be imperative that this study be 
repeated in order to verify these results. In addition, only one biological replicate of each 
genotype was used for initial transplantation and it would be beneficial to verify these 
data with additional biological replicates. 
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Figure 3.3.6. Survival rate of transplanted mice.  
The frequency of recipient mice in each group that became moribund and were sacrificed after 
succumbing to disease was used to calculate the survival rate of mice in each group which was 
compared by Kaplan-Meier analysis. Statistical relevance was determined using a log-rank test 
(WT n=12, PHD1 KO n=11, PHD2 KO n=9, PHD1/2 KO n=7) *p<0.05, **p<0.005, ***p<0.0005. 
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3.3.3 Characterisation of leukaemic disease 
Mice that were positive for CD45.2+ cells in the blood were monitored closely and 
were sacrificed according to Home Office regulations when they were considered 
moribund. Sacrificed mice were analysed to determine any differences in leukaemic 
disease between genotypes. However, as PHD2 KO transplanted mice had 100% survival, 
none of the mice transplanted with PHD2 KO pre-LSCs were available for analysis. Bone 
marrows and spleens were analysed from mice that were sacrificed because of leukaemia 
development and were all seen to contain CD45.2+ cells (Fig. 3.3.7). However, no 
differences were observed between groups, suggesting that at the time these mice 
exhibited signs of leukaemia and had to be culled the leukaemia in each mouse was at a 
similar stage of development. Leukaemic mice all had enlarged spleens that were 
characteristic of leukaemic disease (Fig. 3.3.8). Leukaemic spleens sizes ranged from 1.8-
2.5cm in length and were larger than spleens taken from non-leukaemic mice which are 
within the range of 1.2-1.4cm. Next, the spleen weights were used to assess if there were 
any differences in symptoms. As all of the mice had slightly different body masses at the 
time of sacrifice, spleen weights were expressed as a percentage of total body mass, 
which was then used to compare the enlargement of spleens in WT, PHD1 KO and 
PHD1/2 KO-transplanted mice. The percentage of body mass of the enlarged spleens was 
comparable across all genotypes analysed (Fig. 3.3.9).  
Body weight is also commonly affected by disease. Therefore, the mice were 
weighed periodically throughout the experiment to measure their general health, and 
also at the time of sacrifice to assess if any changes in weight had occurred (Fig. 3.3.9). 
Mice that were weighed more than once appeared to have similar weights suggesting 
that the disease had not affected their body weight. However, as many of the mice 
succumbed to disease early on in the experiment, some mice had only been weighed 
once.  
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Figure 3.3.7. Detection of CD45.2+ cells in sacrificed mice.  
Mice that were thought to be leukaemic (based on the high frequency of CD.45.2+ cells in the 
blood and the development of physical symptoms), were sacrificed. Bone marrow and spleen 
were analysed for the presence of CD45.2+ cells as determined by flow cytometry. Femur and tibia 
of the mice were crushed to extract bone marrow cells. Spleens were extracted and crushed in 
PBS to give a cell suspension. Bone marrow and spleen cells were stained with antibodies specific 
for CD45.1 and CD45.2 and analysed by flow cytometry.  Data presented represent the total mean 
frequency of CD45.2+ cells seen in the bone marrow and the spleen of leukaemic mice (WT n=7, 
PHD1 KO n=4, PHD1/2 KO n=1). 
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Figure 3.3.8. Leukaemic mice had enlarged spleens.  
Spleens were collected, photographed and measured from leukaemic mice at the point of sacrifice to 
assess if the mice had enlarged spleens, one of the characteristic symptoms of leukaemic disease. 
Leukaemic spleens were enlarged and characteristic of the disease. Spleens were also collected from 
several non-leukaemic mice to be used as a control and as a measurement of normal spleen size in 
healthy adult mice.   
Non-leukaemic 
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Figure 3.3.9. Body and spleen weights of leukaemic mice at sacrifice.   
A. Mice were weighed periodically throughout the experiment to help monitor their health. Graph 
represents weights of individual mice at the time of death. B. Body weight at death was used to 
measure the proportion of body mass contributed to by the enlarged spleens. Data shown are 
mean percentage of spleen contribution.  (WT n=8, PHD1 KO n=5, PHD1/2 KO n=2). 
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Blood obtained from leukaemic mice was stained using a Giemsa-Wright 
procedure, which is used to differentiate between different types of blood cells and is 
often used to identify the presence of abnormal, leukaemic cells in the blood. Blood from 
WT leukaemic mice appeared to have a higher frequency of large blast-like cells 
compared to blood obtained from WT non-leukaemic mice (Fig. 3.3.10). The presence of 
leukaemic cells in the blood, as well as visually enlarged spleens in the sacrificed mice, 
suggests that these mice were leukaemic. No other genotypes were analysed using 
Giemsa-Wright staining. The purpose of this experiment was to determine if this staining 
would be advantageous in future experiments and so no quantitative data was collected, 
nonetheless it would be a good additional test to monitor the leukaemic disease using 
blood smears.  
The concentration of white blood cells (WBC) within the blood was also monitored 
over the course of the experiment with a high WBC count being indicative of leukaemia. 
WBC counts of mice that were positive for CD45.2+ cells remained within normal range, 
but increased dramatically at later stages (Fig. 3.3.11). WBC concentration in the blood of 
leukaemic mice at the point of sacrifice was considerably higher than non-leukaemic 
counterparts. Cellularity within the bone marrow and spleen were also analysed (Fig. 
3.3.11). However, cell counts were variable and no difference was seen between the 
different groups. Overall, pre-LSCs generated in vitro recapitulated disease that was 
pathologically, morphologically and phenotypically similar to the disease described in 
other published in vivo studies (Somervaille & Cleary, 2006; So et al, 2010). 
 
 
 
 
 
 
157 
 
 
             
             
 
 
 
 
 
 
 
 
WT – non-leukaemic WT – leukaemic 
Figure 3.3.10. WBCs in peripheral blood samples.  
Peripheral blood samples were acquired from mice via tail vein. Blood was smeared onto glass 
slides and fixed in ethanol. Fixed blood smears were incubated at room temperature in Giemsa-
Wright staining solution. Slides were dried and assessed by standard light microscopy in order to 
detect the presence of WBCs within the blood sample. The purple colour of the stain is incorporated 
into WBCs but not RBCs, allowing the two cell types to be distinguished. The number of WBCs and 
the presence of larger, abnormal WBC-like cells were used to indicate the penetrance of leukaemic 
disease. Blood samples acquired from leukaemic WT mice appeared to have a higher frequency of 
WBCs compared to non-leukaemic WT samples. Arrows indicate WBC (WT n=2). 
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Figure 3.3.11. WBC concentration of blood, bone marrow and spleen.  
Blood (A), bone marrow (B) and spleen (C) were analysed using an automated cell counter to 
determine the concentration of WBCs. Data presented represent WBC concentrations assessed for 
all leukaemic sacrificed mice. Non-leukaemic WBC concentrations from a previous experiment 
were used as control. Data shown are total mean WBC concentrations. (WT n=9, PHD1 KO n=5, 
PHD1/2 KO n=2, non-leukaemic n=6). 
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3.3.4 Immunophenotype of leukaemic cells 
Next the frequency of LSCs was analysed based on the presence of cells that 
carried the LSC expression markers c-Kit, Mac-1 and Gr-1 simultaneously as analysed by 
flow cytometry. As a control, CD45.1+ non-transduced therefore non-leukaemic support 
bone marrow was used to determine the frequency of apparent LSC-like cells within the 
normal bone marrow (background). These individual LSC cell surface markers are seen on 
normal haemopoietic cells although they are associated with different cell types, making 
the simultaneous expression of these quite unique to LSC. c-Kit is used as a marker for 
primitive cells, although Mac-1 and Gr-1 are expressed on more mature cell types. 
However it is possible that cells exist which express these markers simultaneously and 
that these may represent a transient population that is going through the differentiation 
process but, this population is rare.  
Cells were first analysed for c-Kit expression. CD45.1+ cells appeared to have a low 
percentage of c-Kit+ cells within the bone marrow. This population was undetectable in 
the blood and spleen (Fig. 3.3.12). c-Kit+ cells were then gated and further analysed for 
simultaneous expression of Mac-1 and Gr-1 and therefore the presence of LSC-like cells. 
The frequency of LSC-like cells within the CD45.1+ population was low (3.74%) within the 
bone marrow and may represent differentiating cells. LSC-like cells were not detectable 
within the blood or spleen.   
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Figure 3.3.12. Immunophenotype of CD45.1+ support bone marrow cells.  
Bone marrow, blood and spleen cells were extracted from mice and were analysed as a control to 
CD45.2 leukaemic cells to determine the immunophenotype of the normal CD45.1 bone marrow 
cells. Cells were incubated with antibodies specific for LSC markers and analysed by flow 
cytometry. A. Cells were first assessed to determine the frequency of c-Kit+ cells, representing the 
normal HSPC population.  B. Within the c-Kit+ gate, cells were further analysed for the co-
expression of Mac-1 and Gr-1 to determine LSC-like cell frequency within the CD45.1+ control 
population. Data shown represent the mean frequencies of cell populations. (n=13). 
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CD45.2+ cells were then analysed for the expression of LSC markers. The CD45.2+ 
populations within the bone marrow, blood and spleen all contained a higher percentages 
of c-Kit+ cells compared to CD45.1+ cells, with the highest frequency being seen in the 
bone marrow (Fig. 3.3.13A). The frequency of c-Kit+ cells was comparable between WT 
and PHD1 KO cells. Only one sample of PHD1/2 KO cells was available for analysis so no 
statistical comparison was made between this sample and other genotypes. c-Kit+ cells 
were then analysed for the expression of Mac-1 and Gr-1. A significant percentage of cells 
also expressed both Mac-1 and Gr-1, composing a phenotype similar to pre-LSCs 
produced in vitro also in accordance with the literature (Fig. 3.3.13B). However, the 
immunophenotypic profile of the cells also showed that a population of c-Kit+Mac-1+Gr-1- 
cells existed (Fig. 3.3.13C). It is noteworthy that this population did not exist upon 
transplantation (Fig. 3.3.3), but has developed in vivo in correlation with the disease. As 
the relevance of this population is still unclear, both potential LSC populations were 
analysed and are referred to herein as LSC-1 (c-Kit+Mac-1+Gr-1+) and LSC-2 (c-Kit+Mac-
1+Gr-1- ).  
The frequency of c-Kit+ cells, as well as the frequencies of LSC-1 and LSC-2 
populations, were calculated for CD45.2+ leukaemic cells, only in those mice culled 
following development of leukaemia. Blood, bone marrow and spleen were all analysed 
and frequencies were compared across the groups to determine if the absence of PHD 
isoforms had an effect on the development of LSCs. Frequencies of c-Kit+, LSC-1 and LSC-2 
cells were comparable across all groups and no differences were seen.  
Next, the frequency of CD45.2+c-Kit+, CD45.2+LSC-1 and CD45.2+LSC-2 cells were 
determined within the total WBC population of the recipient mouse (Fig. 3.3.14). Each 
group was compared to determine the effect of PHD ablation. However, no differences 
were seen in the overall development of CD45.2+ LSCs in the blood, bone marrow or 
spleen. 
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Figure 3.3.13. Immunophenotype of CD45.2+ leukaemic cells.  
Bone marrow, blood and spleens were analysed by flow cytometry to determine the 
immunophenotype of CD45.2+ cells. A. CD45.2+ cells were analysed for c-Kit expression; within the c-
Kit+ gate, cells were analysed for co-expression of Mac-1 and Gr-1. Cells that were c-Kit+Mac-1+Gr-1+ 
were referred to as ‘LSC-1’. The frequency of CD45.2+ cells which were c-Kit+Mac-1+Gr-1- was 
calculated and referred to as ‘LSC-2’. B. Data presented represent the mean frequency of CD45.2+ 
cells which were c-Kit (i), LSC-1 (ii) and LSC-2 (iii). (WT n=7, PHD1 KO n=4, PHD1/2 KO n=1). 
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Figure 3.3.14. Frequency of CD45.2+ LSCs within WBC population.  
Bone marrow, blood and spleens were analysed by flow cytometry to determine the frequency 
of c-Kit+, LSC-1 and LSC-2 cells within the WBC population of the recipient mouse. A. WBCs were 
gated to determine frequency of WBCs that were c-Kit+, LSC-1 and LSC-2 phenotype.  WBCs were 
analysed for c-Kit expression. Within the c-Kit+ gate, cells were analysed for co- expression of 
Mac-1 and Gr-1. Cells that were c-Kit+Mac-1+Gr-1+ were referred to as LSC-1. The frequency of 
WBCs which were c-Kit+Mac-1+Gr-1- was calculated and referred to as LSC-2. B. Data presented 
represent the mean frequency of WBCs which were c-Kit (i), LSC-1 (ii) and LSC-2 (iii). (WT n=7, 
PHD1 KO n=4, PHD1/2 KO n=1).   
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3.3.5 Apoptotic frequency of leukaemic cells 
Due to the potentially apoptotic phenotype observed in transformed cells in vitro, 
leukaemic cells within the bone marrow were analysed for early and late stage apoptosis 
and viability based on Annexin V binding. The bone marrow of analysed mice was almost 
entirely composed of CD45.2+ cells (95.7%) and therefore, it was not necessary to gate 
this population. C-Kit+ cells were gated in order to analyse the frequency of apoptosis in 
haemopoietic cells (including HSPCs and LSCs). Frequencies of c-Kit+ cells undergoing 
apoptosis were compared across the available groups to determine if any differences in 
apoptotic frequencies were observed within an in vivo leukaemic setting. Apoptotic 
frequencies appeared to be somewhat variable (between 1.26-5.02% in WT cells) and no 
differences were seen between groups (Fig. 3.3.15). However, as mice transplanted with 
PHD2 KO pre-LSCs did not succumb to disease, none were available for analysis (healthy 
mice were not analysed on the day of termination of the experiment).  Considering the 
pro-apoptotic phenotype seen in PHD2 KO pre-LSCs during the in vitro study, it would 
have been interesting to see if this phenotype prevailed in an in vivo setting. 
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Figure 3.3.15. Frequency of apoptosis within WBC population.  
Bone marrow of leukaemic mice was analysed by flow cytometry; Annexin V binding and DAPI 
staining was used to determine the frequencies of WBC undergoing apoptosis. Annexin V+DAPI- 
cells were considered to be in early apoptosis (A), Annexin V+DAPI+ cells were considered to be 
in late apoptosis (B). Cells that were Annexin V-DAPI- were considered to be viable (C).   Data 
presented represent mean frequencies of apoptotic and viable cells. (WT n=7, PHD1 KO n=4, 
PHD1/2 KO n=1). 
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3.3.6 Conclusion 
The ablation of PHD genes, particularly PHD2, appeared to reduce the 
leukaemogenic potential of pre-LSCs. Overall, the results suggested that PHD2 was 
required for leukaemic development and that overall survival rate of the transplanted 
mice was dramatically increased in the absence of PHD2. However, the data were also 
suggestive that the disease, when it occurred, following transplantation of pre-LSCs was 
comparable regardless of PHD absence. Analysis of leukaemic samples suggested that 
once the disease developed within the host, it was unaffected by the absence of PHD, 
indicating that PHD may not play a role in the maintenance of the disease. However, as 
leukaemic frequency and overall survival did appear to be affected by the loss of PHD, it is 
likely that PHD has a role in the establishment of the disease. However, analysis of PHD2 
KO transplanted mice would be required to confirm this. These results are entirely novel 
and PHD2 has not previously been reported to have a role in leukaemogenesis. It would 
be vital to repeat these experiments to verify these potentially exciting findings. 
 
 
3.4 Response of Pre-LSCs to Stressful Stimuli 
It was previously shown in the in vitro assay assessing leukaemic potential, that 
WT and PHD KO pre-LSCs had comparable frequencies of LIC (Fig. 3.1.8). Transplanting 
HSCs to recipient mice is a common assay used to determine the response of the cells to 
the stressful conditions of transplantation. Considering this, it is possible that the 
difference seen in leukaemic potential in vivo was attributed to a difference in response 
to stress by the transplanted pre-LSCs. In order to investigate this possibility, exposure to 
hypoxia was used to mimic the conditions of the bone marrow to determine if the cells 
showed a difference in response to the stressful nature of the transplantation. It is 
noteworthy that PHD isoforms are oxygen dependent so are not active in hypoxic 
conditions; therefore hypoxia signalling may not be altered by lack of PHD. However, 
there are other regulatory elements governing hypoxia signalling.  
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3.4.1 Response of pre-LSCs to hypoxic conditions 
WT and PHD1 KO, and PHD2 KO pre-LSCs were cultured in a specialist hypoxia 
chamber in 1% oxygen for 24 hours.  Unfortunately, PHD1/2 KO pre-LSCs were not 
available for analysis in this experiment. Following treatment, the frequency of Annexin 
V+ (apoptotic) cells was analysed. Flow cytometric analysis of cells showed that PHD1 KO 
cells had a lower frequency of late apoptosis compared to WT cells (13.9% compared to 
19.1%) which was seen to be statistically significant (p=0.043) (Fig.3.4.1). Data also 
showed a trend towards lower total apoptosis in PHD1 KO cells, although this was not 
significant (p=0.115). The data showed that PHD2 KO pre-LSCs had frequencies of 
apoptosis that were comparable to WT pre-LSCs. No differences were seen in the 
frequency of viable cells. This suggests that the hypoxia treatment abrogated the 
apoptotic phenotype of PHD2 KO seen under steady state conditions. This is likely to 
reflect the oxygen-dependent nature of PHD isoforms. Hypoxic conditions would result in 
PHD isoforms becoming inactive in WT cells. Therefore, under hypoxic conditions, WT 
cells are responding effectively under the absence of PHD and so behaving in a similar 
manner to cells which genetically lack PHD.  
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Figure 3.4.1. Apoptotic frequencies of pre-LSC cell lines under hypoxic conditions. 
 Pre-LSC cell lines were subjected to hypoxic conditions for 24 hours to mimic in vivo bone 
marrow hypoxia. Annexin V binding and DAPI staining was used to determine the frequencies of 
pre-LSCs undergoing apoptosis in hypoxic conditions. Annexin V+DAPI- cells were considered to 
be in early apoptosis (A), Annexin V+DAPI+ cells were considered to be in late apoptosis (B). Cells 
that were Annexin V+ (both DAPI+ and DAPI-) were included when calculating total apoptosis (C). 
Cells that were Annexin V-DAPI- were considered to be viable (C).   Data presented represent 
mean frequencies of apoptotic and viable cells. (WT n=3, PHD1 KO n=3, PHD2 KO n=2). 
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Next, the frequencies of cycling cells were determined by Ki67/DAPI staining (Fig. 
3.4.2). Cell cycle frequencies were comparable between WT, PHD1 KO and PHD2 KO pre-
LSCs, suggesting that PHD deficiency did not affect the cell cycle under hypoxic stress.  
Overall, these experiments suggest that cells do not respond differently to hypoxic 
stress in the absence of PHD isoforms. This might indicate that the differences seen in 
vivo were not attributable to a cellular response to hypoxic conditions within the bone 
marrow, but rather reflected a genuine reduction in leukaemic potential in the absence of 
PHD isoforms. 
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Figure 3.4.2. Cell cycle frequencies of pre-LSC cell lines under hypoxic conditions.  
Pre-LSC cell lines were cultured under hypoxic conditions for 24 hours to mimic in vivo bone 
marrow hypoxia and cell frequencies in G0 (A), G1 (B) and S/G2/M phases (C) for WT, PHD1 KO 
and PHD2 KO pre-LSC cell lines determined by Ki67/DAPI staining. Data shown represent mean 
cell cycle frequencies. (WT n=2, PHD1 KO n=3, PHD2 KO n=1).   
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3.5 Response of Pre-LSCs to Chemotherapy and Radiation Treatment 
3.5.1 Concentration-effect curves used to select optimal chemotherapy doses  
Following the difference seen in leukaemic potential, experiments were 
conducted to examine if ablation of PHD isoforms could affect cell response to cancer 
therapy. Absence of PHD2 has already been shown to result in a pro-apoptotic phenotype 
under normal conditions and it was of interest to see if this apparent phenotype was 
heightened in response to stress. An increase in apoptosis in response to chemotherapy, 
coupled with a diminished ability to initiate disease, would reveal PHD2 as a promising 
therapeutic target that could be utilised in leukaemia treatment. 
Doxorubicin (Dox) and cytarabine (or arabinofuranosyl cytidine (AraC)) are 
chemotherapeutic agents commonly used to treat human AML (Wunderlich et al, 2013). 
These agents are also used routinely in research to determine chemotherapeutic 
response in both in vitro and in vivo studies (Lowe et al, 2011; Pardee, 2012). However, 
sensitivity to treatment can vary dramatically between different cell types and so assay 
optimisation depending on the cell lines under study is required. WT pre-LSC cell lines 
were first used to examine the response to treatment with Dox and AraC, in order to 
determine the optimal concentration to be used during the assay. The concentration of 
Dox and AraC used in similar studies in the literature informed the range which should be 
tested with the pre-LSC cell lines (Lowe et al, 2011).  
Cells were treated with increasing concentrations of Dox and counted by trypan 
blue exclusion after 24 hours (Fig. 3.5.1A). Trypan blue exclusion method can be used to 
determine both the viability of the cells, and concentration of the cells to give a measure 
of cell growth. Cell viability is determined by counting both white and blue cells 
separately to give the frequency of healthy cells. Cell growth is determined by counting 
only white cells to give the concentration of the cell suspension. Trypan blue exclusion 
showed that WT cells treated with Dox decreased in viability in a dose-dependent 
manner. However, it was only at higher doses (10ng/mL & 20ng/mL) that the effect was 
prominent. Therefore, a second concentration-effect curve was completed this time with 
cells treated with 0-50ng/mL Dox and counted at 24 and 48 hours (Fig. 3.5.1B). In WT 
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cells, viability was unaffected at lower concentrations; 50ng/mL Dox was required to 
initiate a substantial reduction in viability.  
Similar results were seen at both 24 and 48 hours suggesting that an appropriate 
response could be obtained after 24 hours. Cell concentration of WT cells was reduced at 
both time points following treatment with 10ng/mL Dox. However, a more prominent 
reduction in cell growth was seen following treatment with higher concentrations of Dox 
(25 and 50ng/mL). Similar results were seen at the two time points with 25 and 50ng/mL 
Dox, again suggesting that 24 hours was adequate to observe a response in WT cells. 
However, the exact response of PHD KO cells was unknown so it was difficult to 
determine which concentration of Dox was optimal to observe a difference in response. 
However, based on these results, 25 and 50ng/mL Dox were chosen to investigate 
chemotherapy response in PHD KO cells.  
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Figure 3.5.1. Concentration-effect curves of WT cells following Dox treatment.  
WT cells were treated with increasing concentrations of Dox to determine the most effective 
concentration for use in further experiments. A. Cell viability was assessed using trypan blue 
staining following treatment with 0-20ng/mL Dox. B & C. Cells were subjected to a second 
concentration-effect curve whereby the maximum Dox concentration was increased to 50ng/mL. 
Cell viability and cell growth were both measured using trypan blue staining. 
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Next the viability of cells treated with AraC was determined by trypan blue 
exclusion. WT cells treated with all concentrations of AraC were found to have extremely 
low viability after 24 hours suggesting that the dose curve of 0-48ng/mL was too high for 
these cells (Fig. 3.5.2A). Lower (0-2.4ng/mL) concentrations of AraC were then used. 
However, after treatment with even the lowest concentration of AraC, no cell growth was 
observed and cell viability was drastically reduced (Fig. 3.5.2B). As the response to 
chemotherapy per se in cells lacking PHD was not being tested in this assay, using a 
concentration that already caused a dramatic death response in WT cells may not have 
allowed observation of any subtle differences in sensitivity between WT and PHD KO cells 
as a consequence of their PHD genotype. Therefore, a concentration that exerted an 
effective, but not absolute response in WT cells was optimal to allow both increases and 
decreases in response to be observed. Considering this, a third concentration-effect curve 
was completed using lower concentrations of AraC (0-0.24ng/mL) being much lower than 
those reported in the literature. However, drug sensitivity can vary extensively between 
cell types and the exact sensitivity of the pre-LSC cells had never been examined. Cell 
growth of WT cells treated with AraC was significantly diminished in all treatment groups 
(Fig. 3.5.2C). However, 0.12ng/mL AraC treatment was required before an affect was seen 
in cell viability. Based on these results, 0.12ng/mL AraC was chosen as the optimal 
concentration to assess response to chemotherapy.    
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Figure 3.5.2. Concentration-effect curves of WT cells following AraC treatment.  
WT cells were treated with increasing concentrations of AraC to determine the most effective 
concentration for use in further experiments. A. Cell viability was assesses using Trypan blue 
staining following treatment with 0-48ng/mL AraC. B. Cells were subjected to a second 
concentration-effect curve whereby the maximum AraC concentration was decreased to 2.4ng/mL 
AraC. C. A third concentration-effect curve was completed whereby cells were treated with 
0.24ng/mL AraC. Cell viability and cell growth were both measured using Trypan blue staining. 
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3.5.2 Response of pre-LSCs to chemotherapy treatment 
In order to determine if cells respond differently to chemotherapy in the absence 
of PHD genes, WT, PHD1 KO, PHD2 KO and PHD1/2 KO cells were treated with Dox, AraC 
and a combination of Dox and Ara-C for 24 and 48 hours. For this experiment, only one 
biological replicate was available for PHD1/2 KO cells and therefore, statistical analysis 
was not performed on data from these samples. Two biological replicates were available 
for WT and PHD1 KO. Statistical analyses were performed using two biological replicates 
along with technical replicates in two individual experiments although statistical analysis 
would be more conclusive using three or more replicates. Three biological replicates were 
available of PHD2 KO cells and so these were used to calculate statistical relevance. 
However, it would be essential to repeat these experiments to increase the number of 
replicates and data available for analysis, in order to confirm these results.  
Trypan blue exclusion method was used to determine the viability of the cells. 
Untreated cells were used as a control (No Drug Control, NDC). At 24 hours, a difference 
in viability was observed between NDC groups from different PHD genotypes, that was 
concordant with previous results (Fig. 3.2.7). As each group had a difference in cell death 
prior to drug treatments, results are displayed as the percentage of cell death incurred 
following drug treatment, normalised to the percentage of cell death in each NDC group. 
Therefore, data presented shows the cell death in response to treatment and not total 
cell death. Following 24 hour treatment with 25ng/mL Dox, no difference was seen 
between groups (Fig. 3.5.3). However, in cells treated with 50ng/mL Dox, 0.12ng/mL AraC 
and a combination treatment of AraC and Dox, PHD1 KO, PHD2 KO and PHD1/2 KO pre-
LSCs all had higher frequencies of cell death compared to WT pre-LSCs. Statistical analysis 
showed that differences between PHD1 KO and WT were significant in cells treated with 
50ng/mL Dox, and in cells treated with a combination of Dox and AraC. Differences seen 
between PHD2 KO and WT cells were significant in all treatment groups with the 
exception of 25ng/mL Dox. At 48 hours, a similar trend was observed (Fig. 3.5.3). 
Following 25ng/mL Dox treatment, PHD KO pre-LSCs all showed increased cell death 
compared to WT. As this was not seen after 24 hours treatment, it is likely that at lower 
concentrations, this observation will only manifest following longer treatments. At 48 
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hours, data showed that in all treatment groups, PHD1 KO, PHD2 KO and PHD1/2 KO had 
a higher frequency of cell death compared to WT. Statistics preformed between WT and 
PHD1 KO showed that frequencies of cell death were statistically significant in all 
treatment groups. However, although PHD2 KO cells appeared to have a higher rate of 
cell death than WT in all groups, only cells treated with 50ng/mL Dox showed a difference 
that was statistically significant. 
Next, trypan blue exclusion was again used to determine the concentration of the 
cells (growth), which was determined at 24 and 48 hours (Fig. 3.5.4). In accordance with 
the effect seen in cell death frequencies, cells lacking PHD generally had diminished cell 
growth in comparison to WT in all treatment groups at both 24 and 48 hours. Statistics 
between PHD1 KO and WT showed that the difference was statistically significant in all 
treatment groups except cells treated with 0.12ng/mL AraC. The difference in cell growth 
seen between PHD2 KO and WT cells also proved to be significant in all treatment groups.  
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Figure 3.5.3. Cell death of pre-LSC cell lines following treatment with chemotherapy.  
Pre-LSC cell lines were treated with chemotherapeutic agents Dox and AraC at concentrations 
determined in the concentration-effect curves. Cell death in response to drug treatment was 
normalised against a control group. Cell death was assessed by trypan blue staining which was 
performed at 24 (A) and 48 hours (B) following treatment. Data shown represent the change in 
cell death frequency following treatment, relative to the cell death frequency of control cells 
that did not undergo treatment (NDC). Data represents the mean percentage of cell death 
induced by treatment which was normalised to percentage of cell death seen in NDC cells.  
(WT n=2, PHD1 KO n=2, PHD2 KO n=3, PHD1/2 KO n=1).  *<p.0.05, **<p.0.005. 
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Figure 3.5.4. Cell growth of pre-LSC cell lines following treatment with chemotherapy.  
Pre-LSC cell lines were treated with chemotherapeutic agents Dox and AraC at concentrations 
determined by the concentration-effect curves. Cell concentration was assessed by Trypan blue 
staining which was performed at 24 (A) and 48 hours (B) following treatment. Data presented 
represent mean cell concentrations following treatment. Student t-test was performed to 
determine if PHD KO genotypes have significantly different cell growth compared to WT Pre-LSCs.  
(WT n=2, PHD1 KO n=2, PHD2 KO n=3, PHD1/2 KO n=1).  *<p.0.05, **<p.0.005. 
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The frequency of cells undergoing apoptosis was also determined by flow 
cytometry analysis of Annexin V binding. As with the previous experiment, apoptotic 
frequencies were different in NDC groups so data is presented as the increase in 
apoptosis following drug treatment normalised to NDC groups. At 24 hours, PHD1 KO, 
PHD2 KO and PHD1/2 KO pre-LSCs all showed a higher frequency of drug-induced 
apoptosis compared to WT (Fig. 3.5.5). However, the difference between WT and PHD2 
KO cells was not statistically significant. An increase in drug-induced apoptosis was also 
seen in all PHD KO cells following treatment with 50ng/mL Dox, with statistical 
significance seen between WT and PHD2 KO. Following AraC treatment, PHD1 KO and 
PHD2 KO cells showed increased apoptosis, but this was not seen in PHD1/2 KO cells. 
Following treatment with AraC and Dox combined, PHD1 KO cells showed an increase in 
apoptosis, but this was not seen in PHD2 KO or PHD1/2 KO cells. Overall, PHD1 KO 
appeared to have the highest apoptotic response in all drug groups.  
At 48 hours, a similar trend was seen. PHD1 KO cells, as well as PHD1/2 KO cells, 
showed a higher frequency of apoptosis in all treatment groups compared to WT. PHD2 
KO cells also showed a slight increase in apoptosis which was statistically significant 
following treatment with 50ng/mL Dox. However, some variance was seen between PHD2 
KO samples causing standard deviation to be considerable and therefore no statistical 
differences were seen with other groups. 
Lastly, viability as determined by the frequency of Annexin V- cells was also 
calculated. The frequency of Annexin V- WT pre-LSCs was seen to be higher across all drug 
groups at both 24 and 48 hours when compared to cells lacking PHD (Fig. 3.5.6).  
Overall these results suggested that pre-LSCs lacking PHDs responded better to 
chemotherapy than WT pre-LSCs. It would be important to repeat these experiments to 
ensure that an adequate sample pool is used. However, clarification of these results could 
hold great therapeutic potential and point to PHD being a promising therapeutic target in 
treatment of leukaemia.  
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Figure 3.5.5. Apoptotic frequencies of pre-LSC cell lines following treatment with chemotherapy. 
Pre-LSC cell lines were treated with chemotherapeutic agents Dox and AraC at concentrations 
determined by the concentration-effect curves. Apoptotic frequencies of pre-LSCs were 
determined by Annexin V binding and DAPI staining. Annexin V binding was measured at 24 (A) 
and 48 hours (B) following drug treatment. Data shown represent the change in apoptotic 
frequencies following treatment, relative to apoptotic frequencies of control cells that did not 
undergo treatment. Student t-test was performed to determine if PHD KO genotypes have 
significantly different frequencies compared to WT Pre-LSCs.  (WT n=2, PHD1 KO n=2, PHD2 KO 
n=3, PHD1/2 KO n=1).  *p <0.05, **p<0.005, ***p <0.0005. 
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Figure 3.5.6. Cell viability of pre-LSC cell lines following treatment with chemotherapy.  
Pre-LSC cell lines were treated with chemotherapeutic agents Dox and AraC at concentrations 
determined by the concentration-effect curves.  Frequencies of viable cells were determined by 
Annexin V binding and DAPI staining. Annexin V binding was measured at 24 (A) and 48 hours (B) 
following drug treatment. Data shown represent the change in viability following treatment, relative 
to the viability of control cells that did not undergo treatment (NDC). Data shown represents mean 
apoptotic frequencies of all samples. Student t-test was performed to determine if PHD KO 
genotypes have significantly different frequencies compared to WT Pre-LSCs. (WT n=2, PHD1 KO 
n=2, PHD2 KO n=3, PHD1/2 KO n=1).  *<p.0.05, **<p.0.005. 
 
 
B 
183 
 
3.5.3 Response of pre-LSCs to radiation 
Radiation therapy is also a commonly used cancer therapy modality. In the 
haematological setting, radiation is used prior to bone marrow transplantation to ablate 
host marrow. Therefore, examining the response of pre-LSCs to radiation could give an 
indication of how cells respond during radiation therapy to treat leukaemia. As with the 
response to chemotherapy, the sensitivity of these cells to radiation is unknown. WT pre-
LSCs were subjected to increasing doses of radiation in order to select the optimal dose at 
which differences in responses could be observed. Annexin V binding was analysed by 
flow cytometry to determine the frequency of viable and apoptotic cells. WT pre-LSCs 
showed increasing frequencies of apoptotic cells that correlated with the dose of 
radiation (Fig. 3.5.7). Viability of the cells also reduced as the dose of radiation increased. 
Doses of 4 and 6Gy radiation were selected for additional apoptosis experiments as these 
doses should allow any positive or negative differences to be seen.  
WT, PHD1 KO and PHD2 KO pre-LSCs were then analysed for apoptotic 
frequencies following dosing with 4 and 6Gy radiation. As with the chemotherapy 
response experiment, control groups showed varied apoptotic frequencies. Therefore, 
data is presented as radiation-induced apoptosis and not total apoptosis (Fig. 3.5.8). 
PHD1 KO and PHD2 KO pre-LSCs both had frequencies of apoptotic cells that were slightly 
higher than those seen in WT pre-LSCs. In addition, WT pre-LSCs had a slightly higher 
frequency of viable cells compared to PHD1 KO and PHD2 KO cells. However, these 
differences were small and did not prove to be significant.  
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Figure 3.5.7. Dose response curve of WT cells following radiation treatment.  
WT pre-LSC cell lines were treated with increasing doses of radiation to determine the most 
effective dose for use in further experiments. Annexin V binding and DAPI staining were used to 
assess the frequency of apoptotic cells to determine sensitivity of the cells. A. Total Annexin V+ 
cells (both DAPI+ and DAPI-) were used to calculate total apoptosis. B. Total Annexin V- cells were 
used to calculate the frequency of viable cells.  
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Figure 3.5.8. Apoptotic frequencies of pre-LSC cell lines following radiation treatment.  
Cells were subject to radiation treatment. Annexin binding was used to assess the frequency of 
apoptotic cells and viable cells. A. Data shown represent the change in apoptotic frequencies 
following treatment relative to apoptotic frequencies of control cells that did not undergo 
treatment. B. Data shown represent total viability of cells based on Annexin V- cells. Data shown 
represent mean frequencies of apoptotic and viable cells. (WT n=3, PHD1 KO n=4, PHD2 KO n=1).   
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Next, the effect of radiation treatment on mitochondrial function was assessed. 
Differences in mitochondria can be subtle and so a lesser dose of radiation was chosen for 
this experiment. As mitochondrial dysfunction is often the cause of apoptosis, 
mitochondrial frequencies were analysed at an earlier time point than Annexin V binding 
frequencies, to give a more accurate measure of mitochondrial damage. Frequencies of 
functional and dysfunctional mitochondria were analysed by flow cytometry as previously 
described and used to determine the level of damage sustained by radiation.  Following 
dosing with 2Gy radiation, WT pre-LSCs had a significantly higher frequency of functional 
mitochondria compared to both PHD1 KO and PHD2 KO pre-LSCs, with PHD1 KO pre-LSCs 
showing the most significant decrease in functional mitochondria (Fig. 3.5.9). Statistical 
analysis showed that both PHD1 KO and PHD2 KO had significantly lower frequencies of 
functional mitochondria than WT pre-LSCs. PHD1 KO and PHD2 KO pre-LSCs also had 
significantly higher frequencies of dysfunctional mitochondria compared to WT pre-LSCs. 
These data imply that pre-LSCs lacking PHD1 or PHD2, have a greater response to 
irradiation and suffer more severe mitochondrial damage.  
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Figure 3.5.9. Mitochondrial function of pre-LSC cell lines following irradiation.  
Cells were irradiated and the frequency of functional mitochondria analysed by flow cytometry. 
A. Graph shows frequency of functional mitochondria. B. Graph shows frequency of dysfunctional 
mitochondria. Data shown represent mean frequencies of functional and dysfunctional 
mitochondria. (WT n=4, PHD1 KO n=4, PHD2 KO n=3). 
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Radiation treatment is known to cause double strand breaks in DNA (Podhorecka 
et al, 2010). Phosphorylation of H2AX (γH2AX) is commonly used to identify DNA damage 
within a cell (Podhorecka et al, 2010; Takacova et al, 2012). The frequency of DNA 
damage can be compared between groups to determine if a particular genotype is more 
susceptible to DNA damage following radiation. As this assay was used to detect the 
effect of the treatment rather than the response, it is likely that the high doses of 
radiation used to measure apoptosis, may be too high to detect any subtle differences. 
Therefore, cells were subjected to lower doses of radiation (1 and 2Gy) in order to assess 
DNA damage. As this is an initial response to irradiation, γH2AX+ frequencies were 
analysed 1 hour following dosing. At 1 hour, γH2AX expression was significantly higher in 
cells lacking PHD1 compared to WT cell. However, frequencies were comparable between 
WT and PHD2 KO cells (Fig. 3.5.10). This suggests that cells lacking PHD1 suffer more DNA 
damage or may be more susceptible to damage than WT cells, following radiation.  
Following initial DNA damage, cells attempt to repair the damage. Retention of 
γH2AX at later time points may indicate that cells have failed to repair their damaged 
DNA and so γH2AX expression can be used to indicate which cells are likely die following 
the insult. Additionally, a reduction of γH2AX may suggest that the DNA damage has been 
repaired or that damaged cells have undergone apoptosis. As apoptotic frequencies were 
analysed after 24 hours, γH2AX frequencies were also determined at this time point. At 
24 hours, the expression of γH2AX was reduced in all cells treated with 1 or 2Gy radiation, 
suggesting that by this time point, DNA damage had been repaired. It is also likely that 
cells with irreparable damage had undergone apoptosis (Fig. 3.5.10). The expression of 
γH2AX was similar in WT and PHD2 KO cells, suggesting that the DNA damage response of 
these cells is comparable. However, PHD1 KO cells had a lower retention of γH2AX 
following dosing with 1Gy which proved to be statistically significant. The relevance of 
this is unclear.  
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Figure 3.5.10. DNA damage of pre-LSCs following radiation treatment.  
Pre-LSC cell lines were subject to low doses of radiation treatment to assess DNA damage and to 
look for more subtle differences. Frequency of DNA damage was assessed based on the 
frequency of cells positive for γH2AX expression which was analysed by flow cytometry. A. γH2AX 
expression was assessed 1 hour following irradiation. B. γH2AX expression was also assessed 24 
hours following irradiation. Data shown are mean frequencies of H2AX+ cells. Student t-test was 
performed to determine if PHD KO genotypes have significantly different frequencies compared 
to WT Pre-LSCs. (WT n=4, PHD1 KO n=4, PHD2 KO n=3) *p<0.05, **p<0.005, ***p<0.0005. 
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 Next the cell cycle frequencies of pre-LSCs were analysed according to Ki67 
expression and DAPI incorporation. At 24 hours following irradiation, the frequencies of 
cells in G0 were increased across all genotypes, suggesting that radiation caused a 
reduction in cycling cells (Fig. 3.5.11). According to the literature, gamma radiation is also 
known to cause cells to arrest at the G2 checkpoint, which is thought to convey radiation 
resistance in some cancer cells (Gogineni et al, 2011; Anastasov et al, 2012).  In 
accordance with this, all cells showed an increase in G2/S/M phases which increased in 
correlation with the dose of radiation. Cells also showed a reduction in G1, which also 
correlated with irradiation dose. Ki67 analysis showed that all cells responded to the 
radiation treatment by arresting in G0 and G2 phases and by a reduction in proliferation. 
However, no differences were seen between WT and PHD KO pre-LSCs in cell cycle 
frequencies suggesting that cell cycle response to radiation was unaffected by the 
absence of PHD genes.  
Overall, these data imply that pre-LSCs lacking PHD1 or PHD2 may respond 
differently to radiation treatment in vitro. The frequency of dysfunctional mitochondria 
significantly increased in pre-LSCs lacking PHD1 and PHD2 suggesting that cells incurred 
more mitochondrial damage in response to radiation. Annexin V data indicated that 
although cells lacking PHD isoforms showed marginally higher levels of apoptosis, this 
difference was not significant. The increased levels of γH2AX seen in PHD1 KO cells 
suggested that these cells were more sensitive to damage. However, this effect was not 
seen in PHD2 KO cells and it is possible that although PHD1 and PHD2 appeared to have 
similar phenotypes in some aspects of this study, they also have unique functions and so 
may be responding differently.  
 
 
 
 
 
191 
 
 
 
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
* 
* 
B 
C 
Figure 3.5.11. Cell cycle frequencies of pre-LSCs following radiation treatment.  
Cells were irradiated and cell cycle frequencies assessed based on Ki67/DAPI staining which was 
analysed by flow cytometry. Cell frequencies in G0 (A), G1 (B) and G2/S/M phases (C) for WT, PHD1 
KO and PHD2 KO pre-LSC cell lines 24 hours following treatment. Data shown are means 
frequencies of cells in individual phases of the cell cycle. Student t-test was performed to determine 
if PHD KO genotypes have significantly different frequencies compared to WT Pre-LSCs.  (WT n=4, 
PHD1 KO n=3, PHD2 KO n=3).  *p<0.05. 
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3.5.4 Conclusion 
Overall, cells lacking PHD1 or PHD2 appeared to have a higher frequency of cell 
death in response to common leukaemia treatments, that is, chemotherapy and 
radiation, compared to WT cells. Taken together with the observation that pre-LSCs 
lacking PHD had an impaired ability to generate leukaemia in vivo, these data indicate 
that the eradication of PHD isoforms may help to increase the effectiveness of treatments 
for leukaemia. 
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4 Discussion 
 
4.1 An Experimental Model to Study Leukaemogenesis 
This project aimed to identify a role for PHD isoforms in the transformation and 
function of AML stem cells, by conducting a study that incorporated both in vitro and in 
vivo techniques. This study aimed to optimise an experimental model which would allow 
the generation of pre-LSCs for in vitro study, which were proven capable of forming 
leukaemia in vivo. The results of this study show that the model has multiple benefits and 
has allowed several questions to be answered concerning the biological properties, 
leukaemic potential and response to chemotherapy of pre-LSCs. HSPCs transduced with 
Meis1 and Hoxa9 retroviruses, were seen to successfully generate colonies in 
methylcellulose cultures. Furthermore, cells which were serially replated continued to 
produce colonies, displaying enhanced self renewal, beyond the capacity of non-
transduced HSPCs, characteristic of transformed cells. The successful transformation of 
these cells allowed immortalised cell lines to be generated which could be used to 
explore additional biological functions by performing a variety of biochemical assays. In 
addition, transplantation of cells generated in vitro were capable of forming leukaemia in 
recipient mice with a short latency, demonstrating that HSPCs were transformed in vitro 
to pre-LSCs, which, in an in vivo setting, gave rise to LSCs with leukaemic potential. 
Although the leukaemic potential of these cells did indicate the successful transformation 
of cells by Meis1 and Hoxa9, it would be important to provide evidence of Meis1 and 
Hoxa9 over-expression. Confirmation of the increased expression of these genes through 
qPCR or the presence of protein products by Western blotting, would help to validate the 
successful transformation of pre-LSCs. Final optimisation of this assay would allow further 
work to be conducted to unravel the role of hypoxia signalling in leukaemia. 
 
4.2 The Role of PHD in the Self Renewal and Transformation of HSPCs 
The experimental model developed in this study was used to estimate the self 
renewal capacity of HSPCs transduced with Meis1 and Hoxa9, as well as to investigate the 
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transformation of cells to generate pre-LSCs. This study analysed the ability of cells to 
produce colonies following serial replating. HSPCs extracted from mice lacking individual 
PHD isoforms, as well as several mice lacking various combinations of PHD isoforms, were 
compared to WT HSPCs to determine if the absence of PHD genes affected the self 
renewal capacity. No differences were observed in any of the genotypes. Successful 
transformation of HSPCs to pre-LSCs was based on the ability of cells to produce colonies 
after several rounds of replating. All cells were able to generate colonies suggesting that 
PHD ablation did not affect the transformation of HSPCs to pre-LSCs. However, it would 
be important to ensure that WT and PHD KO cells had equal Meis1 and Hoxa9 expression 
as differential expression of these ocogenes may have contributed to any differences in 
the cells’ ability to transform. . An additional assay was performed to estimate the 
frequency of self renewing cells. In line with previous results, no differences in self 
renewal frequencies were observed. Data presented within this thesis suggests that PHDs 
do not have a role in maintaining self renewal capacity or in the transformation of 
leukaemic cells. 
 
4.3 The Role of PHD in the Biological Functions of Pre-LSCs 
Several biological properties of pre-LSCs were analysed during this study in order 
to identify any dysregulated pathways which may indicate any non-hypoxic functions of 
PHD that are affected in pre-LSCs. PHD has previously been linked to the regulation of 
several biological processes, including cell cycle progression, apoptosis and metabolism. 
However, the cell and cancer-specific properties of PHD make it difficult to speculate if 
PHD has a role in any of these processes in a leukaemic context. Ki67 analysis was used to 
determine the frequency of cells in individual cell cycle phases, which appeared 
comparable between all genotypes. However, PHD1 KO and PHD2 KO cells both showed a 
decrease in cell growth compared to WT cells. It is interesting that this difference was not 
seen at every time point which may have been related to the density of the cells in 
culture hence this assay requires further optimisation. These results have indicated that 
PHD may be involved in the regulation of pre-LSC cell growth, however, more work would 
need to be done to clarify this. In order to explore this hypothesis further, it would be 
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important to determine the proliferation rate of the cells. BrdU incorporation is a useful 
assay that is often used to assess proliferation of cells. This would allow the proliferation 
of cells to be analysed over time to determine if the difference seen in the cell growth of 
PHD KO cells is attributable to enhanced proliferation. 
Apoptotic pathways are often dysregulated in cancers, with resistance to 
apoptosis being a common characteristic of cancer cells. Furthermore, PHD isoforms have 
been associated with the regulation of apoptosis (Lee et al, 2005; Natarajan et al, 2006). 
Data presented in this thesis revealed that pre-LSCs lacking PHD2 and generated after 
several rounds of re-plating in vitro had a higher frequency of apoptosis. However, it is 
possible that this was an artefact of in vitro culture due to the requirement of 
environmental cues from the bone marrow, which were not being received by cells in 
culture and that WT and PHD KO cells responded to this differently. The apoptotic status 
of PHD KO versus WT HSPCs was also assessed in cells isolated directly from the mice 
Unlike the phenotype seen in transformed PHD2 KO pre-LSCs compared to WT pre-LSCs, 
no difference was seen in the apoptotic frequencies of non-transformed PHD KO HSPCs 
compared to WT counterparts directly isolated from bone marrow However, it may be 
that this assay requires further optimisation. Following extraction from the bone marrow, 
cells are washed and RBCs excluded to enrich for the WBC population. It is possible that 
this process is also selecting healthy cells over dead or dying cells that are lost during 
purification. This would give a skewed result that would not include apoptotic cells, 
making it impossible to confirm an accurate reading of apoptotic frequency. Histologic 
analysis of bone marrow sections may provide a more accurate account of apoptosis in 
vivo and this method is commonly used to measure cell death in vivo.  
 Due to the observation of increased apoptosis in PHD2 KO pre-LSCs, along with 
the frequent association of PHD with metabolic regulation (Kaelin & Ratcliffe, 2008), 
mitochondrial function was assessed. No differences were observed in transformed pre-
LSCs or HSPCs isolated directly from the bone marrow, suggesting that increased 
apoptosis was not attributed to mitochondrial dysfunction in the absence of PHD. 
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4.4 The Regulation of HIF Proteins by PHD Isoforms 
PHDs are well known for the role they play in the regulation of HIF. However, the 
exact roles of each isoform are largely undetermined and it is not known if isoforms are 
capable of compensating for the loss of another. Considering this, the stabilisation of HIF 
proteins in WT pre-LSCs and pre-LSCs lacking PHD isoforms was assessed. As PHD is 
known to facilitate the degradation of HIF, it was expected that the ablation of PHD 
would affect the regulation of hypoxia signalling and that HIF proteins may be stabilised. 
HIF-1α and HIF-2α were undetectable in WT, PHD1 KO and PHD2 KO pre-LSCs suggesting 
that the ablation of single isoforms of PHD is not sufficient to stabilise HIF. Interestingly, 
HIF-1α and HIF-2α were stabilised in cells lacking both PHD1 and PHD2. These results give 
some insight into the individual roles of PHDs in the regulation of HIF and suggest that 
PHD1 and PHD2 may be able to compensate for each other. Compensatory functions 
between isoforms may result in altered expression levels of functional isoforms. 
Therefore, it would be important to assess the expression levels of individual PHD 
isoforms in WT and PHD KO cells to determine if the expression of particular isoforms is 
upregulated in response to the ablation of another. Western blotting would show the 
expression levels of PHD isoforms which could be compared between genotypes. Further 
analysis would also be required to validate the regulation of HIF. Gene expression assays 
could investigate the expression of HIF target genes to confirm the stabilisation of HIF.  
 
4.5 The Role of PHD in Leukaemic Development 
 The penetrance of leukaemia in recipient mice following transplantation of pre-
LSCs indicated that PHD may play a role in promoting leukaemic development. Pre-LSCs 
lacking PHD1, PHD2 or both PHD1 and PHD2, all showed a lower penetrance of disease 
compared to WT pre-LSCs, with PHD2 KO having the  lowest frequency of leukaemia. 
Furthermore, survival rate of the mice was significantly increased by PHD ablation. These 
data suggest that PHDs play a critical role in leukaemia development but it will be 
essential to repeat this experiment and to ensure its reproducibility in a larger study. It is 
also possible that this effect is specific for Meis1/Hoxa9 induced leukaemia. It will be 
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important to utilise other AML models to identify if a similar effect is seen in other 
models, such as MML-AF9 or Flt3-ITD.  
 The response of pre-LSCs to hypoxic stress was assessed to investigate if the 
phenotype seen in vivo was attributed to a difference in cellular response to the hypoxic 
conditions of the bone marrow. No differences were seen in hypoxic responses 
suggesting that the phenotype is a difference in leukaemogenicity rather than a response 
to transplantation. 
HIF-1α has been seen to play an essential role in leukaemia. As previously 
discussed, HIF-1α and HIF-2α were stabilised in cells lacking both PHD1 and PHD2, but 
were not stabilised in cells lacking single isoforms. However, the expression of HIF in vivo 
has not been assessed. It is possible that although HIFs are not stabilised by single PHD 
deletion in vitro, they are stabilised in vivo through the ablation of PHD and that the 
diminished leukaemic progression seen in PHD KO cells is attributed to HIF stabilisation. It 
will be important to assess if HIF is expressed in LSCs in vivo and if the reduced leukaemic 
potential seen in PHD KO cells is dependent on HIF stabilisation. However, HIF is quickly 
degraded in normoxic conditions meaning that an ex vivo approach would not be 
appropriate. It would be necessary to detect HIF expression through in vivo imaging 
techniques, such as those developed by Nombela-Arietta et al, in which they combined 
real time imaging of HSCs within the bone marrow with HIF staining to identify HIF-
positive HSCs in vivo (Nombela-Arietta et al, 2013). It would also be interesting to extend 
this study to include a model in which both HIF and PHD are inhibited, to investigate if the 
effect of PHD ablation is abrogated by inhibiting HIF. The availability of HIF KO mice would 
allow a double KO mouse model to be generated by cross breeding HIF KO and PHD KO 
mice. This would achieve various KO combinations and would require a substantial study 
to assess the phenotype of each genotype. However, this would be essential to 
investigate if PHDs’ role in leukaemic development is dependent on HIF. In addition, HIF-
1α has been reported to have an essential role in leukaemia so inhibition of HIF-1α, as 
well as PHD, may result in a more pronounced phenotype. 
Analysis of the apoptotic frequencies of leukaemic cells harvested directly from 
the bone marrow of leukaemic mice, showed no difference in apoptosis between WT and 
PHD KO cells. However, this analysis was done under in vitro conditions and as discussed, 
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an analysis of apoptosis in vivo would be more accurate and the possibility that PHD2 KO 
leukaemic cells are apoptotic in vivo cannot be ruled out. Apoptotic cells are frequently 
present in other cancers (Gregory & Pound, 2010). Studies have shown that cells 
undergoing apoptosis can have a large impact on the microenvironment and that they 
may be involved in the recruitment of tumour-promoting macrophages, which are known 
to play a role in tumour progression in other cancers through the secretion of pro-
tumourigenic factors (Gregory, 2011). The regulation of immune cells by PHD remains 
largely unexplored. However, a recent publication has suggested that PHD2 plays a role in 
the immune response to tumours, in which, ablation of PHD2 in lineage cells resulted in 
reduced tumour growth in a xenograft model, which was attributed to a higher level of 
necrosis (Mamlouk & Wielockx, 2013). This study, along with the observations of a pro-
apoptotic role resulting from the loss ofPHD2 in pre-LSCs, would make it interesting to 
investigate if the recruitment of tumour-promoting macrophages is affected in leukaemia 
in the absence of PHD, possibly explaining the reduced leukaemic penetrance seen in 
PHD2 KO cells. 
 
4.6 The Response to Chemotherapy in Absence of PHD 
 Results of this study suggest that pre-LSCs lacking PHDs have a greater response to 
chemotherapy. Pre-LSCs treated with AraC and doxorubicin showed a higher level of 
apoptosis and a greater reduction in viability in the absence of PHDs. In addition, cell 
growth was also reduced in PHD KO pre-LSC. These results suggest that PHD inhibition 
increases the cells response to chemotherapy and that PHD may play a protective role in 
pre-LSCs. This finding is also in line with studies by Oliveira et al which proposed a 
protective role for PHD. Oliveira et al showed that ablation of PHD2 increased the 
response of solid tumours to chemotherapy which resulted in a reduction of tumour 
mass. In the study by Leitte de Oliveira et al, cells were also assessed for their response to 
radiation in the absence of PHD. Pre-LSCs lacking PHD showed a higher frequency of 
mitochondrial dysfunction, suggesting that ablation of PHD may cause cells to incur more 
cellular damage. It would be interesting to extend this study to assess the response to 
chemotherapy in vivo. The treatment of leukaemic mice with chemotherapy would allow 
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the investigation into the role of PHD in chemotherapy response, within a 
pathophysiological model which would more accurately reflect the therapeutic 
implications of this finding. Chemotherapy response is often assessed using 
methylcellulose based assays similar to those adapted in this study. Repeating this assay 
using a methylcellulose based method would validate the results achieved so far. 
Furthermore, colony production quantification will determine if self renewal of cells is 
affected. Cell cycle arrest is a common response to chemotherapy and this would also 
help to further clarify the response to chemotherapy. Ki67 analysis can show the 
frequencies of cells in individual cell cycle phases, allowing a difference in cell cycle arrest 
to be determined. 
 
4.7 Gene Expression 
Overall these results do suggest that PHD plays a role in the development of 
leukaemia and the response to chemotherapy. However, this study has not identified the 
mechanism by which PHD acts. This report has already discussed the importance of 
investigating the dependence on HIF, however, PHDs are known to interact and regulate 
many other proteins in a HIF-independent manner, and it would be of equal importance 
to identify any dysregulation in non-hypoxia pathways that may contribute to the 
phenotype seen in PHD KO pre-LSC. As PHD2 KO pre-LSC have shown a difference in 
apoptosis, investigating the expression of apoptotic genes would be interesting. 
Furthermore, PHD has been linked to the regulation of apoptosis in other studies. The cell 
specific functions of each PHD isoform makes it difficult to pinpoint which PHD-regulated 
pathway may be affected so large scale gene expression analysis, such as microarray. 
would be extremely advantageous to this study. Performing microarray analysis on WT 
and PHD KO pre-LSC would allow a large scale comparison of the gene expression profiles 
in pre-LSCs that might indicate a difference in how these cells develop. Furthermore, 
microarray analysis of LSCs taken from leukaemic mice would identify differences in the 
gene expression of leukaemic cells in the absence of PHD.  
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4.8 Therapeutic Implications  
The effects seen in cells lacking PHD may be an indication that inhibition of PHD in 
AML, through treatment with PHD inhibitors, may increase the response to 
chemotherapy. This may suggest that PHD inhibition may be a novel therapeutic strategy 
for AML treatment. However, the sensitivity of normal HSCs following PHD inhibition 
would first need to be assessed in order to ensure a ‘therapeutic window’ where LSCs 
would respond efficiently to chemotherapy without normal HSCs being adversely 
affected. This study has provided some insight into the biological functions and sensitivity 
of pre-LSCs lacking PHD in  in vitro conditions, however, it does not explore the properties 
of normal HSCs or the effect of PHD ablation on their function, generating uncertainty 
concerning the side effects of this therapeutic strategy. It would be important to extend 
this study in order to investigate the properties of HSCs lacking PHD isoforms. Serial bone 
marrow transplantation assays as described by Takubo et al, would be useful to explore 
the self renewal capacity of HSCs in vivo as well as their reconstitution ability. Takubo et 
al showed that HSCs lacking HIF-1α exhaust during serial transplantation, suggesting that 
HIF-1α is essential for the maintenance of HSCs. Repeating this assay using HSCs lacking 
individual isoforms of PHD would indicate if PHD has a role in HSC maintenance. As 
previously discussed, studies exploring the role of PHD in HSCs have shown contradictory 
results and it would be important to validate this role before any therapeutic strategies 
were developed. Unpublished studies by Guitart et al have suggested that PHD2 does not 
play an essential role in HSC maintenance and that PHD2 ablation did not affect the self 
renewal capacity or reconstitution ability of HSCs during serial transplantation. If these 
results can be validated, this would suggest that PHD inhibitors may in fact be a viable 
therapeutic option as HSCs would remain unaffected by PHD inhibition, while this 
treatment may cause LSCs to become more sensitive to chemotherapy. 
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